WO2004084940A1 - Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use - Google Patents
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use Download PDFInfo
- Publication number
- WO2004084940A1 WO2004084940A1 PCT/EP2004/003165 EP2004003165W WO2004084940A1 WO 2004084940 A1 WO2004084940 A1 WO 2004084940A1 EP 2004003165 W EP2004003165 W EP 2004003165W WO 2004084940 A1 WO2004084940 A1 WO 2004084940A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- seq idno
- antigen
- particle
- virus
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 188
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 133
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims description 136
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract description 24
- 238000004806 packaging method and process Methods 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 6
- 239000000427 antigen Substances 0.000 claims abstract description 352
- 108091007433 antigens Proteins 0.000 claims abstract description 340
- 102000036639 antigens Human genes 0.000 claims abstract description 340
- 241000700605 Viruses Species 0.000 claims abstract description 161
- 239000000126 substance Substances 0.000 claims abstract description 85
- 230000028993 immune response Effects 0.000 claims abstract description 78
- 229960005486 vaccine Drugs 0.000 claims abstract description 62
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 42
- 230000003612 virological effect Effects 0.000 claims abstract description 31
- 230000005867 T cell response Effects 0.000 claims abstract description 22
- 101710132601 Capsid protein Proteins 0.000 claims description 201
- 230000000890 antigenic effect Effects 0.000 claims description 159
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 151
- 239000000203 mixture Substances 0.000 claims description 150
- 108090000623 proteins and genes Proteins 0.000 claims description 111
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 110
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 claims description 98
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 235000018102 proteins Nutrition 0.000 claims description 91
- 108091081548 Palindromic sequence Proteins 0.000 claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 80
- 150000007523 nucleic acids Chemical group 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 66
- 241000282414 Homo sapiens Species 0.000 claims description 60
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 55
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 55
- 229940029575 guanosine Drugs 0.000 claims description 55
- 230000027455 binding Effects 0.000 claims description 52
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 48
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 48
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 45
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 41
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 39
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 36
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 241001515965 unidentified phage Species 0.000 claims description 28
- 230000004048 modification Effects 0.000 claims description 27
- 238000012986 modification Methods 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 27
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 26
- 230000002708 enhancing effect Effects 0.000 claims description 21
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 20
- 230000003252 repetitive effect Effects 0.000 claims description 20
- 201000001441 melanoma Diseases 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 15
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 15
- 241000700721 Hepatitis B virus Species 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 12
- 241001534160 Escherichia virus Qbeta Species 0.000 claims description 11
- 102000004895 Lipoproteins Human genes 0.000 claims description 11
- 108090001030 Lipoproteins Proteins 0.000 claims description 11
- -1 zinc (Zn) ions Chemical class 0.000 claims description 11
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 241000702670 Rotavirus Species 0.000 claims description 9
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 8
- 241000709738 Enterobacteria phage fr Species 0.000 claims description 8
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 8
- 101710108545 Viral protein 1 Proteins 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 241001672158 Acinetobacter phage AP205 Species 0.000 claims description 6
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 6
- 239000013566 allergen Substances 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 5
- 241000709737 Enterobacteria phage GA Species 0.000 claims description 5
- 241000709743 Enterobacteria phage SP Species 0.000 claims description 5
- 241000709744 Enterobacterio phage MS2 Species 0.000 claims description 5
- 108010015780 Viral Core Proteins Proteins 0.000 claims description 5
- 229910021645 metal ion Inorganic materials 0.000 claims description 5
- 229960002715 nicotine Drugs 0.000 claims description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 5
- 208000003154 papilloma Diseases 0.000 claims description 5
- 241001278054 Enterobacteria phage NL95 Species 0.000 claims description 4
- 241000709749 Pseudomonas phage PP7 Species 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 claims description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 4
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 3
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 3
- 201000005505 Measles Diseases 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 229960002069 diamorphine Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 230000004568 DNA-binding Effects 0.000 claims description 2
- 241000702188 Enterobacteria phage M1 Species 0.000 claims description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims description 2
- 230000004570 RNA-binding Effects 0.000 claims description 2
- 229940025084 amphetamine Drugs 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 229960002428 fentanyl Drugs 0.000 claims description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001252 methamphetamine Drugs 0.000 claims description 2
- 229960001344 methylphenidate Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims 5
- 108010083644 Ribonucleases Proteins 0.000 claims 5
- 229940031689 heterologous vaccine Drugs 0.000 claims 4
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 230000037452 priming Effects 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 229960004242 dronabinol Drugs 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 25
- 201000010099 disease Diseases 0.000 abstract description 20
- 230000002163 immunogen Effects 0.000 abstract description 16
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 15
- 238000002255 vaccination Methods 0.000 abstract description 15
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 7
- 230000007815 allergy Effects 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 101710125418 Major capsid protein Proteins 0.000 description 117
- 101710141454 Nucleoprotein Proteins 0.000 description 113
- 101710094648 Coat protein Proteins 0.000 description 112
- 101710083689 Probable capsid protein Proteins 0.000 description 112
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 108
- 235000001014 amino acid Nutrition 0.000 description 95
- 229940024606 amino acid Drugs 0.000 description 91
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 72
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 66
- 150000001413 amino acids Chemical class 0.000 description 64
- 210000000234 capsid Anatomy 0.000 description 55
- 125000003275 alpha amino acid group Chemical group 0.000 description 47
- 208000015181 infectious disease Diseases 0.000 description 36
- 238000005859 coupling reaction Methods 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 33
- 230000004927 fusion Effects 0.000 description 30
- 238000003780 insertion Methods 0.000 description 27
- 230000037431 insertion Effects 0.000 description 27
- 239000013256 coordination polymer Substances 0.000 description 25
- 230000008878 coupling Effects 0.000 description 25
- 238000010168 coupling process Methods 0.000 description 25
- 239000004971 Cross linker Substances 0.000 description 23
- 125000000539 amino acid group Chemical group 0.000 description 22
- 102000037865 fusion proteins Human genes 0.000 description 22
- 108020001507 fusion proteins Proteins 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 238000012217 deletion Methods 0.000 description 20
- 230000037430 deletion Effects 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 230000002458 infectious effect Effects 0.000 description 18
- 239000013598 vector Substances 0.000 description 16
- 241000283690 Bos taurus Species 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 14
- 208000002672 hepatitis B Diseases 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 241000271566 Aves Species 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 108090000565 Capsid Proteins Proteins 0.000 description 11
- 102100023321 Ceruloplasmin Human genes 0.000 description 11
- 241000829111 Human polyomavirus 1 Species 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000035473 Communicable disease Diseases 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 241000282326 Felis catus Species 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 241001505332 Polyomavirus sp. Species 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 239000007771 core particle Substances 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 241000283073 Equus caballus Species 0.000 description 8
- 241000282324 Felis Species 0.000 description 8
- 102000002067 Protein Subunits Human genes 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 235000009697 arginine Nutrition 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 229920002477 rna polymer Polymers 0.000 description 7
- 241000709661 Enterovirus Species 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 241000712079 Measles morbillivirus Species 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 108020000411 Toll-like receptor Proteins 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 6
- 208000005098 feline infectious peritonitis Diseases 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000001338 self-assembly Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108010001267 Protein Subunits Proteins 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000709747 Enterobacteria phage R17 Species 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 208000008771 Lymphadenopathy Diseases 0.000 description 4
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000714209 Norwalk virus Species 0.000 description 4
- 101710116435 Outer membrane protein Proteins 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 101710107921 Secreted protein BARF1 Proteins 0.000 description 4
- 241000710960 Sindbis virus Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 150000003862 amino acid derivatives Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 208000018555 lymphatic system disease Diseases 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229930000044 secondary metabolite Natural products 0.000 description 4
- 235000015170 shellfish Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 3
- 101150083464 CP gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 241000709739 Enterobacteria phage f2 Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000711386 Mumps virus Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000712464 Orthomyxoviridae Species 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 241000711504 Paramyxoviridae Species 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 241000710924 Togaviridae Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 2
- 241001455214 Acinonyx jubatus Species 0.000 description 2
- 241000701242 Adenoviridae Species 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000712892 Arenaviridae Species 0.000 description 2
- 241000714230 Avian leukemia virus Species 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000008889 California Encephalitis Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000712471 Dhori virus Species 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 208000000655 Distemper Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014584 Encephalitis california Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- 241001598169 Equid alphaherpesvirus 3 Species 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 101710121996 Hexon protein p72 Proteins 0.000 description 2
- 241000713673 Human foamy virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000248484 Ichthyophthirius Species 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 241000701377 Iridoviridae Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 2
- 101001056675 Klebsiella pneumoniae Ferric aerobactin receptor Proteins 0.000 description 2
- 201000009908 La Crosse encephalitis Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 208000006758 Marek Disease Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710190786 PI protein Proteins 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000282372 Panthera onca Species 0.000 description 2
- 241000282373 Panthera pardus Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 241000713137 Phlebovirus Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 241000710884 Powassan virus Species 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000702247 Reoviridae Species 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 241000710801 Rubivirus Species 0.000 description 2
- 208000001203 Smallpox Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 241000713152 Uukuniemi virus Species 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 208000010094 Visna Diseases 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 108700010877 adenoviridae proteins Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 208000008921 border disease Diseases 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229960002143 fluorescein Drugs 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 102000053185 human MLANA Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000002477 vacuolizing effect Effects 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- GNTFNWAZTKLCRE-UHFFFAOYSA-N 4-amino-4-bromo-1,3-dihydropyrimidin-2-one Chemical compound NC1(Br)NC(=O)NC=C1 GNTFNWAZTKLCRE-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 101000689231 Aeromonas salmonicida S-layer protein Proteins 0.000 description 1
- 241000120516 African horse sickness virus Species 0.000 description 1
- 208000007407 African swine fever Diseases 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241001135972 Aleutian mink disease virus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241001167018 Aroa Species 0.000 description 1
- 241000282706 Ateles Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 241001118702 Border disease virus Species 0.000 description 1
- 241000701922 Bovine parvovirus Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- 241000879755 Caracal Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000711969 Chandipura virus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 201000009182 Chikungunya Diseases 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 241001275954 Cortinarius caperatus Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 208000006586 Ectromelia Diseases 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241001278075 Enterobacteria phage MX1 Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000709691 Enterovirus E Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 description 1
- 241000725578 Equid gammaherpesvirus 2 Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010063827 Extramedullary haemopoiesis Diseases 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 208000004729 Feline Leukemia Diseases 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000701915 Feline panleukopenia virus Species 0.000 description 1
- 241000879809 Felis margarita Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000604777 Flavobacterium columnare Species 0.000 description 1
- 241000723754 Flock house virus Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000856850 Goose coronavirus Species 0.000 description 1
- 241001506229 Goose reovirus Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 102100021410 Heat shock 70 kDa protein 14 Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019773 Hepatitis G Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001041756 Homo sapiens Heat shock 70 kDa protein 14 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 244000309469 Human enteric coronavirus Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 241000252498 Ictalurus punctatus Species 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000004467 Infectious Canine Hepatitis Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000120527 Kemerovo virus Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000710912 Kunjin virus Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010024503 Limb reduction defect Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 241000711941 Murine orthopneumovirus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241001135960 Murine rotavirus Species 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 208000006007 Nairobi Sheep Disease Diseases 0.000 description 1
- 241001457453 Nairobi sheep disease virus Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091060545 Nonsense suppressor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000710944 O'nyong-nyong virus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033976 Paravaccinia Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000186813 Renibacterium Species 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000277293 Salvelinus alpinus Species 0.000 description 1
- 241001135555 Sandfly fever Sicilian virus Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 241000702677 Simian rotavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000283975 Sylvilagus Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 241000712908 Tacaribe mammarenavirus Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 101000748795 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) Cytochrome c oxidase polypeptide I+III Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- RKEITGVZZHXKON-SKAWGCAZSA-N Thymidine glycol Chemical compound O=C1NC(=O)C(C)(O)C(O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 RKEITGVZZHXKON-SKAWGCAZSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 102000008208 Toll-Like Receptor 8 Human genes 0.000 description 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000008229 Toll-like receptor 1 Human genes 0.000 description 1
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 208000007885 Vesicular Exanthema of Swine Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 101000936049 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) Outer membrane lipoprotein Blc Proteins 0.000 description 1
- 241001135139 Vibrio ordalii Species 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 206010048249 Yersinia infections Diseases 0.000 description 1
- 208000025079 Yersinia infectious disease Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150037081 aroA gene Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229950009494 bropirimine Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 208000009724 equine infectious anemia Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000025095 immunoproliferative disease Diseases 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 210000001911 interdigitating cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 description 1
- 230000034701 macropinocytosis Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical class OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000003058 natural language processing Methods 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010000222 polyserine Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 101150002764 purA gene Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000003237 recreational drug Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000724775 unclassified viruses Species 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18123—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is related to the fields of vaccinology, immunology and medicine.
- the invention provides compositions and methods for enhancing immunological responses against virus-like particles (VLPs) or against antigens coupled, fused or attached otherwise to VLPs by packaging immunostimulatory substances, in particular immunostimulatory nucleic acids, and even more particular oligonucleotides containing at least one non-methylated CpG sequence, into the NLPs.
- VLPs virus-like particles
- antigens coupled, fused or attached otherwise to VLPs by packaging immunostimulatory substances, in particular immunostimulatory nucleic acids, and even more particular oligonucleotides containing at least one non-methylated CpG sequence, into the NLPs.
- the invention can be used to induce strong and sustained T cell responses particularly useful for the treatment of tumors and chronic viral diseases as well as allergies and other chronic diseases.
- the essence of the immune system is built on two separate foundation pillars: one is specific or adaptive immunity which is characterized by relatively slow response- kinetics and the ability to remember; the other is non-specific or innate immunity exhibiting rapid response-kinetics but lacking memory.
- viruses exhibit a quasi- crystalline surface that displays a regular anay of epitopes which efficiently crosslinks epitope-specific immunoglobulins on B cells (Bachmann & Zinkemagel, Immunol. Today 17:553-558 (1996)). Viral structure is even linked to the generation of anti-antibodies in autoimmune disease and as a part of the natural response to pathogens (see Fehr, T., et al., J. Exp. Med. 185:1785-1792 (1997)). Thus, antigens on viral particles that are organized in an ordered and repetitive anay are highly immunogenic since they can directly activate B cells and induce the generation of a cytotoxic T cell response, another crucial arm of the immune system.
- Viral particles as antigens exhibit two advantages over their isolated components: (1) due to their highly repetitive surface structure, they are able to directly activate B cells, leading to high antibody titers and long-lasting B cell memory; and (2) viral particles, but not soluble proteins, have the potential to induce a cytotoxic T cell response, even if the viruses are non-infectious and adjuvants are absent.
- 5,871,747 which discloses synthetic polymer particles canying on the surface one or more proteins covalently bonded thereto; and a core particle with a non-covalently bound coating, which at least partially covers the surface of said core particle, and at least one biologically active agent in contact with said coated core particle (see, e.g., WO 94/15585).
- VLPs virus-like particles
- DNA rich in non-methylated CG motifs (CpG) exhibits a potent stimulatory activity on B cells, dendritic cells and other APC's in vitro as well as in vivo.
- CpG motifs may differ.
- CpG motifs that stimulate mouse immune cells may not necessarily stimulate human immune cells and vice versa.
- DNA oligomers rich in CpG motifs can exhibit immunostimulatory capacity, their efficiency is often limited, since they are unstable in vitro and in vivo. Thus, they exhibit unfavorable pharmacokinetics. In order to render CpG-oligonucleotides more potent, it is therefore usually necessary to stabilize them by introducing phosphorothioate modifications of the phosphate backbone.
- CpG-oligonucleotides to stimulate immune responses are their lack of specificity, since all APC's and B cells in contact with CpG- oligonucleotides become stimulated.
- the efficiency and specificity of CpG- oligonucleotides may be improved by stabilizing them or packaging them in a way that restricts cellular activation to those cells that also present the relevant antigen.
- immunostimulatory CpG-oligodeoxynucleotides induce strong side effects by causing extramedullary hemopoiesis accomponied by splenomegaly and lymphadenopathy in mice (Sparigan et al., J. Immunol. (1999), 162:2368-74 and Example 18).
- VLPs have been shown to be efficiently presented on MHC class I molecules as they, presumably after uptake by macropinocytosis, are efficiently processed and crossprimed onto MHC class I.
- the mechanism of crosspriming is not clear to date, but TAP-dependent and TAP-independent pathways have been proposed.
- TAP-dependent and TAP-independent pathways have been proposed.
- new and improved vaccines that promote a strong CTL immune response and anti-pathogenic protection as efficiently as natural pathogens in the absence of generalized activation of APCs and other cells.
- This invention is based on the su ⁇ rising finding that specific immunostimulatory substances such as DNA oligonucleotides packaged into VLPs renders them more immunogenic.
- the nucleic acids and oligonucleotides, respectively, present in VLPs can be replaced specifically by the immunostimulatory substances and DNA-oligonucleotides containing CpG motifs, respectively.
- these packaged immunostimulatory substances, in particular immunostimulatory nucleic acids such as unmethylated CpG-containing oligonucleotides retained their immunostimulatory capacity without widespread activation of the innate immune system.
- compositions comprising VLP's and the immunostimulatory substances in accordance with the present invention, and in particular the CpG-VLPs are dramatically more immunogenic than their CpG-free counte ⁇ arts and induce enhanced B and T cell responses.
- the immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself.
- the T cell responses against both the VLPs and antigens are especially directed to the Thl type.
- Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
- the invention provides a composition, typically and preferably for enhancing an immune response in an animal, comprising a virus-like particle and an immunostimulatory substance, preferably an immunostimulatory nucleic acid, an even more preferably an unmethylated CpG-containing oligonucleotide, where the substance, nucleic acid or oligonucleotide is coupled, fused, or otherwise attached to or enclosed by, i.e., bound, to the virus-like particle.
- the composition further comprises an antigen bound to the virus-like particle.
- the immunostimulatory nucleic acids in particular the unmethylated CpG-containing oligonucleotides are stabilized by phosphorothioate modifications of the phosphate backbone.
- the immunostimulatory nucleic acids, in particular the unmethylated CpG- containing oligonucleotides are packaged into the VLPs by digestion of RNA within the VLPs and simultaneous addition of the DNA oligonucleotides containing CpGs of choice.
- the VLPs can be disassembled before they are reassembled in the presence of CpGs.
- the immunostimulatory nucleic acids do not contain CpG motifs but nevertheless exhibit immunostimulatory activities.
- Such nucleic acids are described in WO 01/22972. All sequences described therein are hereby inco ⁇ orated by way of reference.
- the virus-like particle is a recombinant viruslike particle.
- the virus-like particle is free of a lipoprotein envelope.
- the recombinant virus-like particle comprises, or alternatively consists of, recombinant proteins of Hepatitis B virus, BK virus or other human Polyoma virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth-Disease virus, Retrovirus, Norwalk virus or human Papilloma virus, RNA-phages, Q ⁇ -phage, GA-phage, fr-phage and Ty.
- the virus-like particle comprises, or alternatively consists of, one or more different Hepatitis B virus core (capsid) proteins (HBcAgs).
- the virus-like particle comprises recombinant proteins, or fragments thereof, of a RNA-phage.
- Prefened RNA-phages are Q ⁇ -phage, AP 205-phage, GA-phage, fr-phage
- the antigen is a recombinant antigen.
- the antigen can be selected from the group consisting of: (1) a polypeptide suited to induce an immune response against cancer cells; (2) a polypeptide suited to induce an immune response against infectious diseases; (3) a polypeptide suited to induce an immune response against allergens; (4) a polypeptide suited to induce an improved response against self-antigens; and (5) a polypeptide suited to induce an immune response in farm animals or pets.
- the antigen can be selected from the group consisting of: (1) an organic molecule suited to induce an immune response against cancer cells; (2) an organic molecule suited to induce an immune response against infectious diseases; (3) an organic molecule suited to induce an immune response against allergens; (4) an organic molecule suited to induce an improved response against self-antigens; (5) an organic molecule suited to induce an immune response in farm animals or pets; and (6) an organic molecule suited to induce a response against a drug, a hormone or a toxic compound.
- the antigen comprises, or alternatively consists of, a cytotoxic T cell epitope, preferably a Th cell epitope or a combination of at least two of the epitopes, wherein preferably the at least two epitopes are bound directly or by way of a linking sequence.
- the cytotoxic T cell epitope is a viral or a tumor cytotoxic T cell epitope.
- the virus-like particle comprises the Hepatitis B virus core protein and the cytotoxic T cell epitope is fused to the C-terminus of said Hepatitis B virus core protein, preferably by way of a linking sequence.
- the virus-like particle comprises the BK virus VP1 protein and the cytotoxic T cell epitope is fused to the C-terminus of the BK virus VP1 protein, preferably by way of a linking sequence. In one embodiment, they are fused by a leucine linking sequence.
- a method of enhancing an immune response in a human or other animal species comprising introducing into the animal a composition comprising a virus-like particle and immunostimulatory substance, preferably an immunostimulatory nucleic acid, an even more preferably an unmethylated CpG-containing oligonucleotide where the substance, preferably the nucleic acid, and even more preferally the oligonucleotide is bound (i.e. coupled, attached or enclosed) to the virus-like particle.
- the composition further comprises an antigen bound to the virus-like particle.
- the composition is introduced into an animal subcutaneously, intramuscularly, intranasally, intradermally, intravenously or directly into a lymph node.
- the immune enhancing composition is applied locally, near a tumor or local viral reservoir against which one would like to vaccinate.
- the immune response is a T cell response, and the T cell response against the antigen is enhanced.
- the T cell response is a cytotoxic T cell response, and the cytotoxic T cell response against the antigen is enhanced.
- the present invention also relates to a vaccine comprising an immunologically effective amount of the immune enhancing composition of the present invention together with a pharmaceutically acceptable diluent, ca ⁇ ier or excipient.
- the vaccine further comprises at least one adjuvant, such as incomplete Freund's adjuvant.
- the invention also provides a method of immunizing and/or treating an animal comprising administering to the animal an immunologically effective amount of the disclosed vaccine.
- the immunostimulatory substance- containing VLPs preferably the immunostimulatory nucleic acid-containing VLP's, an even more preferably the unmethylated CpG-containing oligonucleotide VLPs are used for vaccination of animals or humans against the VLP itself or against antigens coupled, fused or attached otherwise to the VLP.
- the modified VLPs can be used to vaccinate against tumors, viral diseases, self-molecules and self antigens, respectively, or non- peptidic small molecules, for example.
- the vaccination can be for prophylactic or therapeutic pu ⁇ oses, or both.
- the modified VLPs can be used to vaccinate against allergies in order to induce immune-deviation.
- the desired immune response will be directed against antigens coupled, fused or attached otherwise to the immunostimulatory substance- containing VLPs, preferably the immunostimulatory nucleic acid-containing VLP's, an even more preferably the unmethylated CpG-containing oligonucleotide VLPs.
- the antigens can be peptides, proteins, domains, carbohydrates or small molecules such as, for example, steroid hormones or drugs, such as nicotine.
- the desired immune response can be directed against the VLP itself. This latter application will be used in cases where the VLP originates from a virus against which one would like to vaccinate.
- the route of injection is preferably subcutaneous or intramuscular, but it would also be possible to apply the CpG-containing VLPs intradermally, intranasally, intravenously or directly into the lymph node.
- the CpG-containing antigen-coupled or free VLPs are applied locally, near a tumor or local viral reservoir against which one would like to vaccinate.
- Figure 1 shows the SDS-PAGE analysis of Qb-MelanA VLPs.
- MelanA-peptides were coupled to Qb VLPs, as described in Example 22.
- the final products were mixed with sample buffer and separated under reduced conditions on 16 % Novex®Tris-Glycine gels for 1.5 hours at 125 V.
- the separated proteins were stained by soaking the gel in Coomassie blue solution. Background staining was removed by washing the gel in 50 % methanol, 8% acetic acid.
- the Molecular weight marker (P 77085, New England BioLabs, Beverly, USA) was used as reference for Qb-MelanA migration velocity (lane 1).
- G10 is used for the the oligonucleotide G10-PO
- G3 is used for the oligonucleotide G3-6.
- Supernatants were collected and IFN alpha was measured by ELISA, using a set of antibodies provided by PBL Biomedical Laboratories.
- Figure 2B shows the upregulation of CD69 on human CD8+ PBMC treated with ISS.
- PBMC were obtained from buffy coat and incubated with fivefold dilution of the indicated ISS for 18h. Cells were washed and incubated with anti-CD8-FITC, anti-CD19- PE and anti-CD69-APC (all from BD PharMingen) for 20 min on ice. After washing, cells were analysed on a FACS Calibur using CellQuest software.
- Figure 3 shows the virus titers after immunizing mice with Qbx33 packaged with poly ( C), G3-6, or G6.
- C poly
- G3-6 poly
- G6 poly
- Qbx33 100 ⁇ g Qb VLPs packaged with poly (I:C) and coupled to ⁇ 33 (Qb-pIC-33, also termed QbxZnx ⁇ olyICxp33GGC) , 90 ⁇ g Qbx33 packaged with G3-6 (Qbx33/G3-6), or 90 ⁇ g Qbx33 packaged with G6 (Qbx33/G6).
- mice were challenged with 1.5 xl06 plaque forming units Vaccinia virus, carrying the LCMV-p33 epitope.
- mice were sacrificed and the ovaries were collected.
- a single cell suspension from the ovaries was prepared and added to BCS40 cells in serial dilutions. One day later, the cell layer was stained with a solution containing 50% Ethanol, 2% formaldehyde, 0.8% NaCl and 0.5% Crystal violet) and the viral plaques were counted.
- Figure 4 shows the SDS-PAGE analysis of the coupling reaction of Q ⁇ VLP to gag-G50 peptide.
- the samples were run under reducing conditions on a 12% NuPage gel (Invitrogen).
- Lane 1 is the protein marker, with co ⁇ esponding molecular weights indicated on the left border of the gel; lane 2, derivatized Q ⁇ VLP; lane 3, the supernatant of the coupling reaction of Q ⁇ capsid protein to the gag-G50 peptide; lane 4, the pellet of the coupling reaction of Q ⁇ capsid protein to the gag-G50 peptide.
- Coupling products conesponding to the coupling of a peptide on a Q ⁇ monomer or Q ⁇ dimer are indicated by a ⁇ ows in the Figure.
- Figure 5 shows the SDS-PAGE analysis of the coupling reaction of Q ⁇ VLP to nef-N56 peptide.
- the samples were run under reducing conditions on a 12% NuPage gel (Invitrogen).
- Lane 1 is the protein marker, with conesponding molecular weights indicated on the left border of the gel; lane 2, derivatized Q ⁇ VLP; lane 3, the supernatant of the coupling reaction of Q ⁇ capsid protein to the nef-N56 peptide; lane 4, the pellet of the coupling reaction of Q ⁇ capsid protein to the nef-N56 peptide.
- Coupling products co ⁇ esponding to the coupling of a peptide on a Q ⁇ monomer or Q ⁇ dimer are indicated by anows in the Figure.
- amino acid linker An "amino acid linker”, or also just termed “linker” within this specification, as used herein, either associates the antigen or antigenic determinant with the second attachment site, or more preferably, already comprises or contains the second attachment site, typically - but not necessarily - as one amino acid residue, preferably as a cysteine residue.
- amino acid linker does not intend to imply that such an amino acid linker consists exclusively of amino acid residues, even if an amino acid linker consisting of amino acid residues is a prefened embodiment of the present invention.
- amino acid residues of the amino acid linker are, preferably, composed of naturally occuring amino acids or unnatural amino acids known in the art, all-L or all-D or mixtures thereof.
- an amino acid linker comprising a molecule with a sulfhydryl group or cysteine residue is also encompassed within the invention.
- Such a molecule comprise preferably a C1-C6 alkyl-, cycloalkyl (C5,C6), aryl or heteroaryl moiety.
- a linker comprising preferably a C1-C6 alkyl-, cycloalkyl- (C5,C6), aryl- or heteroaryl- moiety and devoid of any amino acid(s) shall also be encompassed within the scope of the invention.
- Association between the antigen or antigenic determinant or optionally the second attachment site and the amino acid linker is preferably by way of at least one covalent bond, more preferably by way of at least one peptide bond.
- animal As used herein, the term “animal” is meant to include, for example, humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice, mammals, birds, reptiles, fish, insects and arachnids.
- Antibody refers to molecules which are capable of binding an epitope or antigenic determinant.
- the term is meant to include whole antibodies and antigen-binding fragments thereof, including single-chain antibodies.
- the antibodies are human antigen binding antibody fragments and include, but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain.
- the antibodies can be from any animal origin including birds and mammals.
- the antibodies are human, murine, rabbit, goat, guinea pig, camel, horse or chicken.
- human antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulins and that do not express endogenous immunoglobulins, as described, for example, in U.S. Patent No. 5,939,598 by Kucherlapati et al.
- Antigen refers to a molecule capable of being bound by an antibody or a T cell receptor (TCR) if presented by MHC molecules.
- TCR T cell receptor
- An antigen is additionally capable of being recognized by the immune system and/or being capable of inducing a humoral immune response and/or cellular immune response leading to the activation of B- and/or T-lymphocytes. This may, however, require that, at least in certain cases, the antigen contains or is linked to a T helper cell epitope (Th cell epitope) and is given in adjuvant.
- An antigen can have one or more epitopes (B- and T- epitopes).
- antigens as used herein may also be mixtures of several individual antigens.
- a "microbial antigen” as used herein is an antigen of a microorganism and includes, but is not limited to, infectious virus, infectious bacteria, parasites and infectious fungi. Such antigens include the intact microorganism as well as natural isolates and fragments or derivatives thereof and also synthetic or recombinant compounds which are identical to or similar to natural microorganism antigens and induce an immune response specific for that microorganism.
- a compound is similar to a natural microorganism antigen if it induces an immune response (humoral and/or cellular) to a natural microorganism antigen.
- Such antigens are used routinely in the art and are well known to the skilled artisan.
- Retroviridae e.g. human immunodeficiency viruses, such as HIV-1 (also refened to as HTLV-III, LAV or HTLV-III/LAV, or HIN-III); and other isolates, such as HIN-LP
- Picornaviridae e.g. polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses
- Calciviridae e.g. strains that cause gastroenteritis
- Togaviridae e.g. equine encephalitis viruses, rubella viruses
- Flaviridae e.g.
- Coronoviridae e.g. coronaviruses
- Rhabdoviradae e.g. vesicular stomatitis viruses, rabies viruses
- Filoviridae e.g. ebola viruses
- Paramyxoviridae e.g. parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus
- Orthomyxoviridae e.g. influenza viruses
- Bungaviridae e.g. Hantaan viruses, bunga viruses, phleboviruses and ⁇ airo viruses
- Arena viridae hemonhagic fever viruses
- Reoviridae e.g.
- reoviruses reoviruses, orbiviurses and rotaviruses
- Bimaviridae Hepadnaviridae (Hepatitis B virus); Parvovirida (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses);
- Adenoviridae most adenoviruses
- He ⁇ esviridae he ⁇ es simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), he ⁇ es virus
- Poxviridae variola viruses, vaccinia viruses, pox viruses
- Iridoviridae e.g. African swine fever virus
- unclassified viruses e.g.
- Both gram negative and gram positive bacteria serve as antigens in vertebrate animals.
- Such gram positive bacteria include, but are not limited to, Pasteurella species, Staphylococci species and Streptococcus species.
- Gram negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species.
- infectious bacteria include but are not limited to: Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria sps. (e.g. M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M.
- infectious fungi examples include: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis and Candida albicans.
- Other infectious organisms i.e., protists
- Plasmodium such as Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Toxoplasma gondii and Shistosoma.
- compositions and methods of the invention are also useful for treating cancer by stimulating an antigen-specific immune response against a cancer antigen.
- a "tumor antigen” as used herein is a compound, such as a peptide, associated with a tumor or cancer and which is capable of provoking an immune response.
- the compound is capable of provoking an immune response when presented in the context of an MHC molecule.
- Tumor antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells, for example, as described in Cohen, et al., Cancer Research, 54:1055 (1994), by partially purifying the antigens, by recombinant technology or by de novo synthesis of known antigens.
- Tumor antigens include antigens that are antigenic portions of or are a whole tumor or cancer polypeptide. Such antigens can be isolated or prepared recombinantly or by any other means known in the art.
- Cancers or tumors include, but are not limited to, biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma; neuroblastomas; oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; and renal cancer, as well as other carcinomas and sarcomas.
- Antigenic determinant As used herein, the term “antigenic determinant” is meant to refer to that portion of an antigen that is specifically recognized by either B- or T- lymphocytes. B-lymphocytes respond to foreign antigenic determinants via antibody production, whereas T-lymphocytes are the mediator of cellular immunity. Thus, antigenic determinants or epitopes are those parts of an antigen that are recognized by antibodies, or in the context of an MHC, by T-cell receptors.
- Antigen presenting cell As used herein, the term “antigen presenting cell” is meant to refer to a heterogenous population of leucocytes or bone manow derived cells which possess an immunostimulatory capacity.
- these cells are capable of generating peptides bound to MHC molecules that can be recognized by T cells.
- the term is synonymous with the term "accessory cell” and includes, for example, Langerhans' cells, interdigitating cells, B cells, macrophages and dendritic cells.
- accessory cell includes, for example, Langerhans' cells, interdigitating cells, B cells, macrophages and dendritic cells.
- epithelial cells, endothelial cells and other, non-bone manow derived cells may also serve as antigen presenting cells.
- association refers to the binding of the first and second attachment sites that is preferably by way of at least one non-peptide bond.
- the nature of the association may be covalent, ionic, hydrophobic, polar or any combination thereof, preferably the nature of the association is covalent, and again more preferably the association is through at least one, preferably one, non-peptide bond.
- association as it applies to the first and second attachment sites, not only encompass the direct binding or association of the first and second attachment site forming the compositions of the invention but also, alternatively and preferably, the indirect association or binding of the first and second attachment site leading to the compositions of the invention, and hereby typically and preferably by using a heterobifunctional cross-linker.
- first attachment site refers to an element of non-natural or natural origin, typically and preferably being comprised by the virus-like particle, to which the second attachment site typically and preferably being comprised by the antigen or antigenic determinant may associate.
- the first attachment site may be a protein, a polypeptide, an amino acid, a peptide, a sugar, a polynucleotide, a natural or synthetic polymer, a secondary metabolite or compound (biotin, fluorescein, retinol, digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combination thereof, or a chemically reactive group thereof.
- the first attachment site is located, typically and preferably on the surface, of the virus-like particle. Multiple first attachment sites are present on the surface of virus-like particle typically in a repetitive configuration.
- the first attachment site is a amino acid or a chemically reactive group thereof.
- second attachment site refers to an element associated with, typically and preferably being comprised by, the antigen or antigenic determinant to which the first attachment site located on the surface of the virus-like particle may associate.
- the second attachment site of the antigen or antigenic determinant may be a protein, a polypeptide, a peptide, a sugar, a polynucleotide, a natural or synthetic polymer, a secondary metabolite or compound (biotin, fluorescein, retinol, digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a combination thereof, or a chemically reactive group thereof.
- At least one second attachment site is present on the antigen or antigenic detenninant.
- the term "antigen or antigenic determinant with at least one second attachment site” refers, therefore, to an antigen or antigenic construct comprising at least the antigen or antigenic determinant and the second attachment site.
- these antigen or antigenic constructs comprise an "amino acid linker".
- bound refers to binding that may be covalent, e.g., by chemically coupling, or non-covalent, e.g., ionic interactions, hydrophobic interactions, hydrogen bonds, etc. Covalent bonds can be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like.
- bound is broader than and includes terms such as “coupled”, “fused”, “associatede” and “attached”.
- bound also includes the enclosement, or partial enclosement, of the immunostimulatory substance.
- the term "bound” is broader than and includes terms such as “coupled,” “fused,” “enclosed”, “packaged” and “attached.”
- the immunostimulatory substance such as the unmethylated CpG-containing oligonucleotide can be enclosed by the VLP without the existence of an actual binding, neither covalently nor non-covalently.
- Coat protein(s) As used herein, the term “coat protein(s)” refers to the protein(s) of a bacteriophage or a RNA-phage capable of being inco ⁇ orated within the capsid assembly of the bacteriophage or the RNA-phage.
- the term "CP” is used.
- the specific gene product of the coat protein gene of RNA-phage Q ⁇ is refe ⁇ ed to as "Q ⁇ CP”
- the "coat proteins” of bacteriophage Q ⁇ comprise the "Q ⁇ CP” as well as the Al protein.
- the capsid of Bacteriophage Q ⁇ is composed mainly of the Q ⁇ CP, with a minor content of the Al protein.
- the VLP Q ⁇ coat protein contains mainly Q ⁇ CP, with a minor content of Al protein. Coupled: As used herein, the term “coupled” refers to attachment by covalent bonds or by strong non-covalent interactions.
- Coupled preferably refers to attachment by covalent bonds.
- the term “coupled” preferably refers to association and attachment, respectively, by at least one non-peptide bond. Any method normally used by those skilled in the art for the coupling of biologically active materials can be used in the present invention.
- Fusion refers to the combination of amino acid sequences of different origin in one polypeptide chain by in-frame combination of their coding nucleotide sequences.
- the term “fusion” explicitly encompasses internal fusions, i.e., insertion of sequences of different origin within a polypeptide chain, in addition to fusion to one of its termini.
- CpG refers to an oligonucleotide which contains at least one unmethylated cytosine, guanine dinucleotide sequence (e.g. "CpG DNA” or DNA containing a cytosine followed by guanosine and linked by a phosphate bond) and stimulates/activates, e.g. has a mitogenic effect on, or induces or increases cytokine expression by, a vertebrate cell.
- CpGs can be useful in activating B cells, NK cells and antigen-presenting cells, such as monocytes, dendritic cells and macrophages, and T cells.
- the CpGs can include nucleotide analogs such as analogs containing phosphorothioester bonds and can be double-stranded or single-stranded. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity.
- Epitope refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human.
- An "immunogenic epitope,” as used herein, is defined as a portion of a polypeptide that elicits an antibody response or induces a T-cell response in an animal, as determined by any method known in the art. (See, for example, Geysen et al, Proc. Natl. Acad. Sci. USA 81:3998 4002 (1983)).
- antigenic epitope is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art. Immunospecific binding excludes non specific binding but does not necessarily exclude cross reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic. Antigenic epitopes can also be T-cell epitopes, in which case they can be bound immunospecifically by a T-cell receptor within the context of an MHC molecule.
- An epitope can comprise 3 amino acids in a spatial conformation which is unique to the epitope. Generally, an epitope consists of at least about 5 such amino acids, and more usually, consists of at least about 8-10 such amino acids. If the epitope is an organic molecule, it may be as small as Nitrophenyl.
- Immune response refers to a humoral immune response and/or cellular immune response leading to the activation or proliferation of B- and/or T-lymphocytes. In some instances, however, the immune responses may be of low intensity and become detectable only when using at least one substance in accordance with the invention.
- Immunogenic refers to an agent used to stimulate the immune system of a living organism, so that one or more functions of the immune system are increased and directed towards the immunogenic agent.
- An "immunogenic polypeptide” is a polypeptide that elicits a cellular and/or humoral immune response, whether alone or linked to a canier in the presence or absence of an adjuvant. Immunization: As used herein, the terms “immunize” or “immunization” or related terms refer to confe ⁇ ing the ability to mount a substantial immune response
- a mammal comprising antibodies or cellular immunity such as effector CTL
- a target antigen or epitope comprising antibodies or cellular immunity such as effector CTL
- tenns do not require that complete immunity be created, but rather that an immune response be produced which is substantially greater than baseline.
- a mammal may be considered to be immunized against a target antigen if the cellular and/or humoral immune response to the target antigen occurs following the application of methods of the invention.
- Immunostimulatory nucleic acid refers to a nucleic acid capable of inducing and/or enhancing an immune response.
- Immunostimulatory nucleic acids comprise ribonucleic acids and in particular deoxyribonucleic acids.
- immunostimulatory nucleic acids contain at least one CpG motif e.g. a CG dinucleotide in which the C is unmethylated.
- the CG dinucleotide can be part of a palindromic sequence or can be encompassed within a non-palindromic sequence.
- Immunostimulatory nucleic acids not containing CpG motifs as described above encompass, by way of example, nucleic acids lacking CpG dinucleotides, as well as nucleic acids containing CG motifs with a methylated CG dinucleotide.
- the term "immunostimulatory nucleic acid” as used herein should also refer to nucleic acids that contain modified bases such as 4-bromo-cytosine.
- Immunostimulatory substance As used herein, the term “immunostimulatory substance” refers to a substance capable of inducing and/or enhancing an immune response.
- Immunostimulatory substances include, but are not limited to, toll-like receptor activing substances and substances inducing cytokine secretion.
- Toll-like receptor activating substances include, but are not limited to, immunostimulatory nucleic acids, peptideoglycans, lipopolysaccharides, lipoteichonic acids, imidazoquinoline compounds, flagellins, lipoproteins, and immunostimulatory organic substances such as taxol.
- Natural origin As used herein, the term “natural origin” means that the whole or parts thereof are not synthetic and exist or are produced in nature. Non-natural: As used herein, the term generally means not from nature, more specifically, the term means from the hand of man.
- Non-natural origin As used herein, the term “non-natural origin” generally means synthetic or not from nature; more specifically, the term means from the hand of man.
- Ordered and repetitive antigen or antigenic determinant anay generally refers to a repeating pattern of antigen or antigenic determinant, characterized by a typically and preferably uniform spacial anangement of the antigens or antigenic determinants with respect to the core particle and virus-like particle, respectively.
- the repeating pattern may be a geometric pattern.
- Suitable ordered and repetitive antigen or antigenic determinant anays are those which possess strictly repetitive paracrystalline orders of antigens or antigenic determinants, preferably with spacings of 0.5 to 30 nanometers, more preferably 3 to 15 nanometers, even more preferably 3 to 8 nanometers.
- Oligonucleotide refers to a nucleic acid sequence comprising 2 or more nucleotides, generally at least about 6 nucleotides to about 100,000 nucleotides, preferably about 6 to about 2000 nucleotides, and more preferably about 6 to about 300 nucleotides, even more preferably about 20 to about 300 nucleotides, and even more preferably about 20 to about 100 nucleotides.
- oligonucleotide or “oligomer” also refer to a nucleic acid sequence comprising more than 100 to about 2000 nucleotides, preferably more than 100 to about 1000 nucleotides, and more preferably more than 100 to about 500 nucleotides.
- Oligonucleotide also generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Oligonucleotide includes, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double- stranded or a mixture of single- and double-stranded regions.
- oligonucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. Further, an oligonucleotide can be synthetic, genomic or recombinant, e.g., ⁇ - DNA, cosmid DNA, artificial bacterial chromosome, yeast artificial chromosome and filamentous phage such as Ml 3. In a very prefened embodiment of the present invention, the oligonucleotide is a synthetic oligonucleotide.
- oligonucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
- suitable nucleotide modifications/analogs include peptide nucleic acid, inosin, tritylated bases, phosphorothioates, alkylphosphorothioates, 5-nitroindole deoxyribofuranosyl, 5-methyldeoxycytosine and 5,6-dihydro-5,6- dihydroxydeoxythymidine.
- oligonucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. Other nucleotide analogs/modifications will be evident to those skilled in the art.
- the term "packaged” as used herein refers to the state of an immunostimulatory substance, preferably of an immunostimulatory nucleic acid in relation to the VLP.
- the term “packaged” as used herein includes binding that may be covalent, e.g., by chemically coupling, or non-covalent, e.g., ionic interactions, hydrophobic interactions, hydrogen bonds, etc. Covalent bonds can be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds such as thioether bonds, carbon-phosphorus bonds, and the like.
- the term also includes the enclosement, or partial enclosement, of a substance.
- the term “packaged” includes terms such as
- the immunostimulatory substance such as the unmethylated CpG-containing oligonucleotide can be enclosed by the VLP without the existence of an actual binding, neither covalently nor non-covalently.
- the term "packaged” indicates that the immunostimulatory nucleic acid in a packaged state is not accessible to DNAse or RNAse hydrolysis.
- the immunostimulatory nucleic acid is packaged inside the VLP capsids, most preferably in a non-covalent manner.
- compositions of the invention can be combined, optionally, with a phamiaceutically-acceptable carrier.
- pharmaceutically-acceptable carrier means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human or other animal.
- ca ⁇ ier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- Organic molecule As used herein, the term “organic molecule” refers to any chemical entity of natural or synthetic origin.
- organic molecule encompasses, for example, any molecule being a member of the group of nucleotides, lipids, carbohydrates, polysaccharides, lipopolysaccharides, steroids, alkaloids, te ⁇ enes and fatty acids, being either of natural or synthetic origin.
- organic molecule encompasses molecules such as nicotine, cocaine, heroin or other pharmacologically active molecules contained in drugs of abuse.
- an organic molecule contains or is modified to contain a chemical functionality allowing its coupling, binding or other method of attachment to the virus-like particle in accordance with the invention.
- Polypeptide refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). It indicates a molecular chain of amino acids and does not refer to a specific length of the product. Thus, peptides, oligopeptides and proteins are included within the definition of polypeptide. This term is also intended to refer to post-expression modifications of the polypeptide, for example, glycosolations, acetylations, phosphorylations, and the like. A recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence. It may also be generated in any manner, including chemical synthesis.
- a substance which "enhances" an immune response refers to a substance in which an immune response is observed that is greater or intensified or deviated in any way with the addition of the substance when compared to the same immune response measured without the addition of the substance.
- the lytic activity of cytotoxic T cells can be measured, e.g. using a 51Cr release assay, typically and preferably as outlined in Cu ⁇ ent Protocols in Immunology, Editors: John E. Coligan et al.; John Wiley & Sons Inc., with and without the substance.
- the amount of the substance at which the CTL lytic activity is enhanced as compared to the CTL lytic activity without the substance is said to be an amount sufficient to enhance the immune response of the animal to the antigen.
- the immune response in enhanced by a factor of at least about 2, more preferably by a factor of about 3 or more.
- the amount of cytokines secreted may also be altered.
- Effective Amount refers to an amount necessary or sufficient to realize a desired biologic effect.
- An effective amount of the composition would be the amount that achieves this selected result, and such an amount could be determined as a matter of routine by a person skilled in the art.
- an effective amount for treating an immune system deficiency could be that amount necessary to cause activation of the immune system, resulting in the development of an antigen specific immune response upon exposure to antigen.
- the term is also synonymous with "sufficient amount.”
- the effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular composition being administered, the size of the subject, and/or the severity of the disease or condition.
- One of ordinary skill in the art can empirically determine the effective amount of a particular composition of the present invention without necessitating undue experimentation.
- Self antigen refers to proteins encoded by the hos s genome or DNA and products generated by proteins or RNA encoded by the host's genome or DNA are defined as self.
- the tem “self antigen”, as used herein refers to proteins encoded by the human genome or DNA and products generated by proteins or RNA encoded by the human genome or DNA are defined as self.
- inventive compositions, pharmaceutical compositions and vaccines comprising self antigens are in particular capable of breaking tolerance against a self antigen when applied to the host.
- breaking tolerance against a self antigen shall refer to enhancing an immune response, as defined herein, and preferably enhancing a B or a T cell response, specific for the self antigen when applying the inventive compositions, pharmaceutical compositions and vaccines comprising the self antigen to the host.
- proteins that result from a combination of two or several self-molecules or that represent a fraction of a self-molecule and proteins that have a high homology two self- molecules as defined above may also be considered self.
- the antigen is a self antigen.
- Very prefened embodiments of self-antigens useful for the present invention are described WO 02/056905, the disclosures of which are herewith inco ⁇ orated by reference in its entirety.
- treatment refers to prophylaxis and/or therapy.
- the term refers to a prophylactic treatment which increases the resistance of a subject to infection with a pathogen or, in other words, decreases the likelihood that the subject will become infected with the pathogen or will show signs of illness attributable to the infection, as well as a treatment after the subject has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.
- the term "vaccine” refers to a formulation which contains the composition of the present invention and which is in a form that is capable of being administered to an animal.
- the vaccine comprises a conventional saline or buffered aqueous solution medium in which the composition of the present invention is suspended or dissolved.
- the composition of the present invention can be used conveniently to prevent, ameliorate, or otherwise treat a condition.
- the vaccine Upon introduction into a host, the vaccine is able to provoke an immune response including, but not limited to, the production of antibodies, cytokines and/or the activation of cytotoxic T cells, antigen presenting cells, helper T cells, dendritic cells and/or other cellular responses.
- the vaccine of the present invention additionally includes an adjuvant which can be present in either a minor or major proportion relative to the compound of the present invention.
- adjuvant refers to non-specific stimulators of the immune response or substances that allow generation of a depot in the host which when combined with the vaccine of the present invention provide for an even more enhanced immune response.
- adjuvants can be used. Examples include incomplete Freund's adjuvant, aluminum hydroxide and modified muramyldipeptide.
- adjuvant as used herein also refers to typically specific stimulators of the immune response which when combined with the vaccine of the present invention provide for an even more enhanced and typically specific immune response. Examples include, but limited to, GM-CSF, IL-2, IL-12, IFN ⁇ . Further examples are within the knowledge of the person skilled in the art.
- virus-like particle refers to a structure resembling a virus particle but which has not been demonstrated to be pathogenic.
- a virus-like particle in accordance with the invention does not cany genetic information encoding for the proteins of the virus-like particle.
- viruslike particles lack the viral genome and, therefore, are noninfectious.
- virus-like particles can often be produced in large quantities by heterologous expression and can be easily purified.
- Some virus-like particles may contain nucleic acid distinct from their genome.
- a virus-like particle in accordance with the invention is non replicative and noninfectious since it lacks all or part of the viral genome, in particular the replicative and infectious components of the viral genome.
- a virus-like particle in accordance with the invention may contain nucleic acid distinct from their genome.
- a typical and prefened embodiment of a virus-like particle in accordance with the present invention is a viral capsid such as the viral capsid of the conesponding virus, bacteriophage, or RNA-phage.
- viral capsid or “capsid”, as interchangeably used herein, refer to a macromolecular assembly composed of viral protein subunits. Typically and preferably, the viral protein subunits assemble into a viral capsid and capsid, respectively, having a structure with an inherent repetitive organization, wherein said structure is, typically, spherical or tubular.
- capsids of RNA-phages or HBcAg's have a spherical form of icosahedral symmetry.
- capsid-like structure refers to a macromolecular assembly composed of viral protein subunits reproducing the capsid mo ⁇ hology in the above defined sense but deviating from the typical symmetrical assembly while maintaining a sufficient degree of order and repetitiveness.
- virus-like particle of a bacteriophage refers to a virus-like particle resembling the structure of a bacteriophage, being non replicative and noninfectious, and lacking at least the gene or genes encoding for the replication machinery of the bacteriophage, and typically also lacking the gene or genes encoding the protein or proteins responsible for viral attachment to or entry into the host.
- This definition should, however, also encompass virus-like particles of bacteriophages, in which the aforementioned gene or genes are still present but inactive, and, therefore, also leading to non-replicative and noninfectious virus-like particles of a bacteriophage.
- VLP of RNA phage coat protein The capsid structure formed from the self- assembly of 180 subunits of RNA phage coat protein and optionally containing host RNA is refe ⁇ ed to as a "VLP of RNA phage coat protein".
- VLP of RNA phage coat protein A specific example is the VLP of Q ⁇ coat protein.
- the VLP of Q ⁇ coat protein may either be assembled exclusively from Q ⁇ CP subunits (SEQ ID: No 10) generated by expression of a Q ⁇ CP gene containing, for example, a TAA stop codon precluding any expression of the longer Al protein through suppression, see Kozlovska, T.M., et al., Intervirology 39: 9-15 (1996)), or additionally contain Al protein subunits (SEQ ID: No 11) in the capsid assembly.
- the readthrough process has a low efficiency and is leading to an only very low amount of Al protein in the VLPs. An extensive number of examples have been performed with different combinations of ISS packaged and antigen coupled.
- virus particle refers to the mo ⁇ hological form of a virus. In some virus types it comprises a genome sunounded by a protein capsid; others have additional structures (e.g., envelopes, tails, etc.). Non-enveloped viral particles are made up of a proteinaceous capsid that surrounds and protects the viral genome. Enveloped viruses also have a capsid structure su ⁇ ounding the genetic material of the virus but, in addition, have a lipid bilayer envelope that surrounds the capsid. In a prefened embodiment of the invention, the VLP's are free of a lipoprotein envelope or a lipoprotein-containing envelope. In a further prefe ⁇ ed embodiment, the VLP's are free of an envelope altogether.
- certain embodiments of the invention involve the use of recombinant nucleic acid technologies such as cloning, polymerase chain reaction, the purification of DNA and RNA, the expression of recombinant proteins in prokaryotic and eukaryotic cells, etc.
- recombinant nucleic acid technologies such as cloning, polymerase chain reaction, the purification of DNA and RNA, the expression of recombinant proteins in prokaryotic and eukaryotic cells, etc.
- Such methodologies are well known to those skilled in the art and can be conveniently found in published laboratory methods manuals (e.g., Sambrook, J. et al., eds., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel, F.
- compositions of the invention comprise, or alternatively consist essentially of, or alternatively consist of, a virus-like particle and at least one immunostimulatory substance, wherein the immunostimulatory substance is bound to said virus-like particle, and wherein the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein said palindromic sequence is flanked at its 3'- terminus and at its 5'-terminus by less than 10 guanosine entities.
- the invention conveniently enables the practitioner to construct such a composition for various treatment and/or prophylactic prevention pu ⁇ oses, which include the prevention and/or treatment of infectious diseases, as well as chronic infectious diseases, and the prevention and/or treatment of cancers, for example.
- virus-like particles in the context of the present application refer to structures resembling a virus particle but which are not pathogenic. In general, virus-like particles lack the viral genome and, therefore, are noninfectious. Also, virus-like particles can be produced in large quantities by heterologous expression and can be easily purified. In a preferred embodiment, the virus-like particle is a recombinant virus-like particle. The skilled artisan can produce VLPs using recombinant DNA technology and virus coding sequences which are readily available to the public.
- the coding sequence of a virus envelope or core protein can be engineered for expression in a baculovirus expression vector using a commercially available baculovirus vector, under the regulatory control of a virus promoter, with appropriate modifications of the sequence to allow functional linkage of the coding sequence to the regulatory sequence.
- the coding sequence of a virus envelope or core protein can also be engineered for expression in a bacterial expression vector, for example.
- VLPs include, but are not limited to, the capsid proteins of Hepatitis
- the VLP of the invention is not limited to any specific form.
- the particle can be synthesized chemically or through a biological process, which can be natural or non-natural.
- this type of embodiment includes a virus-like particle or a recombinant form thereof.
- the VLP can comprise, or alternatively consist of, recombinant polypeptides of Rotavirus; recombinant polypeptides of Norwalk virus; recombinant polypeptides of Alphavirus; recombinant proteins which form bacterial pili or pilus like structures; recombinant polypeptides of Foot and Mouth Disease virus; recombinant polypeptides of measles virus, recombinant polypeptides of Sindbis virus, recombinant polypeptides of Retrovirus; recombinant polypeptides of Hepatitis B virus (e.g., a HBcAg); recombinant polypeptides of Tobacco mosaic virus; recombinant polypeptides of Flock House Virus; recombinant polypeptides of human Papillomavirus; recombinant polypeptides of Polyoma virus and, in particular, recombinant polypeptides of human Polyoma
- the virus-like particle can further comprise, or alternatively consist of, one or more fragments of such polypeptides, as well as variants of such polypeptides.
- Variants of polypeptides can share, for example, at least 80%, 85%, 90%, 95%, 97%, or 99% identity at the amino acid level with their wild type counte ⁇ arts.
- the virus-like particle comprises, consists essentially of, or alternatively consists of recombinant proteins, or fragments thereof, of a RNA- phage.
- the RNA-phage is selected from the group consisting of a) bacteriophage Q ⁇ ; b) bacteriophage R17; c) bacteriophage fr; d) bacteriophage GA; e) bacteriophage SP; f) bacteriophage MS2; g) bacteriophage Mi l; h) bacteriophage MX1; i) bacteriophage NL95; k) bacteriophage f2; 1) bacteriophage PP7; and m) bacteriophage AP205.
- the virus-like particle comprises, or alternatively consists essentially of, or alternatively consists of recombinant proteins, or fragments thereof, of the RNA-bacteriophage Q ⁇ or of the RNA- bacteriophage fr or of the RNA-bacteriophage AP205.
- the recombinant proteins comprise, or alternatively consist essentially of, or alternatively consist of coat proteins of RNA phages.
- RNA-phage coat proteins forming capsids or VLPs, or fragments of the bacteriophage coat proteins compatible with self-assembly into a capsid or a VLP are, therefore, further prefened embodiments of the present invention.
- Bacteriophage Q ⁇ coat proteins for example, can be expressed recombinantly in E. coli. Further, upon such expression these proteins spontaneously form capsids. Additionally, these capsids form a structure with an inherent repetitive organization.
- Specific prefened examples of bacteriophage coat proteins which can be used to prepare compositions of the invention include the coat proteins of RNA bacteriophages such as bacteriophage Q ⁇ (SEQ ID NO: 10; PIR Database, Accession No.
- bacteriophage MXl GenBank Accession No. AAC 14699
- bacteriophage NL95 GenBank Accession No. AAC14704
- bacteriophage f2 GenBank Accession No. P03611
- bacteriophage PP7 SEQ ID NO: 22
- bacteriophage AP205 SEQ ID NO: 31.
- Al protein of bacteriophage Q ⁇ or C-terminal truncated forms missing as much as 100, 150 or 180 amino acids from its C-terminus may be inco ⁇ orated in a capsid assembly of Q ⁇ coat proteins.
- the percentage of Q ⁇ Al protein relative to Q ⁇ CP in the capsid assembly will be limited, in order to ensure capsid formation.
- Further specific examples of bacteriophage coat proteins are described in WO 02/056905 on page 45 and 46 inco ⁇ orated herein by reference.
- Further preferred virus-like particles of RNA-phages, in particular of Q ⁇ in accordance of this invention are disclosed in WO 02/056905, the disclosure of which is herewith inco ⁇ orated by reference in its entirety.
- the virus-like particle comprises, or alternatively consists essentially of, or alternatively consists of recombinant proteins, or fragments thereof, of a RNA-phage, wherein the recombinant proteins comprise, consist essentially of or alternatively consist of mutant coat proteins of a RNA phage, preferably of mutant coat proteins of the RNA phages mentioned above.
- the mutant coat proteins of the RNA phage have been modified by removal of at least one lysine residue by way of substitution, or by addition of at least one lysine residue by way of substitution; altematively, the mutant coat proteins of the RNA phage have been modified by deletion of at least one lysine residue, or by addition of at least one lysine residue by way of insertion.
- the deletion, substitution or addition of at least one lysine residue allows varying the degree of coupling, i.e. the amount of antigens per subunits of the VLP of the RNA-phages, in particular, to match and tailor the requirements of the vaccine.
- At least 1.0 antigen peptide per subunit are linked to the VLP of the RNA-phage. This value is calculated as an average over all the subunits or monomers of the VLP of the RNA-phage.
- at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or at least 2.0 antigen polypeptides are linked to the VLP of the RNA-phages as being calculated as a coupling average over all the subunits or monomers of the VLP of the RNA-phage.
- the virus-like particle comprises, or alternatively consists essentially of, or alternatively consists of recombinant proteins, or fragments thereof, of the RNA-bacteriophage Q ⁇ , wherein the recombinant proteins comprise, or alternatively consist essentially of, or alternatively consist of coat proteins having an amino acid sequence of SEQ ID NO: 10, or a mixture of coat proteins having amino acid sequences of SEQ ID NO: 10 and of SEQ ID NO: 11 or mutants of SEQ ID NO: 11 and wherein the N-terminal methionine is preferably cleaved.
- the virus-like particle comprises, consists essentially of or alternatively consists of recombinant proteins of Q ⁇ , or fragments thereof, wherein the recombinant proteins comprise, or alternatively consist essentially of, or alternatively consist of mutant Q ⁇ coat proteins.
- these mutant coat proteins have been modified by removal of at least one lysine residue by way of substitution, or by addition of at least one lysine residue by way of substitution.
- these mutant coat proteins have been modified by deletion of at least one lysine residue, or by addition of at least one lysine residue by way of insertion.
- Q ⁇ mutants for which exposed lysine residues are replaced by arginines can also be used for the present invention.
- the following Q ⁇ coat protein mutants and mutant Q ⁇ VLPs can, thus, be used in the practice of the invention: "Q ⁇ -240" (Lysl3-Arg; SEQ ID NO:20), "Q ⁇ -243" (Asn 10-Lys; SEQ ID NO:21), "Q ⁇ -250” (Lys 2-Arg, Lysl3-Arg; SEQ ID NO:22), “Q ⁇ -251” (SEQ ID NO:23) and "Q ⁇ -259” (Lys 2-Arg, Lysl6-Arg; SEQ ID NO:24).
- the virus-like particle comprises, consists essentially of or alternatively consists of recombinant proteins of mutant Q ⁇ coat proteins, which comprise proteins having an amino acid sequence selected from the group of a) the amino acid sequence of SEQ ID NO: 20; b) the amino acid sequence of SEQ ID NO:21; c) the amino acid sequence of SEQ ID NO: 22; d) the amino acid sequence of SEQ ID NO:23; and e) the amino acid sequence of SEQ ID NO: 24.
- mutant Q ⁇ coat protein VLPs and capsids are disclosed in WO02/056905. In particular is hereby refened to Example 18 of above mentioned application.
- the virus-like particle comprises, or alternatively consists essentially of, or alternatively consists of recombinant proteins of Q ⁇ , or fragments thereof, wherein the recombinant proteins comprise, consist • essentially of or alternatively consist of a mixture of either one of the foregoing Q ⁇ mutants and the conesponding Al protein.
- the virus-like particle comprises, or alternatively essentially consists of, or alternatively consists of recombinant proteins, or fragments thereof, of RNA-phage AP205.
- the AP205 genome consists of a maturation protein, a coat protein, a replicase and two open reading frames not present in related phages; a lysis gene and an open reading frame playing a role in the translation of the maturation gene (Klovins ., et al., J. Gen. Virol. 83: 1523-33 (2002)).
- AP205 coat protein can be expressed from plasmid pAP283- 58 (SEQ ID NO: 30), which is a derivative of pQblO (Kozlovska, T. M. et al., Gene
- Vectors pQblO and pQbl85 are vectors derived from pGEM vector, and expression of the cloned genes in these vectors is controlled by the tip promoter (Kozlovska, T. M. et al., Gene 137:133-37 (1993)).
- Plasmid pAP283-58 (SEQ ID NO:30) comprises a putative AP205 ribosomal binding site in the following sequence, which is downstream of the Xbal site, and immediately upstream of the ATG start codon of the AP205 coat protein: tctagaATTTTCTGCGCACCCAT
- the vector pQbl85 comprises a Shine Delagamo sequence downstream from the Xbal site and upstream of the start codon (tctagaTTAACCCAACGCGTAGGAGTCAGGCCatg (SEQ ID NO: 46), Shine Delagarno sequence underlined).
- the virus-like particle comprises, or alternatively essentially consists of, or alternatively consists of recombinant coat proteins, or fragments thereof, of the RNA-phage AP205.
- This preferred embodiment of the present invention thus, comprises AP205 coat proteins that form capsids.
- Such proteins are recombinantly expressed, or prepared from natural sources.
- AP205 coat proteins produced in bacteria spontaneously form capsids, as evidenced by Electron Microscopy (EM) and immunodiffusion.
- the structural properties of the capsid formed by the AP205 coat protein (SEQ ID NO: 31) and those formed by the coat protein of the AP205 RNA phage are nearly indistinguishable when seen in EM.
- AP205 VLPs are highly immunogenic, and can be linked with antigens and/or antigenic determinants to generate vaccine constructs displaying the antigens and/or antigenic determinants oriented in a repetitive manner. High titers are elicited against the so displayed antigens showing that bound antigens and/or antigenic determinants are accessible for interacting with antibody molecules and are immunogenic.
- the virus-like particle comprises, or alternatively essentially consists of, or alternatively consists of recombinant mutant coat proteins, or fragments thereof, of the RNA-phage AP205.
- Assembly-competent mutant forms of AP205 VLPs including AP205 coat protein with the subsitution of proline at amino acid 5 to threonine (SEQ ID NO: 32), may also be used in the practice of the invention and leads to a further prefened embodiment of the invention.
- These VLPs, AP205 VLPs derived from natural sources, or AP205 viral particles may be bound to antigens to produce ordered repetitive arrays of the antigens in accordance with the present invention.
- AP205 P5-T mutant coat protein can be expressed from plasmid pAP281-32 (SEQ ID No. 33), which is derived directly from pQbl85, and which contains the mutant AP205 coat protein gene instead of the Q ⁇ coat protein gene.
- Vectors for expression of the AP205 coat protein are transfected into E. coli for expression of the AP205 coat protein. Methods for expression of the coat protein and the mutant coat protein, respectively, leading to self-assembly into VLPs are described in WO 04/007538 which is inco ⁇ orated by reference in its entirety.
- Suitable E. coli strains include, but are not limited to, E. coli K802, JM 109, RR1.
- Suitable vectors and strains and combinations thereof can be identified by testing expression of the coat protein and mutant coat protein, respectively, by SDS-PAGE and capsid formation and assembly by optionally first purifying the capsids by gel filtration and subsequently testing them in an immunodiffusion assay (Ouchterlony test) or Electron Microscopy (Kozlovska, T. M. et al, Gene 137:133-37 (1993)).
- AP205 coat proteins expressed from the vectors pAP283-58 and pAP281-32 may be devoid of the initial Methionine amino-acid, due to processing in the cytoplasm of E. coli. Cleaved, uncleaved forms of AP205 VLP, or mixtures thereof are further preferred embodiments of the invention.
- the virus-like particle comprises, or alternatively essentially consists of, or alternatively consists of a mixture of recombinant coat proteins, or fragments thereof, of the RNA-phage AP205 and of recombinant mutant coat proteins, or fragments thereof, of the RNA-phage AP205.
- the virus-like particle comprises, or alternatively essentially consists of, or alternatively consists of fragments of recombinant coat proteins or recombinant mutant coat proteins of the RNA-phage AP205.
- Recombinant AP205 coat protein fragments capable of assembling into a VLP and a capsid, respectively are also useful in the practice of the invention. These fragments may be generated by deletion, either internally or at the termini of the coat protein and mutant coat protein, respectively. Insertions in the coat protein and mutant coat protein sequence or fusions of antigen sequences to the coat protein and mutant coat protein sequence, and compatible with assembly into a VLP, are further embodiments of the invention and lead to chimeric AP205 coat proteins, and particles, respectively. The outcome of insertions, deletions and fusions to the coat protein sequence and whether it is compatible with assembly into a VLP can be determined by electron microscopy.
- the particles formed by the AP205 coat protein, coat protein fragments and chimeric coat proteins described above can be isolated in pure form by a combination of fractionation steps by precipitation and of purification steps by gel filtration using e.g. Sepharose CL-4B, Sepharose CL-2B, Sepharose CL-6B columns and combinations thereof as described in WO 04/007538 which is inco ⁇ orated by reference in its entirety.
- Other methods of isolating virus-like particles are known in the art, and may be used to isolate the virus-like particles (VLPs) of bacteriophage AP205.
- VLPs virus-like particles
- the use of ultracentrifugation to isolate VLPs of the yeast retrotransposon Ty is described in U.S. Patent No. 4,918,166, which is inco ⁇ orated by reference herein in its entirety.
- RNA bacteriophages The crystal structure of several RNA bacteriophages has been determined (Golmohammadi, R. et al, Structure 4:543-554 (1996)). Using such information, one skilled in the art could readily identify surface exposed residues and modify bacteriophage coat proteins such that one or more reactive amino acid residues can be inserted. Thus, one skilled in the art could readily generate and identify modified fom s of bacteriophage coat proteins which can be used in the practice of the invention.
- variants of proteins which form capsids or capsid-like structures can also be used for the inventive compositions and vaccine compositions.
- modified RNA bacteriophages as well as variants of proteins and N- and C terminal truncation mutants which form capsids or capsid like structures, as well as methods for preparing such compositions and vaccine compositions, respectively, which are suitable for use in the present invention are described in WO 02/056905 on page 50, line 33 to page 52, line 29.
- the invention thus includes compositions and vaccine compositions prepared from proteins which form capsids or VLPs, methods for preparing these compositions from individual protein subunits and VLPs or capsids, methods for preparing these individual protein subunits, nucleic acid molecules which encode these subunits, and methods for vaccinating and/or eliciting immunological responses in individuals using these compositions of the present invention.
- the VLP's are free of a lipoprotein envelope or a lipoprotein-containing envelope. In a further prefened embodiment, the VLP's are free of an envelope altogether.
- the lack of a lipoprotein envelope or lipoprotein-containing envelope and, in particular, the complete lack of an envelope leads to a more defined virus-like particle in its structure and composition. Such more defined virus-like particles, therefore, may minimize side-effects.
- the lack of a lipoprotein-containing envelope or, in particular, the complete lack of an envelope avoids or minimizes inco ⁇ oration of potentially toxic molecules and pyrogens within the virus-like particle.
- the invention provides a vaccine composition of the invention comprising a virus-like particle, wherein preferably said virus-like particle is a recombinant virus-like particle.
- the virus-like particle comprises, or alternatively consist essentially of, or alternatively consists of, recombinant proteins, or fragments thereof, of a RNA-phage, preferably of coat proteins of RNA phages.
- the recombinant proteins of the virus-like particle of the vaccine composition of the invention comprise, or alternatively consist essentially of, or alternatively consist of mutant coat proteins of RNA phages, wherein the RNA-phage is selected from the group consisting of: (a) bacteriophage Q ⁇ ; (b) bacteriophage R17; (c) bacteriophage fr; (d) bacteriophage GA; (e) bacteriophage SP; (f) bacteriophage MS2; (g) bacteriophage Ml 1; (h) bacteriophage MXl; (i) bacteriophage NL95; (k) bacteriophage f2; (1) bacteriophage PP7; and (m) bacteriophage AP205.
- the mutant coat proteins of said RNA phage have been modified by removal, or by addition of at least one lysine residue by way of substitution.
- the mutant coat proteins of said RNA phage have been modified by deletion of at least one lysine residue or by addition of at least one lysine residue by way of insertion.
- the virus-like particle comprises recombinant proteins or fragments thereof, of RNA-phage Q ⁇ or alternatively of RNA- phage fr, or of RNA-phage AP205.
- the invention includes virus-like particles or recombinant forms thereof. Skilled artisans have the knowledge to produce such particles and attach antigens thereto. Further prefe ⁇ ed embodiments of the present invention hereto are disclosed in the Example Section.
- the virus-like particle comprises, or alternatively consists essentially of, or alternatively consists of recombinant proteins, or fragments thereof, of the BK virus (BKV), wherein the recombinant proteins comprise, or alternatively consist essentially of, or alternatively consist of proteins having an amino acid sequence of SEQ ID NO: 12.
- BK virus (BKV) is a non-enveloped double stranded DNA virus belonging to the polyoma virus subfamily of the papovaviridae.
- VP1 is the major capsid protein of BKV.
- VP1 has 362 amino acids (SEQ ID NO: 12, Gene Bank entry: AAA46882) and is 42 kDa in size.
- capsid structures (Salunke D.M., et al., Cell 46(6):895-904 (1986); Sasnauskas, K., et al., Biol. Chem. 380(3):381-6 (1999); Sasnauskas, K., et al., 3rd International Workshop "Virus-like particles as vaccines” Berlin, September 26-29 (2001); Touze, A., et al., J Gen Virol. 82(Pt 12):3005-9 (2001).
- the capsid is organized in 72 VP1 pentamers forming an icosahedral structure.
- the capsids have a diameter of approximately 45 nm.
- the particles used in compositions of the invention are composed of a Hepatitis B capsid (core) protein (HBcAg) or a fragment of a HBcAg which has been modified to either eliminate or reduce the number of free cysteine residues.
- core particles suitable for use in compositions of the invention include those comprising modified HBcAgs, or fragments thereof, in which one or more of the naturally resident cysteine residues have been either deleted or substituted with another amino acid residue (e.g., a serine residue).
- the HBcAg is a protein generated by the processing of a Hepatitis B core antigen precursor protein.
- a number of isotypes of the HBcAg have been identified and their amino acids sequences are readily available to those skilled in the art.
- the HBcAg protein having the amino acid sequence shown in SEQ ID NO: 16 is 185 amino acids in length and is generated by the processing of a 212 amino acid Hepatitis B core antigen precursor protein. This processing results in the removal of 29 amino acids from the N terminus of the Hepatitis B core antigen precursor protein.
- the HBcAg protein that is 185 amino acids in length is generated by the processing of a 214 amino acid Hepatitis B core antigen precursor protein.
- vaccine compositions of the invention will be prepared using the processed form of a HBcAg (i.e., a HBcAg from which the N terminal leader sequence of the Hepatitis B core antigen precursor protein have been removed).
- the HBcAgs when HBcAgs are produced under conditions where processing will not occur, the HBcAgs will generally be expressed in "processed" form.
- bacterial systems such as E. coli, generally do not remove the leader sequences, also refened to as "signal peptides," of proteins which are normally expressed in eukaryotic cells.
- signal peptides proteins which are normally expressed in eukaryotic cells.
- these proteins will generally be expressed such that the N terminal leader sequence of the Hepatitis B core antigen precursor protein is not present.
- Hepatitis B virus-like particles which can be used for the present invention, is disclosed, for example, in WO 00/32227, and hereby in particular in Examples 17 to 19 and 21 to 24, as well as in WO 01/85208, and hereby in particular in Examples 17 to 19, 21 to 24, 31 and 41, and in WO 02/056905. For the latter application, it is in particular refened to Example 23, 24, 31 and 51. All three documents are explicitly inco ⁇ orated herein by reference.
- the present invention also includes HBcAg variants which have been modified to delete or substitute one or more additional cysteine residues.
- the vaccine compositions of the invention include compositions comprising HBcAgs in which cysteine residues not present in the amino acid sequence shown in SEQ ID NO: 16 have been deleted.
- side reactions include disulfide exchanges, reaction with chemical substances or metabolites that are, for example, injected or formed in a combination therapy with other substances, or direct oxidation and reaction with nucleotides upon exposure to UV light.
- Toxic adducts could thus be generated, especially considering the fact that HBcAgs have a strong tendency to bind nucleic acids.
- the toxic adducts would thus be distributed between a multiplicity of species, which individually may each be present at low concentration, but reach toxic levels when together.
- HBcAgs in vaccine compositions which have been modified to remove naturally resident cysteine residues is that sites to which toxic species can bind when antigens or antigenic determinants are attached would be reduced in number or eliminated altogether.
- HBcAg variants suitable for use in the practice of the present invention have been identified. Yuan et al., (J. Virol. 73:10122 10128 (1999)), for example, describe variants in which the isoleucine residue at position co ⁇ esponding to position 97 in SEQ ID NO:25 is replaced with either a leucine residue or a phenylalanine residue.
- HBcAg variants differ in amino acid sequence at a number of positions, including amino acid residues which conesponds to the amino acid residues located at positions 12, 13, 21, 22, 24, 29, 32, 33, 35, 38, 40, 42, 44, 45, 49, 51, 57, 58, 59, 64, 66, 67, 69, 74, 77, 80, 81, 87, 92, 93, 97, 98, 100, 103, 105, 106, 109, 113, 116, 121, 126, 130, 133, 135, 141, 147, 149, 157, 176, 178, 182 and 183 in SEQ ID NO: 28.
- HBcAgs suitable for use in the present invention can be derived from any organism so long as they are able to enclose or to be coupled or otherwise attached to, in particular as long as they are capable of packaging, an unmethylated CpG-containing oligonucleotide and induce an immune response.
- HBcAgs As noted above, generally processed HBcAgs (i.e., those which lack leader sequences) will be used in the vaccine compositions of the invention.
- the present invention includes vaccine compositions, as well as methods for using these compositions, which employ the above described variant HBcAgs. Further included within the scope of the invention are additional HBcAg variants which are capable of associating to form dimeric or multimeric structures.
- the invention further includes vaccine compositions comprising HBcAg polypeptides comprising, or alternatively consisting of, amino acid sequences which are at least 80%, 85%>, 90%, 95%, 97% or 99% identical to any of the wild-type amino acid sequences, and forms of these proteins which have been processed, where appropriate, to remove the N terminal leader sequence.
- the amino acid sequence of a polypeptide has an amino acid sequence that is at least 80%, 85%, 90%, 95%, 97% or 99% identical to one of the wild-type amino acid sequences, or a subportion thereof, can be determined conventionally using known computer programs such the Bestfit program.
- Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference amino acid sequence, the parameters are set such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.
- HBcAg variants and precursors are relatively similar to each other.
- reference to an amino acid residue of a HBcAg variant located at a position which conesponds to a particular position in SEQ ID NO:28 refers to the amino acid residue which is present at that position in the amino acid sequence shown in SEQ ID NO:28.
- the homology between these HBcAg variants is for the most part high enough among Hepatitis B viruses that infect mammals so that one skilled in the art would have little difficulty reviewing both the amino acid sequence shown in SEQ ID NO:28 and in SEQ ID NO: 16, respectively, and that of a particular HBcAg variant and identifying "conesponding" amino acid residues.
- the HBcAg amino acid sequence shown in SEQ ID NO:27 which shows the amino acid sequence of a HBcAg derived from a virus which infect woodchucks, has enough homology to the HBcAg having the amino acid sequence shown in SEQ ID NO:28 that it is readily apparent that a three amino acid residue insert is present in SEQ ID NO:27 between amino acid residues 155 and 156 of SEQ ID NO:28.
- the invention also includes vaccine compositions which comprise HBcAg variants of Hepatitis B viruses which infect birds, as wells as vaccine compositions which comprise fragments of these HBcAg variants.
- vaccine compositions which comprise HBcAg variants of Hepatitis B viruses which infect birds, as wells as vaccine compositions which comprise fragments of these HBcAg variants.
- cysteine residues naturally present in these polypeptides could be either substituted with another amino acid residue or deleted prior to their inclusion in vaccine compositions of the invention.
- cysteine residues of the Hepatitis B virus capsid protein have been either deleted or substituted with another amino acid residue.
- Expression and purification of an HBcAg- Lys variant has been described in Example 24 of WO 02/056905 and the construction of a HBcAg devoid of free cysteine residues and containing an inserted lysine residue has been described in Example 31 of WO 02/056905.
- compositions and vaccine compositions, respectively, of the invention will contain HBcAgs from which the C terminal region (e.g., amino acid residues 145 185 or 150 185 of SEQ ID NO: 28) has been removed.
- additional modified HBcAgs suitable for use in the practice of the present invention include C terminal truncation mutants. Suitable truncation mutants include HBcAgs where 1, 5, 10, 15, 20, 25, 30, 34, 35, amino acids have been removed from the C terminus.
- HBcAgs suitable for use in the practice of the present invention also include N terminal truncation mutants. Suitable truncation mutants include modified HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from the N terminus.
- HBcAgs suitable for use in the practice of the present invention include N and C terminal truncation mutants.
- Suitable truncation mutants include HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, and 17 amino acids have been removed from the N terminus and 1, 5, 10, 15, 20, 25, 30, 34, 35 amino acids have been removed from the C terminus.
- compositions and vaccine compositions comprising HBcAg polypeptides comprising, or alternatively essentially consisting of, or alternatively consisting of, amino acid sequences which are at least 80%, 85%, 90%), 95%, 97%, or 99% identical to the above described truncation mutants.
- a lysine residue is introduced into a HBcAg polypeptide, to mediate the binding of the antigen or antigenic determinant to the VLP of HBcAg.
- compositions of the invention are prepared using a HBcAg comprising, or alternatively consisting of, amino acids 1-144, or 1-149, 1- 185 of SEQ ID NO:28, which is modified so that the amino acids conesponding to positions 79 and 80 are replaced with a peptide having the amino acid sequence of Gly- Gly-Lys-Gly-Gly (SEQ ID NO: 18) resulting in the HBcAg polypeptide having the sequence shown in SEQ ID NO:29).
- SEQ ID NO: 18 amino acid sequence of Gly- Gly-Lys-Gly-Gly
- the cysteine residues at positions 48 and 107 of SEQ ID NO:28 are mutated to serine.
- the invention further includes compositions comprising the conesponding polypeptides having amino acid sequences shown in any of the hereinabove mentioned Hepatitis B core antigen precursor variants which also have above noted amino acid alterations. Further included within the scope of the invention are additional HBcAg variants which are capable of associating to form a capsid or VLP and have the above noted amino acid alterations.
- compositions and vaccine compositions respectively, comprising HBcAg polypeptides which comprise, or alternatively consist of, amino acid sequences which are at least 80%, 85%), 90%), 95%», 91% or 99%) identical to any of the wild-type amino acid sequences, and forms of these proteins which have been processed, where appropriate, to remove the N terminal leader sequence and modified with above noted alterations.
- compositions or vaccine compositions of the invention may comprise mixtures of different HBcAgs.
- these vaccine compositions may be composed of HBcAgs which differ in amino acid sequence.
- vaccine compositions could be prepared comprising a "wild type" HBcAg and a modified HBcAg in which one or more amino acid residues have been altered (e.g., deleted, inserted or substituted).
- prefened vaccine compositions of the invention are those which present highly ordered and repetitive antigen anays.
- the invention is based on the su ⁇ rising finding that immunostimulatory substances, and herein in particular specific DNA-oligonucleotides containing CpG motifs, can be packaged into VLPs.
- the nucleic acids present in VLPs can be replaced specifically by the specific DNA-oligonucleotides containing CpG motifs.
- the specific CpG-VLPs are more immunogenic and elicit more specific effects than their CpG-free counte ⁇ arts and induce enhanced B and T cell responses.
- the immune response against antigens coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself.
- the T cell responses against both the VLPs and antigens are especially directed to the Thl type.
- the packaged nucleic acids and CpGs, respectively are protected from degradation, i.e., they are more stable.
- nonspecific activation of cells from the innate immune system is dramatically reduced.
- the innate immune system has the capacity to recognize invariant molecular pattern shared by microbial pathogens. Recent studies have revealed that this recognition is a crucial step in inducing effective immune responses.
- the main mechanism by which microbial products augment immune responses is to stimulate APC, expecially dendritic cells to produce proinflammatory cytokines and to express high levels costimulatory molecules for T cells.
- RNA molecules that contain immunostimulatory sequences, in particular unmethylated CpG dinucleotides within specific flanking bases (referred to as CpG motifs) and 2) double-stranded RNA synthesized by various types of viruses represent important members of the microbial components that enhance immune responses.
- Synthetic double stranded (ds) RNA such as polyinosinic-polycytidylic acid (poly I:C) are capable of inducing dendritic cells to produce proinflammatory cytokines and to express high levels of costimulatory molecules.
- DNA or synthetic oligodeoxynucleotides induce human PBMC and mouse spleen cells to produce type I interferon (IFN) (reviewed in Yamamoto et al, Springer Semin Immunopathol. 22:11-19).
- Poly (I:C) was originally synthesized as a potent inducer of type I IFN but also induces other cytokines such as IL-12.
- Preferred ribonucleic acid encompass polyinosinic-polycytidylic acid double- stranded RNA (poly I:C). Ribonucleic acids and modifications thereof as well as methods for their production have been described by Levy, H.B (Methods Enzymol.
- ribonucleic acids comprise polynucleotides of inosinic acid and cytidiylic acid such poly (IC) of which two strands forms double stranded RNA. Ribonucleic acids can be isolated from organisms.
- Ribonucleic acids also encompass further synthetic ribonucleic acids, in particular synthetic poly (I:C) oligonucleotides that have been rendered nuclease resistant by modification of the phosphodiester backbone, in particular by phosphorothioate modifications.
- the ribose backbone of poly (I:C) is replaced by a deoxyribose.
- TLR active toll-like receptors
- TLR2 is activated by peptidoglycans, lipoproteins, lipopolysacchrides, lipoteichonic acid and Zymosan, and macrophage-activating lipopeptide MALP-2
- TLR3 is activated by double-stranded RNA such as poly (I:C)
- TLR4 is activated by lipopolysaccharide, lipoteichoic acids and taxol and heat-shock proteins such as heat shock protein HSP-60 and Gp96
- TLR5 is activated by bacterial flagella, especially the flagellin protein
- TLR6 is activated by peptidoglycans
- TLR7 is activated by imiquimoid and imidazoquinoline compounds, such as R-848, loxoribine and bropirimine and TLR9 is activated
- Ligands for TLR1, TLR8 and TLR 10 are not known so far. However, recent reports indicate that same receptors can react with different ligands and that further receptors are present. The above list of ligands is not exhaustive and further ligands are within the knowledge of the person skilled in the art.
- the immunostimulatory substance of the present invention is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of the unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein the palindromic sequence is flanked at its 3 '-terminus and at its 5 '-terminus by less than 10 guanosine entities.
- the oligonucleotide preferably comprises about 10 to about 30 nucleotides.
- the CpG-containing oligonucleotide contains one or more phosphorothioate modifications of the phosphate backbone.
- a CpG-containing oligonucleotide having one or more phosphate backbone modifications or having all of the phosphate backbone modified and a CpG- containing oligonucleotide wherein one, some or all of the nucleotide phosphate backbone modifications are phosphorothioate modifications are included within the scope of the present invention.
- the CpG-containing oligonucleotide can also be recombinant, genomic, synthetic, cDNA, plasmid-derived and single or double stranded.
- the nucleic acids can be synthesized de novo using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (Beaucage, S. L., and Carathers, M. H, Tet. Let. 22: 1859 (1981); nucleoside H-phosphonate method (Garegg et al, Tet. Let. 27:4051-4054 (1986); Froehler et al., Nucl. Acid. Res.
- CpGs can be produced on a large scale in plasmids, (see Sambrook, T., et al., "Molecular Cloning: A Laboratory Manual,” Cold Spring Harbor laboratory Press, New York, 1989) which after being administered to a subject are degraded into oligonucleotides.
- Oligonucleotides can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.
- the unmethylated CpG-containing oligonucleotide of the invention can be bound to the VLP by any way known in the art provided the composition enhances an immune response in an animal.
- the oligonucleotide can be bound either covalently or non-covalently.
- the VLP can enclose, fully or partially, the unmethylated CpG-containing oligonucleotide.
- the unmethylated CpG-containing oligonucleotide can be bound to a VLP site such as an oligonucleotide binding site (either naturally or non-naturally occuning), a DNA binding site or a RNA binding site.
- a VLP site such as an oligonucleotide binding site (either naturally or non-naturally occuning), a DNA binding site or a RNA binding site.
- the VLP site comprises an arginine-rich repeat or a lysine-rich repeat.
- compositions of the invention are to activate dendritic cells for the pu ⁇ ose of enhancing a specific immune response against antigens.
- the immune response can be enhanced using ex vivo or in vivo techniques.
- the ex vivo procedure can be used on autologous or heterologous cells, but is preferably used on autologous cells.
- the dendritic cells are isolated from peripheral blood or bone manow, but can be isolated from any source of dendritic cells. Ex vivo manipulation of dendritic cells for the pu ⁇ oses of cancer immunotherapy have been described in several references in the art, including Engleman, E.
- the dendritic cells can also be contacted with the inventive compositions using in vivo methods.
- the CpGs are administered in combination with the VLP optionally coupled, fused or otherwise attached to an antigen directly to a subject in need of immunotherapy.
- VLPs/CpGs be administered in the local region of the tumor, which can be accomplished in any way known in the art, e.g., direct injection into the tumor.
- a further aspect of the present invention and a prefened embodiment of the present invention is to provide a composition, typically and preferably for enhancing an immune response in an animal, comprising (a) a virus-like particle; (b) an immunostimulatory substance; and (c) at least one antigen or antigenic determinant; wherein said antigen is bound to said virus-like particle; and wherein said immunostimulatory substance is bound to said virus-like particle, and wherein said immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO: 1), and wherein said palindromic sequence is flanked at its 3 '-terminus and at its 5'- terminus by less than 10 guanosine entities.
- inventive immunostimulatory substances i.e. the unmethylated CpG-containing oligonucleotides, wherein the CpG motif of said unmethylated CpG- containing oligonucleotides are part of a palindromic sequence, wherein the palindromic sequence is GACGATCGTC (SEQ ID NO: 1), and wherein the palindromic sequence is flanked at its 3 '-terminus and at its 5 '-terminus by less than 10 guanosine entities, are effective at stimulating immune cells in vitro.
- these inventive immunostimulatory substances have unexpectedly found to be very efficiently packaged into VLPs.
- the packaging ability was hereby enhanced as compared to the conesponding immunostimulatory substance having the sequence GACGATCGTC (SEQ ID NO: 1) flanked by 10 guanosine entitites at the 5' and 3' terminus. The latter was previously found to be able to stimulate blood cells in vitro (Kuramoto E. et al., Japanese Journal Cancer Research 83, 1128-1131 (1992).
- the palindromic sequence comprises, or alternatively consist essentially of, or alternatively consists of or is GACGATCGTC (SEQ ID NO: 1), wherein said palindromic sequence is flanked at its 5'- terminus by at least 3 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3 '-terminus by at least 6 and at most 9 guanosine entities.
- the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said umnethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said unmethylated CpG-containing oligonucleotide has a nucleic acid sequence selected from (a) GGGGACGATCGTCGGGGGG ((SEQ ID NO: 2); and typically abbreviated herein as G3-6), (b) GGGGGACGATCGTCGGGGGG ((SEQ ID NO: 3); and typically abbreviated herein as G4-6), (c) GGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 4); and typically abbreviated herein as G5-6), ' (d) GGGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 5); and typically abbreviated herein as G6-6), (e)
- the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO: 1), and wherein said palindromic sequence is flanked at its 5 '-terminus by at least 4 and at most 9 guanosine entities and wherein said palindromic sequence is flanked at its 3 '-terminus by at least 6 and at most 9 guanosine entities.
- the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said unmethylated CpG-containing oligonucleotide has a nucleic acid sequence selected from (a) GGGGGACGATCGTCGGGGGG ((SEQ ID NO: 3); and typically abbreviated herein as G4-6), (b) GGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 4); and typically abbreviated herein as G5-6), (c) GGGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 5); and typically abbreviated herein as G6-6), (d)
- GGGGGGGGACGATCGTCGGGGGGGGG ((SEQ ID NO: 6); and typically abbreviated herein as G7-7), (e) GGGGGGGGGACGATCGTCGGGGGGGG ((SEQ ID NO: 7); and typically abbreviated herein as G8-8), (f) GGGGGGGGGGACGATCGTCGGGGGGGGG ((SEQ ID NO: 8); and typically abbreviated herein as G9-9).
- the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said palindromic sequence is GACGATCGTC (SEQ ID NO: 1), and wherein said palindromic sequence is flanked at its 5 '-terminus by at least 5 and at most 8 guanosine entities and wherein said palindromic sequence is flanked at its 3 '-terminus by at least 6 and at most 8 guanosine entities.
- the experimental data show that the ease of packaging of the prefened inventive immunostimulatory substances, i.e. the guanosine flanked, palindromic and unmethylated CpG-containing oligonucleotides, wherein the palindromic sequence is GACGATCGTC (SEQ ID NO: 1), and wherein the palindromic sequence is flanked at its 3 '-terminus and at its 5 '-terminus by less than 10 guanosine entities, into VLP's increases if the palindromic sequences are flanked by fewer guanosine entities.
- decreasing the number of guanosine entities flanking the palindromic sequences leads to a decrease of stimulating blood cells in vitro.
- packagability is paid by decreased biological activity of the indicated inventive immunostimulatory substances.
- the present prefened embodiments represent, thus, a compromise between packagability and biological activity.
- the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said unmethylated CpG-containing oligonucleotide has a nucleic acid sequence selected from (a) GGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 4); and typically abbreviated herein as G5-6), (b) GGGGGGGACGATCGTCGGGGGG ((SEQ ID NO: 5); and typically abbreviated herein as G6-6), (c) GGGGGGGGGGACGATCGTCGGGGGGG ((SEQ ID NO: 6); and typically abbreviated herein as G7-7), (d) GGGGGGGGGACGATCGTCGGGGGGGG ((SEQ ID NO: 7); and typically abbreviated herein as G8-8).
- the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, wherein said unmethylated has the nucleic acid sequence of SEQ ID NO: 7, i.e.the immunostimulatory substance is G8-8.
- the optimal sequence used to package into VLPs is a compromise between packagability and biological activity.
- the G8-8 immunostimulatoy substance is a very preferred embodiment of the present invention since it is biologically highly active while it still reasonably well packaged.
- the inventive composition can further comprise an antigen or antigenic determinant bound to the virus-like particle.
- the invention provides for compositions that vary according to the antigen or antigenic determinant selected in consideration of the desired therapeutic effect. Very prefened antigens or antigenic determinants suitable for use in the present invention are disclosed in WO 00/32227, in WO 01/85208 and in WO 02/056905, the disclosures of which are herewith inco ⁇ orated by reference in their entireties.
- the antigen can be any antigen of known or yet unknown provenance. It can be isolated from bacteria, viruses or other pathogens or can be a recombinant antigen obtained from expression of suitable nucleic acid coding therefor. It can also be isolated from prions, tumors, self-molecules, non-peptidic hapten molecules, allergens and hormones. In a prefened embodiment, the antigen is a recombinant antigen. The selection of the antigen is, of course, dependent upon the immunological response desired and the host.
- the immune response is induced against the VLP itself.
- a virus-like particle is coupled, fused or otherwise attached to an antigen/immunogen against which an enhanced immune response is desired.
- the at least one antigen or antigenic determinant is fused to the virus-like particle.
- a VLP is typically composed of at least one subunit assembling into a VLP.
- the antigen or antigenic determinant is fused to at least one subunit of the virus-like particle or of a protein capable of being inco ⁇ orated into a VLP generating a chimeric VLP-subunit-antigen fusion.
- Fusion of the antigen or antigenic determinant can be effected by insertion into the VLP subunit sequence, or by fusion to either the N- or C-terminus of the VLP-subunit or protein capable of being inco ⁇ orated into a VLP.
- the fusion to either ends of the subunit sequence or internal insertion of the peptide within the subunit sequence are encompassed.
- Fusion may also be effected by inserting antigen or antigenic determinant sequences into a variant of a VLP subunit where part of the subunit sequence has been deleted, that are further refened to as truncation mutants.
- Truncation mutants may have N- or C-terminal, or internal deletions of part of the sequence of the VLP subunit.
- the specific VLP HBcAg with, for example, deletion of amino acid residues 79 to 81 is a truncation mutant with an internal deletion. Fusion of antigens or antigenic determinants to either the N- or C-terminus of the truncation mutants VLP-subunits also lead to embodiments of the invention.
- fusion of an epitope into the sequence of the VLP subunit may also be effected by substitution, where for example for the specific VLP HBcAg, amino acids 79-81 are replaced with a foreign epitope.
- fusion as refened to hereinafter, may be effected by insertion of the antigen or antigenic determinant sequence in the sequence of a VLP subunit, by substitution of part of the sequence of the VLP subunit with the antigen or antigenic determinant, or by a combination of deletion, substitution or insertions.
- the chimeric antigen or antigenic determinant -VLP subunit will be in general capable of self-assembly into a VLP.
- VLP displaying epitopes fused to their subunits are also herein refened to as chimeric VLPs.
- the viras-like particle comprises or alternatively is composed of at least one VLP subunit.
- the virus-like particle comprises or alternatively is composed of a mixture of chimeric VLP subunits and non-chimeric VLP subunits, i.e. VLP subunits not having an antigen fused thereto, leading to so called mosaic particles. This may be advantageous to ensure formation of, and assembly to a VLP.
- the proportion of chimeric VLP-subunits may be 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95% or higher.
- Flanking amino acid residues may be added to either end of the sequence of the peptide or epitope to be fused to either end of the sequence of the subunit of a VLP, or for internal insertion of such peptidic sequence into the sequence of the subunit of a VLP.
- Glycine and serine residues are particularly favored amino acids to be used in the flanking sequences added to the peptide to be fused.
- Glycine residues confer additional flexibility, which may diminish the potentially destabilizing effect of fusing a foreign sequence into the sequence of a VLP subunit.
- the VLP is a Hepatitis B core antigen VLP.
- Fusion proteins of the antigen or antigenic determinant to either the N-terminus of a HBcAg (Neyrinck, S. et al., Nature Med. 5:1157-1163 (1999)) or insertions in the so called major immunodominant region (MIR) have been described (Pumpens, P. and Grens, E., Intervirology 44:98-114 (2001)), WO 01/98333), and are preferred embodiments of the invention.
- MIR major immunodominant region
- HBcAg contains a long arginine tail (Pumpens, P. and Grens, E., Intervirology 44:98-114 (2001)) which is dispensable for capsid assembly and capable of binding nucleic acids (Pumpens, P. and Grens, E., Intervirology 44:98-114 (2001)).
- HBcAg either comprising or lacking this arginine tail are both embodiments of the invention.
- the VLP is a VLP of a RNA phage.
- the major coat proteins of RNA phages spontaneously assemble into VLPs upon expression in bacteria, and in particular in E. coli.
- Specific examples of bacteriophage coat proteins which can be used to prepare compositions of the invention include the coat proteins of RNA bacteriophages such as bacteriophage Q ⁇ (SEQ ID NO: 10; PIR Database, Accession No. VCBPQ ⁇ refening to Q ⁇ CP and SEQ ID NO: 11; Accession No. AAA16663 refe ⁇ ing to Q ⁇ Al protein) and bacteriophage fr (SEQ ID NO: 13; PIR Accession No. VCBPFR).
- the at least one antigen or antigenic determinant is fused to a Q ⁇ coat protein.
- Fusion protein constructs wherein epitopes have been fused to the C-terminus of a truncated form of the Al protein of Q ⁇ , or inserted within the Al protein have been described (Kozlovska, T. M., et al., Intervirology, 39:9-15 (1996)).
- the Al protein is generated by suppression at the UGA stop codon and has a length of 329 aa, or 328 aa, if the cleavage of the N-terminal methionine is taken into account.
- efficient display of the fused epitope on the VLPs is mediated by the expression of the plasmid encoding the Q ⁇ Al protein fusion having a UGA stop codong between CP and CP extension in a E. coli strain harboring a plasmid encoding a cloned UGA suppressor tRNA which leads to translation of the UGA codon into T ⁇ (pISM3001 plasmid (Smiley B.K., et al, Gene 134:33-40 (1993))).
- the CP gene stop codon is modified into UAA, and a second plasmid expressing the Al protein-antigen fusion is cotransformed.
- the second plasmid encodes a different antibiotic resistance and the origin of replication is compatible with the first plasmid (Kozlovska, T. M., et al., Intervirology 39:9-15 (1996)).
- CP and the Al protein-antigen fusion are encoded in a bicistronic manner, operatively linked to a promoter such as the T ⁇ promoter, as described in Figure 1 of Kozlovska et al., Intervirology, 39:9-15 (1996).
- the antigen or antigenic determinant is inserted between amino acid 2 and 3 (numbering of the cleaved CP, that is wherein the N-terminal methionine is cleaved) of the fr CP, thus leading to an antigen or antigenic determinant -fr CP fusion protein.
- Vectors and expression systems for construction and expression of fr CP fusion proteins self-assembling to VLP and useful in the practice of the invention have been described (Pushko P. et al., Prot. Eng. 6:883-891 (1993)).
- the antigen or antigenic determinant sequence is inserted into a deletion variant of the fr CP after amino acid 2, wherein residues 3 and 4 of the fr CP have been deleted (Pushko P. et al., Prot. Eng. 6:883-891 (1993)).
- the antigen or antigenic determinant is fused to a capsid protein of papiUomavirus.
- the antigen or antigenic determinant is fused to the major capsid protein LI of bovine papiUomavirus type 1 (BPV-1).
- BPV- 1 bovine papiUomavirus type 1
- Vectors and expression systems for construction and expression of BPV- 1 fusion proteins in a baculovirus/insect cells systems have been described (Chackerian, B. et al, Proc. Natl. Acad. Sci.USA 96:2373-2378 (1999), WO 00/23955).
- the antigen or antigenic detem inant is fused to a Ty protein capable of being inco ⁇ orated into a Ty VLP.
- the antigen or antigenic determinant is fused to the pi or capsid protein encoded by the TYA gene (Roth, J.F., Yeast 16:785-795 (2000)).
- the yeast retrotransposons Tyl, 2, 3 and 4 have been isolated from Saccharomyces Serevisiae, while the retrotransposon Tfl has been isolated from Schizosaccharomyces Pombae (Boeke, J.D. and Sandmeyer, S.B., "Yeast Transposable elements," in The molecular and Cellular Biology of the Yeast Saccharomyces: Genome dynamics, Protein Synthesis, and Energetics, p. 193, Cold Spring Harbor Laboratory Press (1991)).
- the retrotransposons Tyl and 2 are related to the copia class of plant and animal elements, while Ty3 belongs to the gypsy family of retrotransposons, which is related to plants and animal retrovirases.
- the pi protein also refened to as Gag or capsid protein, has a length of 440 amino acids.
- PI is cleaved during maturation of the VLP at position 408, leading to the p2 protein, the essential component of the VLP.
- an antigen or antigenic determinant may be fused to pi by inserting a sequence coding for the antigen or antigenic determinant into the BamHl site of the pMA5620 plasmid (Adams, S.E., et al, Nature 329:68-70 (1987)).
- fusion proteins comprising amino acids 1-381 of pi of Tyl -15, fused C-terminally to the N-terminus of the foreign epitope.
- N-terminal fusion of an antigen or antigenic determinant, or internal insertion into the pi sequence, or substitution of part of the pi sequence are also meant to fall within the scope of the invention.
- insertion of an antigen or antigenic detenninant into the Ty sequence between amino acids 30-31, 67-68, 113-114 and 132-133 of the Ty protein pi leads to prefened embodiments of the invention.
- VLPs suitable for fusion of antigens or antigenic determinants are, for example, Retrovirus-like-particles (WO9630523), HIV2 Gag (Kang, Y.C., et al, Biol. Chem. 380:353-364 (1999)), Cowpea Mosaic Viras (Taylor, K.M.et al., Biol. Chem. 380:387-392 (1999)), parvovirus VP2 VLP (Rueda, P. et al., Virology 263:89-99 (1999)), HBsAg (US 4,722,840, EP0201416B1).
- VLPs suitable for the practice of the invention are also those described in Intervirology 39:1 (1996). Further examples of VLPs contemplated for use in the invention are: HPV-1, HPV-6, HPV-11, HPV-16, HPV-18, HPV-33, HPV-45, CRPV, COPV, HIV GAG, Tobacco Mosaic Viras. Viras-like particles of SV-40, Polyomavirus, Adenoviras, He ⁇ es Simplex Viras, Rotavirus and Norwalk viras have also been made, and chimeric VLPs of those VLPs comprising an antigen or antigenic determinant are also within the scope of the present invention.
- antigens fused to the viras-like particle by insertion within the sequence of the viras-like particle building monomer are also within the scope of the present invention.
- antigens can be inserted in a form of the virus-like particle building monomer containing deletions.
- the virus- like particle building monomer may not be able to form viras-like structures in the absence of the inserted antigen.
- recombinant DNA technology can be utilized to fuse a heterologous protein to a VLP protein (Kratz, P.A., et al., Proc. Natl. Acad. Sci. USA 96:1915 (1999)).
- the present invention encompasses VLPs recombinantly fused or chemically conjugated (including both covalently and non covalently conjugations) to an antigen (or portion thereof, preferably at least 10, 20 or 50 amino acids) of the present invention to generate fusion proteins or conjugates.
- the fusion does not necessarily need to be direct, but can occur through linker sequences.
- linker sequences are typically added at one or both ends of the epitopes.
- Such linker sequences preferably comprise sequences recognized by the proteasome, proteases of the endosomes or other vesicular compartment of the cell.
- One way of coupling is by a peptide bond, in which the conjugate can be a contiguous polypeptide, i.e. a fusion protein.
- the conjugate can be a contiguous polypeptide, i.e. a fusion protein.
- different peptides or polypeptides are linked in frame to each other to form a contiguous polypeptide.
- a first portion of the fusion protein comprises an antigen or immunogen and a second portion of the fusion protein, either N-terminal or C-terminal to the first portion, comprises a VLP.
- a second portion of the fusion protein either N-terminal or C-terminal to the first portion, comprises a VLP.
- internal insertion into the VLP, with optional linking sequences on both ends of the antigen, can also be used in accordance with the present invention.
- HBcAg When HBcAg is used as the VLP, it is prefened that the antigen is linked to the C- terminal end of the HBcAg particle.
- LCMV lymphocytic choriomeningitis viras
- the 185 amino acids long wild type HBc protein assembles into highly structured particles composed of 180 subunits assuming icosahedral geometry.
- a flexible linker sequence e.g. a polyglycine/polyserine-containing sequence such as [Gly4 Ser]2 (Huston et al, Meth. Enzymol 203:46-88 (1991)
- the fusion protein can be constructed to contain an "epitope tag", which allows the fusion protein to bind an antibody (e.g. monoclonal antibody) for example for labeling or purification pu ⁇ oses.
- An example of an epitope tag is a Glu-Glu-Phe tripeptide which is recognized by the monoclonal antibody YL1/2.
- the invention also relates to the chimeric DNA which contains a sequence coding for the VLP and a sequence coding for the antigen/immunogen.
- the DNA can be expressed, for example, in insect cells transformed with Baculovirases, in yeast or in bacteria. There are no restrictions regarding the expression system, of which a large selection is available for routine use. Preferably, a system is used which allows expression of the proteins in large amounts. In general, bacterial expression systems are prefe ⁇ ed on account of their efficiency.
- a bacterial expression system suitable for use within the scope of the present invention is the one described by Clarke et al., J. Gen. Virol. 71: 1109-1117 (1990); Borisova et al., J. Virol.
- yeast expression system An example of a suitable yeast expression system is the one described by Emr, Methods Enzymol. 185:231-3 (1990); Baculovirus systems, which have previously been used for preparing capsid proteins, are also suitable. Constitutive or inducible expression systems can be used. By the choice and possible modification of available expression systems it is possible to control the form in which the proteins are obtained.
- the antigen to which an enhanced immune response is desired is coupled, fused or otherwise attached in frame to the Hepatitis B virus capsid (core) protein (HBcAg).
- core protein HBV capsid
- the at least one antigen or antigenic determinant is bound to the virus-like particle by at least one covalent bond.
- the least one antigen or antigenic determinant is bound to the viras-like particle by at least one covalent bond, said covalent bond being a non-peptide bond leading to an antigen or antigenic determinant array and antigen or antigenic determinant - VLP conjugate, respectively.
- This antigen or antigenic determinant anay and conjugate, respectively has typically and preferably a repetitive and ordered structure since the at least one antigen or antigenic determinant is bound to the VLP in an oriented manner.
- equal and more than 120, more preferably equal and more than 180, even more preferably more than 270, and again more preferably equal and more than 360 antigens of the invention are bound to the VLP.
- the formation of a repetitive and ordered antigen or antigenic determinant -VLP anay and conjugate, respectively, is ensured by an oriented and directed as well as defined binding and attachment, respectively, of the at least one antigen or antigenic determinant to the VLP as will become apparent in the following.
- the typical inherent highly repetitive and organized structure of the VLPs advantageously contributes to the display of the antigen or antigenic determinant in a highly ordered and repetitive fashion leading to a highly organized and repetitive antigen or antigenic determinant -VLP anay and conjugate, respectively.
- the prefened inventive conjugates and anays differ from prior art conjugates in their highly organized structure, dimensions, and in the repetitiveness of the antigen on the surface of the anay.
- the prefened embodiment of this invention furthermore, allows expression of the particle in an expression host guaranteeing proper folding and assembly of the VLP, to which the antigen is then further coupled
- the present invention discloses methods of binding of antigen or antigenic determinant to VLPs.
- the at least one antigen or antigenic determinant is bound to the VLP by way of chemical cross-linking, typically and preferably by using a heterobifunctional cross-linker.
- a heterobifunctional cross-linker is known to the art.
- the hetero-bifunctional cross-linker contains a functional group which can react with prefened first attachment sites, i.e. with the side-chain amino group of lysine residues of the VLP or at least one VLP subunit, and a further functional group which can react with a prefe ⁇ ed second attachment site, i.e.
- the first step of the procedure is the reaction of the VLP with the cross-linker.
- the product of this reaction is an activated VLP, also called activated canier.
- unreacted cross-linker is removed using usual methods such as gel filtration or dialysis.
- the antigen or antigenic determinant is reacted with the activated VLP, and this step is typically called the coupling step.
- Unreacted antigen or antigenic determinant may be optionally removed in a fourth step, for example by dialysis.
- Several hetero-bifunctional cross-linkers are known to the art.
- cross- linkers include the prefened cross- linkers SMPH (Pierce), Sulfo-MBS, Sulfo-EMCS, Sulfo-GMBS, Sulfo-SIAB, Sulfo- SMPB, Sulfo-SMCC, SVSB, SIA and other cross-linkers available for example from the Pierce Chemical Company (Rockford, IL, USA) , and having one functional group reactive towards amino groups and one functional group reactive towards cysteine residues.
- the above mentioned cross-linkers all lead to formation of a thioether linkage.
- Another class of cross-linkers suitable in the practice of the invention is characterized by the introduction of a disulfide linkage between the antigen or antigenic determinant and the VLP upon coupling.
- Preferred cross-linkers belonging to this class include for example SPDP and Sulfo-LC-SPDP (Pierce).
- the extent of derivatization of the VLP with cross-linker can be influenced by varying experimental conditions such as the concentration of each of the reaction partners, the excess of one reagent over the other, the pH, the temperature and the ionic strength.
- the degree of coupling, i.e. the amount of antigens or antigenic determinants per subunits of the VLP can be adjusted by varying the experimental conditions described above to match the requirements of the vaccine.
- a particularly favored method of binding of antigens or antigenic determinants to the VLP is the linking of a lysine residue on the surface of the VLP with a cysteine residue on the antigen or antigenic determinant.
- fusion of an amino acid linker containing a cysteine residue, as a second attachment site or as a part thereof, to the antigen or antigenic determinant for coupling to the VLP may be required.
- amino acid linkers are favored.
- amino acid linkers are the hinge region of Immunoglobulins, glycine serine linkers (GGGGS)n (SEQ ID NO: 49), and glycine linkers (G)n all further containing a cysteine residue as second attachment site and optionally further glycine residues.
- amino acid linkers are N-terminal gammal: CGDKTHTSPP (SEQ ID NO: 50); C-terminal gamma 1: DKTHTSPPCG (SEQ ID NO: 51); N-terminal gamma 3: CGGPKPSTPPGSSGGAP (SEQ ID NO: 52); C-terminal gamma 3: PKPSTPPGSSGGAPGGCG (SEQ ID NO: 53); N-terminal glycine linker: GCGGGG (SEQ ID NO: 54); C-terminal glycine linker: GGGGCG (SEQ ID NO: 55); C- terminal glycine-lysine linker: GGKKGC (SEQ ID NO: 56); N-terminal glycine-lysine linker: CGKKGG (SEQ ID NO: 57).
- amino acid linkers particularly suitable in the practice of the invention when a hydrophobic antigen or antigenic determinant is bound to a VLP, are CGKKGG (SEQ ID NO: 58), or CGDEGG (SEQ ID NO: 59) for N-terminal linkers, or GGKKGC (SEQ ID NO: 60) and GGEDGC (SEQ ID NO: 61), for the C-terminal linkers.
- CGKKGG SEQ ID NO: 58
- CGDEGG SEQ ID NO: 59
- GGKKGC SEQ ID NO: 60
- GGEDGC SEQ ID NO: 61
- the terminal cysteine is optionally C-terminally amidated.
- GGCG SEQ ID NO: 62
- GGC GGC or GGC-NH2
- NH2 stands for amidation
- linkers at the C-terminus of the peptide or CGG at its N-terminus are prefened as amino acid linkers.
- glycine residues will be inserted between bulky amino acids and the cysteine to be used as second attachment site, to avoid potential steric hindrance of the bulkier amino acid in the coupling reaction.
- the amino acid linker GGC-NH2 is fused to the C-terminus of the antigen or antigenic determinant.
- the cysteine residue present on the antigen or antigenic determinant has to be in its reduced state to react with the hetero-bifunctional cross-linker on the activated VLP, that is a free cysteine or a cysteine residue with a free sulfhydryl group has to be available.
- the cysteine residue to function as binding site is in an oxidized form, for example if it is forming a disulfide bridge, reduction of this disulfide bridge with e.g. DTT, TCEP or ⁇ -mercaptoethanol is required.
- Other methods of binding the antigen or antigenic determinant to the VLP include methods wherein the antigen or antigenic determinant is cross-linked to the VLP using the carbodiimide EDC, and NHS.
- the antigen or antigenic determinant is attached to the VLP using a homo-bifunctional cross-linker such as glutaraldehyde, DSG, BM[PEO]4, BS3, (Pierce Chemical Company, Rockford, IL, USA) or other known homo-bifunctional cross-linkers whith functional groups reactive towards amine groups or carboxyl groups of the VLP.
- VLP binding methods include methods where the VLP is biotinylated, and the antigen or antigenic determinant expressed as a streptavidin-fusion protein, or methods wherein both the antigen or antigenic determinant and the VLP are biotinylated, for example as described in WO 00/23955.
- the antigen or antigenic determinant may be first bound to streptavidin or avidin by adjusting the ratio of antigen or antigenic determinant to streptavidin such that free binding sites are still available for binding of the VLP, which is added in the next step.
- all components may be mixed in a "one pot" reaction.
- ligand-receptor pairs where a soluble form of the receptor and of the ligand is available, and are capable of being cross-linked to the VLP or the antigen or antigenic determinant, may be used as binding agents for binding antigen or antigenic determinant to the VLP.
- either the ligand or the receptor may be fused to the antigen or antigenic determinant, and so mediate binding to the VLP chemically bound or fused either to the receptor, or the ligand respectively. Fusion may also be effected by insertion or substitution.
- the VLP is the VLP of a RNA phage
- the VLP in a more prefened embodiment, is the VLP of RNA phage Q ⁇ coat protein.
- One or several antigen molecules i.e. one or several antigens or antigenic determinants, can be attached to one subunit of the capsid or VLP of RNA phages coat proteins, preferably through the exposed lysine residues of the VLP of RNA phages, if sterically allowable.
- a specific feature of the VLP of the coat protein of RNA phages and in particular of the Q ⁇ coat protein VLP is thus the possibility to couple several antigens per subunit. This allows for the generation of a dense antigen array.
- the binding and attachment, respectively, of the at least one antigen or antigenic determinant to the viras-like particle is by way of interaction and association, respectively, between at least one first attachment site of the virus-like particle and at least one second attachment of the antigen or antigenic determinant.
- VLPs or capsids of Q ⁇ coat protein display a defined number of lysine residues on their surface, with a defined topology with three lysine residues pointing towards the interior of the capsid and interacting with the RNA, and four other lysine residues exposed to the exterior of the capsid. These defined properties favor the attachment of antigens to the exterior of the particle, rather than to the interior of the particle where the lysine residues interact with RNA.
- VLPs of other RNA phage coat proteins also have a defined number of lysine residues on their surface and a defined topology of these lysine residues.
- the first attachment site is a lysine residue and/or the second attachment comprises sulfhydryl group or a cysteine residue.
- the first attachment site is a lysine residue and the second attachment is a cysteine residue.
- the antigen or antigenic determinant is bound via a cysteine residue, to lysine residues of the VLP of RNA phage coat protein, and in particular to the VLP of Q ⁇ coat protein.
- VLPs derived from RNA phages are their high expression yield in bacteria that allows production of large quantities of material at affordable cost.
- inventive conjugates and anays differ from prior art conjugates in their highly organized structure, dimensions, and in the repetitiveness of the antigen on the surface of the anay.
- use of the VLPs as caniers allow the formation of robust antigen anays and conjugates, respectively, with variable antigen density.
- the use of VLPs of RNA phages, and hereby in particular the use of the VLP of RNA phage Q ⁇ coat protein allows to achieve very high epitope density.
- a density of more than 1.5 epitopes per subunit has been reached by coupling for example the human A ⁇ l-6 peptide to the VLP of Q ⁇ coat protein (WO 2004/016282).
- the preparation of compositions of VLPs of RNA phage coat proteins with a high epitope density can be effected using the teaching of this application.
- an average number of antigen or antigenic determinant per subunit of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6 , 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.42.5, 2.6, 2.7, 2.8, 2.9, or higher is prefened.
- the second attachment site as defined herein, may be either naturally or non- naturally present with the antigen or the antigenic determinant. In the case of the absence of a suitable natural occuning second attachment site on the antigen or antigenic determinant, such a, then non-natural second attachment has to be engineered to the antigen.
- lysine residues are exposed on the surface of the VLP of Q ⁇ coat protein. Typically these residues are derivatized upon reaction with a cross-linker molecule. In the instance where not all of the exposed lysine residues can be coupled to an antigen, the lysine residues which have reacted with the cross-linker are left with a cross- linker molecule attached to the D -amino group after the derivatization step. This leads to disappearance of one or several positive charges, which may be detrimental to the solubility and stability of the VLP.
- Q ⁇ -240 (Lysl3-Arg; SEQ ID NO:20), Q ⁇ -250 (Lys 2-Arg, Lysl3-Arg; SEQ ID NO: 22) and Q ⁇ - 259 (Lys 2-Arg, Lysl6-Arg; SEQ ID NO:24).
- the constructs were cloned, the proteins expressed, the VLPs purified and used for coupling to peptide and protein antigens.
- Q ⁇ - 251 (SEQ ID NO: 23) was also constructed, and guidance on how to express, purify and couple the VLP of Q ⁇ -251 coat protein can be found throughout the application.
- a Q ⁇ mutant coat protein with one additional lysine residue suitable for obtaining even higher density anays of antigens.
- This mutant Q ⁇ coat protein, Q ⁇ -243 (Asn 10-Lys; SEQ ID NO: 21) was cloned, the protein expressed, and the capsid or VLP isolated and purified, showing that introduction of the additional lysine residue is compatible with self-assembly of the subunits to a capsid or VLP.
- antigen or antigenic determinant anays and conjugates, respectively may be prepared using VLP of Q ⁇ coat protein mutants.
- a particularly favored method of attachment of antigens to VLPs, and in particular to VLPs of RNA phage coat proteins is the linking of a lysine residue present on the surface of the VLP of RNA phage coat proteins with a cysteine residue added to the antigen.
- a cysteine residue In order for a cysteine residue to be effective as second attachment site, a sulfhydryl group must be available for coupling. Thus, a cysteine residue has to be in its reduced state, that is, a free cysteine or a cysteine residue with a free sulfhydryl group has to be available.
- cysteine residue to function as second attachment site is in an oxidized form, for example if it is forming a disulfide bridge
- reduction of this disulfide bridge with e.g. DTT, TCEP or ⁇ - mercaptoethanol is required.
- concentration of reductand, and the molar excess of reductand over antigen has to be adjusted for each antigen.
- a titration range, starting from concentrations as low as 10 ⁇ M or lower, up to 10 to 20 mM or higher reductand if required is tested, and coupling of the antigen to the canier assessed.
- the pH of the dialysis or equilibration buffer is lower than 7, preferably 6. The compatibility of the low pH buffer with antigen activity or stability has to be tested.
- Epitope density on the VLP of RNA phage coat proteins can be modulated by the choice of cross-linker and other reaction conditions.
- the cross-linkers Sulfo- GMBS and SMPH typically allow reaching high epitope density.
- Derivatization is positively influenced by high concentration of reactands, and manipulation of the reaction conditions can be used to control the number of antigens coupled to VLPs of RNA phage coat proteins, and in particular to VLPs of Q ⁇ coat protein.
- the position at which it should be fused, inserted or generally engineered has to be chosen.
- the selection of the position of the second attachment site may, by way of example, be based on a crystal stracture of the antigen.
- Such a crystal stracture of the antigen may provide information on the availability of the C- or N-termini of the molecule (determined for example from their accessibility to solvent), or on the exposure to solvent of residues suitable for use as second attachment sites, such as cysteine residues.
- Exposed disulfide bridges as is the case for Fab fragments, may also be a source of a second attachment site, since they can be generally converted to single cysteine residues through mild reduction, with e.g.
- the second attachment site will be added such that it allows generation of antibodies against the site of interaction with the natural ligands.
- the location of the second attachment site will be selected such that steric hindrance from the second attachment site or any amino acid linker containing the same is avoided.
- an antibody response directed at a site distinct from the interaction site of the self-antigen with its natural ligand is desired.
- the second attachment site may be selected such that it prevents generation of antibodies against the interaction site of the self-antigen with its natural ligands.
- Other criteria in selecting the position of the second attachment site include the oligomerization state of the antigen, the site of oligomerization, the presence of a cofactor, and the availability of experimental evidence disclosing sites in the antigen structure and sequence where modification of the antigen is compatible with the function of the self- antigen, or with the generation of antibodies recognizing the self-antigen.
- the antigen or antigenic determinant comprises a single second attachment site or a single reactive attachment site capable of association with the first attachment sites on the core particle and the VLPs or VLP subunits, respectively.
- This further ensures a defined and uniform binding and association, respectively, of the at least one, but typically more than one, preferably more than 10, 20, 40, 80, 120, 150, 180, 210, 240, 270, 300, 360, 400, 450 antigens to the core particle and VLP, respectively.
- the provision of a single second attachment site or a single reactive attachment site on the antigen thus, ensures a single and uniform type of binding and association, respectively leading to a very highly ordered and repetitive anay.
- the binding and association, respectively is effected by way of a lysine- (as the first attachment site) and cysteine- (as a second attachment site) interaction, it is ensured, in accordance with this prefened embodiment of the invention, that only one cysteine residue per antigen, independent whether this cysteine residue is naturally or non-naturally present on the antigen, is capable of binding and associating, respectively, with the VLP and the first attachment site of the core particle, respectively.
- an amino acid linker is bound to the. antigen or the antigenic determinant by way of at least one covalent bond.
- the amino acid linker comprises, or alternatively consists of, the second attachment site.
- the amino acid linker comprises a sulfhydryl group or a cysteine residue.
- the amino acid linker is cysteine.
- the attachment site is selected to be a lysine or cysteine residue that is fused in frame to the HBcAg.
- the antigen is fused to the C-terminus of HBcAg via a three leucine linker.
- an antigen or antigenic determinant is linked to the VLP through a lysine residue, it may be advantageous to either substitute or delete one or more of the naturally resident lysine residues, as well as other lysine residues present in HBcAg variants.
- lysine residues when the naturally resident lysine residues are eliminated, another lysine will be introduced into the HBcAg as an attachment site for an antigen or antigenic determinant. Methods for inserting such a lysine residue are known in the art. Lysine residues may also be added without removing existing lysine residues.
- the C terminus of the HBcAg has been shown to direct nuclear localization of this protein. (Eckhardt et al, J. Virol. 65:575 582 (1991)). Further, this region of the protein is also believed to confer upon the HBcAg the ability to bind nucleic acids.
- HBcAgs suitable for use in the practice of the present invention also include N terminal truncation mutants.
- Suitable truncation mutants include modified HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from the N terminus.
- variants of viras-like particles containing internal deletions within the sequence of the subunit composing the viras-like particle are also suitable in accordance with the present invention, provided their compatibility with the ordered or particulate structure of the virus-like particle.
- internal deletions within the sequence of the HBcAg are suitable (Preikschat, P., et al., J. Gen. Virol. 80:1777-1788 (1999)).
- HBcAgs suitable for use in the practice of the present invention include N- and C terminal truncation mutants. Suitable truncation mutants include HBcAgs where 1, 2, 5, 7, 9, 10, 12, 14, 15, and 17 amino acids have been removed from the N terminus and 1, 5, 10, 15, 20, 25, 30, 34, 35, 36, 37, 38, 3940, 41, 42 or 48 amino acids have been removed from the C terminus.
- Vaccine compositions of the invention can comprise mixtures of different HBcAgs. Thus, these vaccine compositions can be composed of HBcAgs which differ in amino acid sequence.
- vaccine compositions could be prepared comprising a "wild type" HBcAg and a modified HBcAg in which one or more amino acid residues have been altered (e.g., deleted, inserted or substituted). In most applications, however, only one type of a HBcAg will be used.
- the virus-like particle comprises at least one first attachment site and the antigen or antigenic determinant comprises at least one second attachment site.
- the first attachment site comprises, or preferably consists of, an amino group or a lysine residue.
- the second attachment site is preferably selected from the group consisting of (a) an attachment site not naturally occuning with said antigen or antigenic determinant; and (b) an attachment site naturally occuning with said antigen or antigenic determinant.
- the second attachment site comprises, or preferably consists of, a sulfhydryl group or a cysteine residue.
- the binding of the antigen or antigenic determinant to the virus-like particle is effected through association between the first attachment site and the second attachment site, wherein preferably the association is through at least one non-peptide bond, and wherein preferably the antigen or antigenic determinant and the virus-like particle interact through said association to form an ordered and repetitive antigen anay.
- the first attachment site is a lysine residue and the second attachment site is a cysteine residue.
- the first attachment site is an amino group and the second attachment site is a sulfhydryl group.
- the antigen or antigenic determinat comprises one or more cytotoxic T cell epitopes, Th cell epitopes, or a combination of the two epitopes.
- the antigen or antigenic determinant comprises one, two, or more cytotoxic T cell epitopes.
- the antigen or antigenic determinant comprises one, two, or more Th cell epitopes.
- the antigen or antigenic determinant comprises one, two or more cytotoxic T cell epitopes and one, two or more Th cell epitopes.
- the antigen is a protein, polypeptide or peptide.
- the antigen is DNA.
- the antigen can also be a lipid, a carbohydrate, or an organic molecule, in particular a small organic molecule such as nicotine.
- Antigens of the invention can be selected from the group consisting of the following: (a) polypeptides suited to induce an immune response against cancer cells; (b) polypeptides suited to induce an immune response against infectious diseases; (c) polypeptides suited to induce an immune response against allergens; (d) polypeptides suited to induce an immune response in farm animals or pets; and (e) fragments (e.g., a domain) of any of the polypeptides set out in (a) (d).
- Prefened antigens include those from a pathogen (e.g. virus, bacterium, parasite, fungus) and tumors (especially tumor-associated antigens or "tumor markers"). Other prefe ⁇ ed antigens are autoantigens and self antigens, respectively.
- the antigen is the peptide p33 derived from lymphocytic choriomeningitis viras (LCMV).
- the p33 peptide represents one of the best studied CTL epitopes (Pircher et al., "Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen," Nature 342:559 (1989); Tissot et al., “Characterizing the functionality of recombinant T-cell receptors in vitro: a pMHC tetramer based approach," J Immunol Methods 236:147 (2000); Bachmann et al, "Four types of Ca2+-signals after stimulation of naive T cells with T cell agonists, partial agonists and antagonists," Eur. J. Immunol.
- p33-specific T cells have been shown to induce lethal diabetic disease in transgenic mice (Ohashi et al., "Ablation of 'tolerance' and induction of diabetes by viras infection in viral antigen transgenic mice," Cell 65:305 (1991)) as well as to be able to prevent growth of tumor cells expressing p33 (K ⁇ ndig et al., "Fibroblasts act as efficient antigen-presenting cells in lymphoid organs," Science 268:1343 (1995); arriver et al., "CTL tumor therapy specific for an endogenous antigen does not cause autoimmune disease," J. Exp. Med. 186:645 (1997)).
- This specific epitope therefore, is particularly well suited to study autoimmunity, tumor immunology as well as viral diseases.
- the antigen or antigenic determinant is one that is useful for the prevention of infectious disease.
- Such treatment will be useful to treat a wide variety of infectious diseases affecting a wide range of hosts, e.g., human, cow, sheep, pig, dog, cat, other mammalian species and non-mammalian species as well.
- Treatable infectious diseases are well known to those skilled in the art, and examples include infections of viral etiology such as HIV, influenza, He ⁇ es, viral hepatitis, Epstein Bar, polio, viral encephalitis, measles, chicken pox, Papilloma viras etc.; or infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.; or infections of parasitic etiology such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis, amoebiasis, etc.
- viral etiology such as HIV, influenza, He ⁇ es, viral hepatitis, Epstein Bar, polio, viral encephalitis, measles, chicken pox, Papilloma viras etc.
- infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.
- antigens or antigenic determinants selected for the compositions of the invention will be well known to those in the medical art; examples of antigens or antigenic determinants include the following: the HIV antigens gpl40 and gpl60; the influenza antigens hemagglutinin, M2 protein and neuraminidase, Hepatitis B surface antigen or core and circumsporozoite protein of malaria or fragments thereof.
- antigens include infectious microbes such as viruses, bacteria and fungi and fragments thereof, derived from natural sources or synthetically.
- Infectious viruses of both human and non-human vertebrates include retrovirases, RNA viruses and DNA viruses.
- the group of retrovirases includes both simple retrovirases and complex retrovirases.
- the simple retrovirases include the subgroups of B-type retrovirases, C-type retrovirases and D-type retrovirases.
- An example of a B-type retroviras is mouse mammary tumor virus (MMTV).
- the C-type retrovirases include subgroups C-type group A (including Rous sarcoma virus (RSV), avian leukemia virus (ALV), and avian myeloblastosis virus (AMV)) and C-type group B (including murine leukemia virus
- C-type group A including Rous sarcoma virus (RSV), avian leukemia virus (ALV), and avian myeloblastosis virus (AMV)
- C-type group B including murine leukemia virus
- the D-type retrovirases include. Mason-Pfizer monkey viras (MPMV) and simian retroviras type 1 (SRV-1).
- the complex retrovirases include the subgroups of lentivirases, T-cell leukemia virases and the foamy virases.
- Lentivirases include HIV-1, but also include HIV-2, SIV, Visna viras, feline immunodeficiency viras (FIV), and equine infectious anemia viras (EIAV).
- the T-cell leukemia viruses include HTLV-1, HTLV-II, simian T-cell leukemia viras (STLV), and bovine leukemia virus (BLV).
- the foamy virases include human foamy virus (HFV), simian foamy viras (SFV) and bovine foamy viras (BFV).
- Swine influenza viras, and Avian and Equine Influenza virases influenza type B (many human subtypes), and influenza type C (possible separate genus); the family paramyxoviridae, including the genus Paramyxoviras (Parainfluenza virus type 1, Sendai virus, Hemadso ⁇ tion virus, Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumps virus), the genus Morbiluvirus (Measles virus, subacute sclerosing panencephalitis viras, distemper virus, Rinde ⁇ est viras), the genus Pneumovirus (respiratory syncytial virus (RSV), Bovine respiratory syncytial virus and Pneumonia virus of mice); forest virus, Sindbis viras, Chikungunya virus, O'Nyong-Nyong viras, Ross river virus, Venezuelan equine encephalitis viras, Western equine ence
- Illustrative DNA viruses that are antigens in vertebrate animals include, but are not limited to: the family Poxviridae, including the genus Orthopoxviras (Variola major, Variola minor, Monkey pox Vaccinia, Cowpox, Buffalopox, Rabbitpox, Ectromelia), the genus Leporipoxviras (Myxoma, Fibroma), the genus Avipoxviras (Fowlpox, other avian poxvirus), the genus Capripoxvirus (sheeppox, goatpox), the genus Suipoxvirus (Swinepox), the genus Parapoxviras (contagious postular dermatitis viras, pseudocowpox, bovine papular stomatitis viras); the family Iridoviridae (African swine fever viras, Frog viruses 2 and 3, Lymp
- the antigen comprises one or more cytotoxic T cell epitopes, Th cell epitopes, or a combination of the two epitopes.
- the methods of the prefe ⁇ ed embodiments are particularly well suited for treatment of other mammals or other animals, e.g., birds such as hens, chickens, turkeys, ducks, geese, quail and pheasant. Birds are prime targets for many types of infections.
- An example of a common infection in chickens is chicken infectious anemia viras
- CIAV CIAV was first isolated in Japan in 1979 during an investigation of a Marek's disease vaccination break (Yuasa et al., Avian Dis. 23:366-385 (1979)). Since that time, CIAV has been detected in commercial poultry in all major poultry producing countries (van Bulow et al., pp. 690-699 in "Diseases of Poultry", 9th edition, Iowa State University Press 1991).
- Vaccination of birds, like other vertebrate animals can be performed at any age. Normally, vaccinations are performed at up to 12 weeks of age for a live microorganism and between 14-18 weeks for an inactivated microorganism or other type of vaccine. For in ovo vaccination, vaccination can be performed in the last quarter of embryo development.
- the vaccine can be administered subcutaneously, by spray, orally, intraocularly, intratracheally, nasally, in ovo or by other methods described herein.
- Cattle and livestock are also susceptible to infection. Disease which affect these animals can produce severe economic losses, especially amongst cattle.
- the methods of the invention can be used to protect against infection in livestock, such as cows, horses, pigs, sheep and goats.
- Cows can be infected by bovine viruses.
- Bovine viral dianhea viras (BVDV) is a small enveloped positive-stranded RNA viras and is classified, along with hog cholera viras (HOCV) and sheep border disease viras (BDV), in the pestiviras genus.
- HOCV hog cholera viras
- BDV sheep border disease viras
- Pestivirases were previously classified in the Togaviridae family, some studies have suggested their reclassification within the Flaviviridae family along with the flaviviras and hepatitis C viras (HCV) groups.
- Equine he ⁇ esvirases comprise a group of antigenically distinct biological agents which cause a variety of infections in horses ranging from subclinical to fatal disease. These include Equine he ⁇ esviras-1 (EHV-1), a ubiquitous pathogen in horses. EHV-1 is associated with epidemics of abortion, respiratory tract disease, and central nervous system disorders. Other EHV's include EHV-2, or equine cytomegaloviras, EHV-3, equine coital exanthema virus, and EHV-4, previously classified as EHV-1 subtype 2.
- EHV-1 Equine he ⁇ esvirases
- Sheep and goats can be infected by a variety of dangerous microorganisms including visna-maedi.
- Cats both domestic and wild, are susceptible to infection with a variety of microorganisms.
- feline infectious peritonitis is a disease which occurs in both domestic and wild cats, such as lions, leopards, cheetahs, and jaguars.
- the methods of the invention can be used to vaccinate cats to prevent them against infection.
- Domestic cats may become infected with several retrovirases, including but not limited to feline leukemia virus (FeLV), feline sarcoma viras (FeSV), endogenous type C oncomaviras (RD-114), and feline syncytia-forming viras (FeSFV).
- FeLV feline leukemia virus
- FeSV feline sarcoma viras
- RD-114 endogenous type C oncomaviras
- FeSFV feline syncytia-forming viras
- FIP is primarily a disease of domestic cats, it has been diagnosed in lions, mountain lions, leopards, cheetahs, and the jaguar. Smaller wild cats that have been afflicted with FIP include the lynx and caracal, sand cat and pallas cat.
- the fish immune system has many features similar to the mammalian immune system, such as the presence of B cells, T cells, lymphokines, complement, and immunoglobulins. Fish have lymphocyte subclasses with roles that appear similar in many respects to those of the B and T cells of mammals. Vaccines can be administered orally or by immersion or injection.
- Aquaculture species include but are not limited to fin-fish, shellfish, and other aquatic animals.
- Fin-fish include all vertebrate fish, which may be bony or cartilaginous fish, such as, for example, salmonids, ca ⁇ , catfish, yellowtail, seabream and seabass.
- Salmonids are a family of fin-fish which include trout (including rainbow trout), salmon and Arctic char.
- shellfish include, but are not limited to, clams, lobster, shrimp, crab and oysters.
- Other cultured aquatic animals include, but are not limited to, eels, squid and octopi.
- Polypeptides of viral aquaculture pathogens include but are not limited to glycoprotein or nucleoprotein of viral hemonhagic septicemia viras (VHSV); G or N proteins of infectious hematopoietic necrosis viras (IHNN); VP1, VP2, VP3 or ⁇ structural proteins of infectious pancreatic necrosis viras (IP ⁇ V); G protein of spring viremia of ca ⁇ (SVC); and a membrane-associated protein, tegumin or capsid protein or glycoprotein of channel catfish viras (CCV).
- VHSV glycoprotein or nucleoprotein of viral hemonhagic septicemia viras
- IHNN infectious hematopoietic necrosis viras
- IP ⁇ V infectious pancreatic necrosis viras
- SVC SVC
- Polypeptides of bacterial pathogens include but are not limited to an iron-regulated outer membrane protein, (IROMP), an outer membrane protein (OMP), and an A-protein of Aeromonis salmonicida which causes furunculosis, ⁇ 57 protein of Renibacterium salmoninaram which causes bacterial kidney disease (BKD), major surface associated antigen (msa), a surface expressed cytotoxin (mpr), a surface expressed hemolysin (ish), and a flagellar antigen of Yersiniosis; an extracellular protein (ECP), an iron-regulated outer membrane protein (IROMP), and a structural protein of Pasteurellosis; an OMP and a flagellar protein of Vibrosis anguillarum and V.
- IROMP iron-regulated outer membrane protein
- OMP outer membrane protein
- Vibrosis anguillarum and V.
- ordalii a flagellar protein, an OMP protein, aroA, and purA of Edwardsiellosis ictaluri and E. tarda; and surface antigen of Ichthyophthirius; and a stractural and regulatory protein of Cytophaga columnari; and a stractural and regulatory protein of Rickettsia.
- Polypeptides of a parasitic pathogen include but are not limited to the surface antigens of Ichthyophthirius.
- vaccine compositions suitable for use in methods for preventing and/or attenuating diseases or conditions which are caused or exacerbated by "self gene products (e.g., tumor necrosis factors).
- vaccine compositions of the invention include compositions which lead to the production of antibodies that prevent and/or attenuate diseases or conditions caused or exacerbated by "self gene products.
- diseases or conditions include graft versus host disease, IgE mediated allergic reactions, anaphylaxis, adult respiratory distress syndrome, Crohn's disease, allergic asthma, acute lymphoblastic leukemia (ALL), non Hodgkin's lymphoma ( ⁇ HL), Graves' disease, systemic lupus erythematosus (SLE), inflammatory autoimmune diseases, myasthenia gravis, immunoproliferative disease lymphadenopathy (IPL), angioimmunoproliferative lymphadenopathy (AIL), immunoblastive lymphadenopathy (IBL), rheumatoid arthritis, diabetes, prion diseases, multiple sclerosis, Alzheimer disease and osteoporosis.
- IPL immunoproliferative disease lymphadenopathy
- AIL angioimmunoproliferative lymphadenopathy
- IBL immunoblastive lymphadenopathy
- compositions of the invention are an immunotherapeutic that can be used for the treatment and/or prevention of allergies, cancer or drug addiction.
- antigens or antigenic detenninants for the preparation of compositions and for use in methods of treatment for allergies would be known to those skilled in the medical arts treating such disorders.
- Representative examples of such antigens or antigenic determinants include the following: bee venom phospholipase A2, Bet v I (birch pollen allergen), 5 Dol m V (white-faced hornet venom allergen), and Der p I (House dust mite allergen), as well as fragments of each which can be used to elicit immunological responses.
- antigens or antigenic determinants for compositions and methods of treatment for cancer would be known to those skilled in the medical arts treating such disorders (see Renkvist et al., Cancer. Immunol. Immunother. 50:3-15 (2001) which is inco ⁇ orated by reference), and such antigens or antigenic determinants are included within the scope of the present invention.
- antigens or antigenic determinants include the following: Her2 (breast cancer); GD2 (neuroblastoma); EGF-R (malignant glioblastoma); CEA (medullary thyroid cancer); CD52 (leukemia); human melanoma protein gplOO; human melanoma protein gplOO epitopes such as amino acids 154-162 (sequence: KTWGQYWQV) (SEQ ID NO: 63), 209-217 (ITDQVPFSV) (SEQ ID NO: 64), 280-288 (YLEPGPVTA) (SEQ ID NO: 65), 457 ⁇ 166 (LLDGTATLRL) (SEQ ID NO: 66) and 476-485 (VLYRYGSFSV) (SEQ ID NO: 67); human melanoma protein melan-A/MART-1 ; human melanoma protein melan- A/MART-1 epitopes such as amino acids 26-
- CEA epitopes such as amino acids 571-579 (YLSGANLNL) (SEQ ID NO: 75); p53 protein; p53 protein epitopes such as amino acids 65-73 (RMPEAAPPV) (SEQ ID NO: 76), 149-157 (STPPPGTRV) (SEQ ID NO: 77) and 264- 272 (LLGRNSFEV) (SEQ ID NO: 78); Her2/neu epitopes such as amino acids 369-377 (KIFGSLAFL) (SEQ ID NO: 79) and 654-662 (IISAVVGIL) (SEQ ID NO: 80); NY- ESO-1 peptides 157-165 and 157-167, 159-167; HPV16 E7 protein; HPV16 E7 protein epitopes such as amino acids 86-93 (TLGIVCPI) (SEQ ID NO: 81); as well as fragments or mutants of each which can be used to elicit immunological responses.
- RMPPEAAPPV amino acids 65
- the natural MelanA/Mart-1 epitopes and for example the MelanA/Mart-1 26-35 epitope bind with low affinity to human HLA-2 only.
- in vivo presentation of the natural MelanA epitopes and peptides, respectively, upon vaccination may be a limiting factor. This is particularly important if Melan A epitopes and peptides, respectively, bound, coupled or fused to VLPs are used for vaccination, since under these conditions, MelanA peptides load HLA molecules by cross-presentation.
- the process of cross- presentation is, however, not as efficient as classical pathways of antigen presentation and the affinity of the MelanA peptide for HLA is even more important.
- a further aspect of the present invention and a prefened embodiment of the present invention is to provide a composition for enhancing an immune response in an animal comprising (a) a virus-like particle; and (b) an immunostimulatory substance, wherein said immunostimulatory substance is bound to said viras-like particle, and wherein said composition further comprises at least one antigen or antigenic determinant, wherein said antigen or antigenic determinant is bound to said viras-like particle, and wherein said at least one antigen or antigenic determinant comprises, alternatively consists essentially of, or alternatively consists of a human melanoma MelanA peptide analogue, and wherein said human melanoma MelanA peptide analogue is bound to said viras-like particle.
- natural human Melan A peptide or "normal human Melan A peptide” as used herein, shall refer to a peptide comprising, or alternatively consisting essentially of, or consisting of the amino acid sequence EAAGIGILTV (SEQ ID NO: 68) representing amino acids positions 26-35 of the normal human MelanA protein sequence or AAGIGILTV (SEQ ID NO: 69) representing amino acids positions 27-35 of the normal human MelanA protein sequence.
- MelanA peptide analogue as used herein shall be defined as a peptide in which the amino acid sequence of the corresponding naturaally occuring normal MelanA peptide is altered by at least one amino acid or amino acid derivative, wherein this alteration may comprise an amino acid substitution and/or deletion and/or insertion or a combination thereof.
- MelanA peptide analogue A as used herein shall be defined as a peptide in which the amino acid sequence of the conesponding naturaally occuring normal MelanA peptide is altered by three, preferably two, and even more preferably one, amino acid or amino acid derivative, wherein this alteration may comprise an amino acid substitution and/or deletion and/or insertion or a combination thereof.
- the term "MelanA peptide analogue A" as used herein shall be defined as a peptide in which the amino acid sequence of the conesponding naturaally occuring normal MelanA peptide is altered by three, preferably two, and even more preferably one, amino acid or amino acid derivative, wherein this alteration may comprise an amino acid substitution and/or deletion and/or insertion or a combination thereof, and wherein this alteration is at position 26, 27, 28 and/or 35 of the normal human MelanA protein sequence (SEQ ID NO: 109).
- the Melan A peptide analogue is capable of allowing an efficient binding to MHC molecules.
- the use of a MelanA peptide analogue thus, allows, in particular, the introduction of such anchor residues leading to an improved binding to MHC molecules.
- the introduction of such anchor residues leading to an improved binding to MHC molecules is in particular advantageous, if the natural and normal, respectively, MelanA peptide does not contain such anchor residues or does not contains only such anchor residues which are inferior to the newly introduced anchor residue(s) replacing the natural and normal, respectively anchor residue.
- the modification of the normal human MelanA peptide leading to the MelanA peptide analogue, and hereby preferably the introduction of these anchor residues is effected either by (i) induced mutation (e.g. chemical induction, inadiation or other procedures known to a person skilled in the art) and subsequent selection of modified peptides with improved binding to MHC or (ii) of selection of modified peptides with improved binding to MHC arising from natural mutations arising at any level of protein sythesis, including but not limited to mutations arising at the DNA, transcriptional, RNA or translational level of protein expression or (iii) or by systematic or random amino acid exchanges, deletions, substitutions or insertions by using classical peptide synthesis known by the person skilled in the art.
- induced mutation e.g. chemical induction, inadiation or other procedures known to a person skilled in the art
- selection of modified peptides with improved binding to MHC arising from natural mutations arising at any level of protein sythesis
- the identification of such anchor residues is typically and preferably effected by using the SYFPEITHI database as described by Rammensee et al. in Immunogenetics 50:213-219 (1999).
- the SYFPEITHI database allows calculating the efficiency of HLA binding for any peptide of choice and it is possible to optimize the peptides regarding the efficiency of HLA binding using this program.
- identification of preferred peptide analogues can be achieved by MHC-peptide binding assays involving but not limited to whole cell assays of T cell activation or recognition or MHC upregualtion in mutant cell lines, MHC-tetramer- peptide binding assays, competitive binding assays with labelled peptides, surface plasmon resonance assays, all known to the person skilled in the art.
- the MelanA peptide analogue is characterized by two, more preferably by a single amino acid substitution with respect to the conesponding normal MelanA peptide.
- the MelanA peptide analogue is protected from protease or peptidase mediated degradation.
- MelanA peptide analogues that are protected from protease or peptidase degradation leads to increased stability of the peptide in vivo after application of the peptide to a subject or and/or to increased stability of the peptide during storage in the presence of proteases or peptidases.
- the consequence of this increased stability is more efficient and prolonged presentation of the human melanoma MelanA peptide analogue on MHC and thus the enhanced stimulation of a specific T cell response.
- the human MelanA peptide analogue is protected by substitution of selected amino acid residues of the natural human MelanA peptide by non natural amino acid derivatives as exemplified in Blanchet et al, J. Immunol. 167:5852-5861 (2001) and references cited therein.
- This overcomes the limitation typically imposed by the fact that chemically modified MelanA peptides and MelanA peptide analogues, respectively, may not be recognized by the T cells equally well as compared to the natural and normal, respectively, MelanA peptide.
- the antigen comprises, alternatively consists essentially of, or alternatively consists of a human melanoma MelanA/MART-1 peptide analogue having an amino acid sequence which is selected from the group consisting of (a) LAGIGILTV (SEQ ID NO: 89); (b) MAGIGILTV (SEQ ID NO: 90), (c) EAAGIGILTV (SEQ ID NO: 68), (d) EAMGIGILTV (SEQ ID NO: 91), (e) ELAGIGILTV (SEQ ID NO: 35), (f) EMAGIGILTV (SEQ ID NO: 92), (g) YAAGIGILTV (SEQ ID NO: 93), and (h) FAAGIGILTV (SEQ ID NO: 94).
- LAGIGILTV SEQ ID NO: 89
- MAGIGILTV SEQ ID NO: 90
- EAAGIGILTV SEQ ID NO: 68
- EAMGIGILTV SEQ ID NO: 91
- the human melanoma MelanA/MART-1 peptide analogue comprises, alternatively consists essentially of, or alternatively consists of the sequence ELAGIGILTV (SEQ ID NO: 35).
- this very prefened embodiment induces expansion of functional MelanA-specific CD8+T cells in HLA-A2 transgenic mice and represents a good compromise between HLA-binding and TCR-recognition (cf. Valmori at al., J. Immunol. 160: 1750-1758 (1998)).
- the human melanoma MelanA/MART-1 peptide analogue with the second attachment site has an amino acid sequence selected from (a) CGHGHSYTTAEELAGIGILTV (SEQ ID NO: 40); and typically abbreviated herein as MelanA 16-35 A/L), (b) CGGELAGIGILTV (SEQ ID NO: 42); and typically abbreviated herein as MelanA 26-35 A/L), (c) CSYTTAEELAGIGILTVILGVL (SEQ ID NO: 43); and typically abbreviated herein as MelanA 20-40 A/L), (d) CGGELAGIGILTVILGVL (SEQ ID NO: 44); and typically abbreviated herein as MelanA 26-40 A/L), (e) ELAGIGILTVGGC (SEQ ID NO: 45); typically abbreviated herein as MelanA 26-35-C A/L), (f) CSPKSLELAGIGILTV
- the human melanoma MelanA/MART-1 peptide analogue with the second attachment has an amino acid sequence of CGHGHSYTTAEELAGIGILTV (SEQ ID NO: 40).
- antigens or antigenic determinants include, for example, opioids and mo ⁇ hine derivatives such as codeine, fentanyl, heroin, morphium and opium; stimulants such as amphetamine, cocaine, MDMA (methylenedioxymethamphetamine), methamphetamine, methylphenidate and nicotine; hallucinogens such as LSD, mescaline and psilocybin; as well as cannabinoids such as hashish and marijuana.
- opioids and mo ⁇ hine derivatives such as codeine, fentanyl, heroin, morphium and opium
- stimulants such as amphetamine, cocaine, MDMA (methylenedioxymethamphetamine), methamphetamine, methylphenidate and nicotine
- hallucinogens such as LSD, mescaline and psilocybin
- cannabinoids such as hashish and marijuana.
- antigens or antigenic determinants for compositions and methods of treatment for other diseases or conditions associated with self antigens would be also known to those skilled in the medical arts treating such disorders.
- Representative examples of such antigens or antigenic determinants are, for example, lymphotoxins (e.g.
- Lymphotoxin ⁇ (LT ⁇ ), Lymphotoxin ⁇ (LT ⁇ )), and lymphotoxin receptors, Receptor activator of nuclear factor kappaB ligand (RANKL), vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGF-R), Interleukin 17 and amyloid beta peptide (A ⁇ l-42), TNF ⁇ , MIF, MCP-1, SDF-1, Rank-L, M-CSF, Angiotensin II, Endoglin, Eotaxin, Grehlin, BLC, CCL21, IL-13, IL-17, IL-5, IL-8, IL-15, Bradykinin, Resistin, LHRH, GHRH, GIH, CRH, TRH and Gastrin, as well as fragments of each which can be used to elicit immunological responses.
- RNKL nuclear factor kappaB ligand
- VEGF vascular endot
- the antigen or antigenic determinant is selected from the group consisting of: (a) a recombinant polypeptide of HIV; (b) a recombinant polypeptide of Influenza virus (e.g., an Influenza virus M2 polypeptide or a fragment thereof); (c) a recombinant polypeptide of Hepatitis C virus; (d) a recombinant polypeptide of Hepatitis B virus (e) a recombinant polypeptide of Toxoplasma; (f) a recombinant polypeptide of Plasmodium falciparum; (g) a recombinant polypeptide of Plasmodium vivax; (h) a recombinant polypeptide of Plasmodium ovale; (i) a recombinant polypeptide of Plasmodium malariae; (j) a recombinant polypeptide of breast cancer cells; (k) a recombinant polypeptide of HIV
- the antigen or antigenic determinant is a polypeptide, a polyprotein, a peptide, an epitope or a polyepitope of HIV.
- Said polypeptide, polyprotein, peptide, epitope or polyepitope of HIV is fused, coupled, bound or otherwise attached to the VLP or packaged VLP as set out throughout the present application, and leading to prefened embodiments of the invention.
- HIV is a retroviras and belongs to the family of the lentivirases. Two types of HIV viruses have been discovered, HIV-1 and HIV-2. HIV-2 is mainly found in the countries of Western Africa, while HIV-1 is the most common form of HIV elsewhere.
- DNA immunisation may lead to integration of DNA into the genome
- plasmid DNA may contain resistance genes
- viral promoters are used, and antibodies to DNA may be elicited in the host.
- large amounts of DNA are required.
- live attenuated or replication deficient virases always bears the risk of recombination, which might lead to more virulent species, which is a concern particularly in immunocompromised individuals.
- the use of viral vectors is expected to lead to the infection of a large number of different cell types in the body, and indeed infection is required for the efficacy of the vaccine.
- adenoviral vectors may be inefficient or lead to side effects in patients sero-positive for adenovirus. There is therefore a need for a safe and immunogenic vaccine technology to induce strong and potent CTL responses against HIV.
- a further aspect of the present invention and a prefened embodiment of the present invention is to provide a composition for enhancing an immune response in an animal comprising: (a) a virus-like particle; (b) an immunostimulatory substance; and (c) at least one antigen or antigenic detenninant; wherein said immunostimulatory substance is bound to said viras-like particle, and wherein said antigen comprises, alternatively consists essentially of, or alternatively consists of at least one HIV polypeptide, and wherein said at least one HIV polypeptide is bound to said virus-like particle.
- a "HIV polypeptide" as used herein shall include a polypeptide, a polyprotein, a peptide, an epitope of HIV.
- HIV polypeptide as used herein shall refer to a polypeptide of HIV comprising, or alternatively consisting essentially of, or alternatively consisting of an epitope of HIV.
- the antigen or antigenic determinant comprises, or alternatively consists essentially of, or alternatively consists of a polyepitope of HIV.
- polyepitope of HIV shall refer to a combination of at least two HIV polypeptides, wherein said at least two HIV polypeptides are bound directly or by way of a linking sequence.
- the antigen comprises, or alternatively consists essentially of, or alternatively consists of is a combination of at least two HIV polypeptides, wherein said at least two HIV polypeptides are bound directly or by way of a linking sequence.
- VLPs bound, coupled, or otherwise fused to HIV antigens are particularly suited as a safe, non-infectious and non-replicative vaccine to induce T-cells and in particular CTLs against HIV.
- VLPs are particularly effective when they are packaged with immunostimulatory substances and sequences, respectively.
- the use of a defined vaccine and thus defined doses of antigen is another advantage over the use of viral vectors, where the antigen dose is more difficult to evaluate.
- VLPs target preferentially dendritic cells and macrophages (Ruedl, C. et al, Eur. J. Immunol. 32: 818-825 (2002)), ensuring antigen delivery to the most relevant antigen presenting cells.
- VLP based vaccines have therefore a much higher specificity than viral-vector or DNA based vaccines.
- Suitable HIV antigens and poylpetides, respectively, for preparation of the compositions of the invention include the following HIV protein subunits: p!7-GAG, p24-GAG, pl5-GAG, Protease, reverse transcriptase (RT), Integrase, Vif, Vpr, Vpu, Tat, Rev, gp-41-Env, gp-120-Env and Nef (Addo, M.M. et al., J. Virol. 77: 2081-2092 (2003)). Both the whole protein subunits and fragments thereof are suitable in preparing the compositions of the invention. In particular, chemically synthesized peptides having the sequence of fragments of these subunits are also included.
- Polyepitopes which may be obtained as recombinant polypeptides or as chemically synthesized long peptides, are used in a favored embodiment of the invention for binding, coupling or otherwise attachment to the VLP and preferably packaged VLP.
- the DNA sequence encoding a polyepitope may also be fused in frame to the sequence of a VLP subunit, leading to VLPs or packaged VLPs fused to the polyepitope.
- the HIV antigen is coupled to the VLP using a cross-linker containing a maleimide moiety
- the HIV antigen, a peptide or recombinant polypeptide is modified according to the disclosures of the invention to include a cysteine residue for reaction with the maleimide moiety introduced in the VLP after the derivatization step of the cross-linking procedure.
- a prominent feature of HIV infection is the ability of the viras to escape from immune control, through accumulation of mutations which are selected for by the strong CTL response elicited in the host (McMichael, A.J. & Rowland- Jones, S.L. Nature 410: 980-987 (2001)).
- a composition of the invention suitable for eliciting a T-cell response against a plurality of epitope will for example be prepared by coupling at least two, or alternatively a plurality of epitopes, in the form of chemically synthesized peptides modified accordingly for cross-linking, to a VLP or packaged VLP.
- VLPs or packaged VLPs each coupled to at least two, or alternatively several different HIV polypeptides and therefore epitopes are obtained.
- a peptide and polypeptide, respectively, containing at least two, or altematively several consecutive HIV epitopes either originating from the same or from different HIV antigens, i.e. a prefened polyepitope of HIV for the present invention is coupled, bound, fused or otherwise attached to a VLP or packaged VLP.
- at least two, or alternatively several different polyepitopes may also be coupled, fused or otherwise attached to one VLP or packaged VLP.
- at least two, or alternatively several different HIV antigens, in the form of recombinant polypeptides are coupled or bound to one VLP or packaged VLP.
- a polyprotein that is a fusion protein comprising two or more HIV polypeptides, modified according to the disclosures of the present invention for coupling, binding or fusion to a VLP, is used as antigen or antigenic determinant.
- combination of peptides, polyepitopes and recombinant polypeptides are coupled, bound or otherwise attached to one VLP or packaged VLP.
- the HIV antigens are fused to one VLP or packaged VLP.
- Immunisation of an animal or subject with a plurality of HIV antigens is also achieved in one further embodiment of the invention by mixing different particles, each coupled, bound, fused or otherwise attached to one, two or more HIV antigens, said HIV antigens being a peptide, an epitope a recombinant polypeptide or a polyepitope.
- sequences of epitopes to be coupled, fused, bound or otherwise attached to a VLP or packaged VLP as peptide, polyepitope or included in a recombinant polypeptide or polyprotein are therefore preferably consensus sequences, obtained from the database (see above reference, or website: http://hiv-web.lanl.gov/seq-db.html) or obtained by aligning all sequences of a given antigen from the database.
- sequences from one clade of virus are selected, in function of the most prevalent clade in the geographical region where the compositions of the invention or vaccines are intended to be injected.
- Aligning sequences of the database would be known to one skilled in the art.
- the program Blast Altschul, S.F et al, J. Mol. Biol. 215:403-410 (1990); Altschul, S.F. et al., Nature Genet. 6:119-129 (1994)
- FASTA Pearson, W.R. Methods Enzymol. 183:63- 98 (1990)
- the antigen or antigenic determinant comprises therefore p24-GAG-CTL and/or NEF-CTL and/or Th cell epitopes.
- Th cell epitopes are believed to contribute to the induction and maintenance of CTL responses, and therefore, in preferred embodiments of the invention, Th cell epitopes are included in the composition of the invention.
- Th cell epitopes may be included in a polyepitope or polyprotein.
- peptides comprising Th cell epitopes may be coupled to VLPs or packaged VLPs, or the composition of the invention may be a mixture of particles, each coupled to an individual peptide, and one or more of said peptides may comprise one or more Th cell epitopes.
- the antigen or antigenic determinant with the second attachment site is selected from the group of the GAG polyepitopes gag-G50 (SEQ ID NO: 86), gag-G68n (SEQ ID NO: 88) and of the Nef polyepitope nef-N56 (SEQ ID NO: 87).
- Gag-50, gag-68n and nef-N56 comprise polyepitopes derived from the Clade B consensus sequences of gag and nef (The Identification of Optimal HIV-Derived CTL Epitopes in Diverse Populations Using HIV Clade-Specific Consensus, pp. 1-1-20 in HIV Molecular Immunology 2001.
- the nef-N56 polyepitope starting with the aminoacid number 66 of the Nef- protein consensus sequence (SEQ ID NO: 96), comprises amino acids 66-99 (VGFPVRPQVPLRPMTYKAAVDLSHFLKEKGGLEG, (SEQ ID NO: 98), followed by amino acids 131-150 (PGIRYPLTFGWCFKLVPVEP, (SEQ ID NO: 99) of the HIV-1 clade B Nef-protein consensus sequence (SEQ ID NO: 96).
- the resulting polypeptide i.e. the combination of SEQ ID NO: 98 and SEQ ID NO: 99, has the amino acid sequence of SEQ ID NO: 104.
- the nef-N56 polyepitope additionally comprises an N-terminal Cysteine and Glycine for coupling (SEQ ID NO: 87).
- gag-G50 polyepitope starts at the N-terminus of p24-GAG, from position 139 of the HIV-1 clade B GAG-protein consensus sequence (SEQ ID NO: 97).
- the sequence "KVVEE” ((SEQ ID NO: 100) which represents the amino acids 157-161 from the GAG consensus sequence (SEQ ID NO: 97)), and where the density of epitopes is lowest, is deleted.
- gag-G50 comprises amino acids 139-156 (QGQMVHQAISPRTLNAWV, (SEQ ID NO: 101)), followed by amino acids 162-191
- the gag-G50 polyepitope comprises an N-terminal Cysteine for coupling (SEQ ID NO: 106).
- the gag-G50 polyepitope additionally comprises a C-terminal lysine residue (SEQ ID NO: 86).
- gag-G68n epitope (SEQ ID NO: 88) is based on G50 epitope, with the addition of the more C-terminal "GEIYKRWIILGLNKIVRMY" sequence, conesponding to aminoacids 259-277 (SEQ ID NO: 103) from GAG-protein consensus sequence (SEQ ID NO: 97) to the N-terminus of the sequence of gag-G50 (excluding the N-terminal cysteine). Therefore, the resulting HIV polypeptide, i.e. the combination of SEQ ID NO: 103, SEQ ID NO: 101 and SEQ ID NO: 102, has the amino acid sequence of SEQ ID NO: 172.
- the gag-G68n epitope comprises an N-terminal Cysteine for coupling (SEQ ID NO: 108).
- the gag-G68n epitope additionally comprises a C-terminal lysine residue (SEQ ID NO: 88).
- the polyepitopes of the invention comprise a cysteine residue at the N-terminus for coupling, rather than a C-terminal cysteine, since there are more protecting strategies for N-terminal cysteines, and peptides may be further trimmed at their N-terminus for proper presentation by aminopeptidases (Goldberg A.L. et al., Mol. Immunol. 39: 147-164 (2002)). Introduction of the cysteine residue for coupling to the C-terminus rather than the N-terminus however also leads to an embodiment of this invention.
- the polyepitopes gag-G50 (SEQ ID NO: 86), nef-N56 (SEQ ID NO: 87) or gag-G68n (SEQ ID NO: 88) are coupled to the RNA phage VLPs or packaged VLPs Q ⁇ , AP205, GA, MS-2 and fr, or to HBcAg VLPs or packaged VLPs modified to harbour an additional lysine residue in their immunodominant region, i.e. HBcAgl-1851ys described in WO 02/56905 which is inco ⁇ orated hereby in its entirety by way of reference.
- the two polyepitopes gag-G50 and nef-N56 are coupled both on a single VLP.
- the VLP is the VLP of RNA phages Q ⁇ , AP205, GA, MS-2 and Fr, or HBcAgl-1851ys being described in WO 02/56905 which is inco ⁇ orated hereby in its entirety by way of reference.
- the gag-G50 and gag-G68n, and the nef- N56 epitopes are fused to the N-terminus of the VLP of phage fr, or to the C-terminus of phage Q ⁇ .
- GAG protein (Berthet-Colominas, C. et al, EMBO J. 18: 1124-1136 (1999))
- Nef protein or protein fragments (Franken, P. et al., Prot. Sci. 6: 2681-2683 (1997)) of HIV
- GAG and NEF proteins, or fragments thereof, modified to include a cysteine residue for coupling according to the disclosure of the present invention are coupled to VLPs or packaged VLPs.
- compositions of the invention comprising a polypeptide, a polyprotein, a peptide, an epitope or a polyepitope of HIV and optionally a further adjuvant, are useful as vaccines for induction of HIV specific T-cells in humans.
- the vaccine comprises a Q ⁇ or AP205 VLP packaged with the G8-8 oligodeoxynucleotide and optionally a further adjuvant.
- the T-cell response induced upon vaccination is assessed in proliferation assays (for Th cell response, Belshe R.B. et al., J. Inf. Dis. 183: 1343-1352 (2001)), in ELISPOT assays (Oxenius, A.
- gag-G50, gag-G68n and nef-N56 devoid of the N- terminal cysteine are inserted between amino acid 2 and 3 (numbering of the cleaved CP, that is wherein the N-terminal methionine is cleaved) of the fr CP.
- gag-G50, gag-G68n and nef-N56 devoid of the N-terminal cysteine are fused to the Al protein of Q ⁇ VLP, as described above.
- the antigen being coupled, fused or otherwise attached to the viras-like particle, is a T cell epitope, either a cytotoxic or a Th cell epitope.
- the antigen is a combination of at least two, preferably different, epitopes, wherein the at least two epitopes are linked directly or by way of a linking sequence. These epitopes are preferably selected from the group consisting of cytotoxic and Th cell epitopes.
- a mosaic viras-like particle e.g. a viras-like particle composed of subunits attached to different antigens and epitopes, respectively, is within the scope of the present invention.
- Such a composition of the present invention can be, for example, obtained by transforming E.coli with two compatible plasmids encoding the subunits composing the viras-like particle fused to different antigens and epitopes, respectively.
- the mosaic virus-like particle is assembled either directly in the cell or after cell lysis.
- such an inventive composition can also be obtained by attaching a mixture of different antigens and epitopes, respectively, to the isolated viras-like particle.
- the antigen of the present invention can be synthesized or recombinantly expressed and coupled to the virus-like particle, or fused to the viras-like particle using recombinant DNA techniques.
- Exemplary procedures describing the attachment of antigens to virus-like particles are disclosed in WO 00/32227, in WO 01/85208 and in WO 02/056905, the disclosures of which are herewith incorporated by reference in its entirety.
- the invention also provides a method of producing a composition, typically and preferably for enhancing an immune response in an animal, comprising a VLP and an immunostimulatory substance, preferably an unmethylated CpG-containing oligonucleotide bound to the VLP which comprises incubating the VLP with the immunostimulatory substance and oligonucleotide, respectively, adding RNase and purifying said composition, wherein preferably the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of the unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein the palindromic sequence is flanked at its 3 '-terminus and at its 5 '-terminus by less than 10 guanosine entities.
- the method further comprises the step of binding an antigen or antigenic determinant to said virus-like particle.
- the anigen or antigenic determinant is bound to the viras-like particle before incubating the viras-like particle with the immunostimulatory substance.
- the anigen or antigenic determinant is bound to the viras-like particle after purifying the composition.
- the method comprises incubating the VLP with RNase, adding the immunostimulatory substance and oligonucleotide, respectively, and purifying the composition, wherein preferably the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of the unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein the palindromic sequence is flanked at its 3 '-terminus and at its 5'-terminus by less than 10 guanosine entities.
- the method further comprises the step of binding an antigen or antigenic determinant to said virus-like particle.
- the anigen or antigenic determinant is bound to the viras-like particle before incubating the virus-like particle with the RNase. In another prefened embodiment, the anigen or antigenic determinant is bound to the virus-like particle after purifying the composition.
- the VLP is produced in a bacterial expression system.
- the RNase is RNase A.
- the invention further provides a method of producing a composition for enhancing an immune response in an animal comprising a VLP bound to an immunostimulatory substance, preferably to an unmethylated CpG-containing oligonucleotide which comprises disassembling the VLP, adding the immunostimulatory substance and oligonucleotide, respectively, and reassembling the VLP, wherein preferably the immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of the unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein the palindromic sequence is flanked at its 3 '-terminus and at its 5' -terminus by less than 10 guanosine entities.
- the method can further comprise removing nucleic acids of the disassembled VLP and/or purifying the composition after reassembly.
- the method further comprises the step of binding an antigen or antigenic determinant to the virus-like particle.
- the anigen or antigenic determinant is bound to the viras-like particle before disassembling the viras- like particle.
- the anigen or antigenic determinant is bound to the virus-like particle after reassembling the viras-like particle and preferably after purifying the composition.
- the invention also provides vaccine compositions which can be used for preventing and/or attenuating diseases or conditions.
- Vaccine compositions of the invention comprise, or alternatively consist of, an immunologically effective amount of the inventive immune enhancing composition together with a pharmaceutically acceptable diluent, canier or excipient.
- the vaccine can also optionally comprise an adjuvant.
- the invention provides a vaccine comprising an immunologically effective amount of the inventive immune response enhancing composition together with a pharmaceutically acceptable diluent, canier or excipient, wherein the composition comprises, (a) a viras-like particle; (b) at least one immunostimulatory substance; and (c) at least one antigen or antigenic determinant; wherein the antigen or antigenic determinant is bound to the virus-like particle, and wherein the immunostimulatory substance is bound to the viras-like particle, and wherein the antigen comprises, alternatively consists essentially of, or alternatively consists of a human melanoma MelanA peptide analogue.
- the vaccine further comprises an adjuvant.
- the invention further provides vaccination methods for preventing and/or attenuating diseases or conditions in animals.
- the invention provides vaccines for the prevention of infectious diseases in a wide range of animal species, particularly mammalian species such as human, monkey, cow, dog, cat, horse, pig, etc.
- Vaccines can be designed to treat infections of viral etiology such as HIV, influenza, He ⁇ es, viral hepatitis, Epstein Bar, polio, viral encephalitis, measles, chicken pox, etc.; or infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.; or infections of parasitic etiology such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis, amoebiasis, etc.
- viral etiology such as HIV, influenza, He ⁇ es, viral hepatitis, Epstein Bar, polio, viral encephalitis, measles, chicken pox, etc.
- infections of bacterial etiology such as pneumonia, tuberculosis, syphilis, etc.
- infections of parasitic etiology such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis, amo
- the invention provides vaccines for the prevention of cancer in a wide range of species, particularly mammalian species such as human, monkey, cow, dog, cat, horse, pig, etc.
- Vaccines can be designed to treat all types of cancer including, but not limited to, lymphomas, carcinomas, sarcomas and melanomas.
- RNA-phage derived VLPs in particular the VLP derived from Q ⁇ , do very efficiently induce a memory CD8 + T cell response in a homologous prime-boost vaccination scheme.
- live vaccinia viras immunizations are very ineffective for the induction of a primary CD8 + T cell response and homologous boosting with vaccinia does hardly lead to an expansion of memory CD8 + T cells.
- the invention provides a method of immunizing or treating an animal comprising priming a T cell response in the animal by administering an immunologically effective amount of the inventive vaccine.
- the method further comprises the step of boosting the immune response in the animal, wherein preferably the boosting is effected by administering an immunologically effective amount of a vaccine of the invention or an immunologically effective amount of a heterologous vaccine, wherein even more preferably the heterologous vaccine is a DNA vaccine, peptide vaccine, recombinant viras or a dendritic cell vaccine.
- the invention further provides a method of immunizing or treating an animal comprising the steps of priming a T cell response in the animal, and boosting a T cell response in the animal, wherein the boosting is effected by administering an immunologically effective amount of the vaccine of the invention.
- the primimg is effected by administering an immunologically effective amount of a vaccine of the invention or an immunologically effective amount of a heterologous vaccine, wherein even more preferably said heterologous vaccine is a DNA vaccine, peptide vaccine, recombinant viras or a dendritic cell vaccine.
- the invention further provides for a composition
- a composition comprising a viras-like particle, at least one immunostimulatory substance; and at least one antigen or antigenic determinant; wherein said antigen or antigenic determinant is bound to said viras-like particle, and wherein said immunostimulatory substance is bound to said viras-like particle, and wherein said antigen comprises a cytotoxic T cell epitope, a Th cell epitope or a combination of at least two of said epitopes, wherein said at least two epitopes are bound directly or by way of a linking sequence, and wherein preferably said cytotoxic T cell epitope is a viral or a tumor cytotoxic T cell epitope.
- the present invention provides a composition, typically and preferably for enhancing an immune response in an animal comprising: (a) a virus- like particle; (b) an immunostimulatory substance; wherein said immunostimulatory substance (b) is bound to said viras-like particle (a); and (c) an antigen, wherein said antigen is mixed with said virus-like particle (a), and wherein said immunostimulatory substance is an unmethylated CpG-containing oligonucleotide, wherein the CpG motif of said unmethylated CpG-containing oligonucleotide is part of a palindromic sequence, and wherein said palindromic sequence is flanked at its 3 '-terminus and at its 5 '-terminus by less than 10 guanosine entities.
- the term "mixed” refers to the combination of two or more substances, ingredients, or elements that are added together, are not chemically combined with each other and are capable of being separated. Methods of mixing antigens with viras-like particles are described in WO 04/000351, which is inco ⁇ orated herein by reference in its entirety.
- compositions of the invention when administered to an animal, they can be in a composition which contains salts, buffers, adjuvants or other substances which are desirable for improving the efficacy of the composition.
- materials suitable for use in preparing pharmaceutical compositions are provided in numerous sources including REMINGTON'S PHARMACEUTICAL SCIENCES (Osol, A, ed., Mack Publishing Co., (1990)).
- adjuvants can be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette Guerin) and Corynebacterium parvum. Such adjuvants are also well known in the art.
- compositions of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS 21, QS 18, CRL1005, Aluminum salts, MF 59, and Virosomal adjuvant technology.
- the adjuvants can also comprise a mixture of these substances.
- compositions of the invention are said to be “pharmacologically acceptable” if their administration can be tolerated by a recipient individual. Further, the compositions of the invention will be administered in a "therapeutically effective amount” (i.e., an amount that produces a desired physiological effect).
- compositions of the present invention can be administered by various methods known in the art.
- the particular mode selected will depend of course, upon the particular composition selected, the severity of the condition being treated and the dosage required for therapeutic efficacy.
- the methods of the invention generally speaking, can be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
- modes of administration include oral, rectal, parenteral, intracistemal, infravaginal, intraperitoneal, topical (as by powders, ointments, drops or transdermal patch), bucal, or as an oral or nasal spray.
- parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrastemal, subcutaneous and intraarticular injection and infusion.
- the composition of the invention can also be injected directly in a lymph node.
- Components of compositions for administration include sterile aqueous (e.g., physiological saline) or non-aqueous solutions and suspensions.
- nonaqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Caniers or occlusive dressings can be used to increase skin permeability and enhance antigen abso ⁇ tion.
- Combinations can be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially.
- Administration "in combination” further includes the separate administration of one of the compounds or agents given first, followed by the second. Dosage levels depend on the mode of administration, the nature of the subject, and the quality of the canier/adjuvant formulation. Typical amounts are in the range of about 0.1 ⁇ g to about 20 mg per subject.
- Prefe ⁇ ed amounts are at least about 1 ⁇ g to about 1 mg, more preferably at least about 10 to about 400 ⁇ g per subject.
- Multiple administration to immunize the subject is prefened, and protocols are those standard in the art adapted to the subject in question.
- compositions can conveniently be presented in unit dosage form and can be prepared by any of the methods well-known in the art of pharmacy. Methods include the step of bringing the compositions of the invention into association with a canier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compositions of the invention into association with a liquid canier, a finely divided solid canier, or both, and then, if necessary, shaping the product.
- compositions suitable for oral administration can be presented as discrete units, such as capsules, tablets or lozenges, each containing a predetermined amount of the compositions of the invention.
- Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, an elixir or an emulsion.
- Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compositions of the invention described above, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art.
- Other embodiments of the invention include processes for the production of the compositions of the invention and methods of medical treatment for cancer and allergies using said compositions.
- HBcAg containing peptide p33 from LCMV is given in SEQ ID NO: 15.
- the p33 -HBcAg VLPs were generated as follows: Hepatitis B clone pEco63 containing the complete viral genome of Hepatitis B virus was purchased from ATCC. The gene encoding HBcAg was introduced into the EcoRI/Hindlll restriction sites of expression vector pkk223.3 (Pharmacia) under the control of a strong tac promoter.
- the p33 peptide (KAVYNFATM) (SEQ ID NO: 82) derived from lymphocytic choriomeningitis virus (LCMV) was fused to the C-terminus of HBcAg (1-185) via a three leucine-linker by standard PCR methods.
- a clone of E. coli K802 selected for good expression was transfected with the plasmid, and cells were grown and resuspended in 5 ml lysis buffer (10 mM Na2HPO4, 30 mM NaCl, 10 mM EDTA, 0.25 % Tween-20, pH 7.0). 200 ⁇ l of lysozyme solution (20 mg/ml) was added.
- p33-HBcAg VLP HBcAg-p33 VLP
- p33- VLPs p33- VLPs and HBc33 are used interchangeably.
- the cD ⁇ A of GA phage coat protein was amplified from GA phage by reverse transcription followed by a PCR amplification step, using the RevertAid First strand cD ⁇ A synthesis Kit (Fermentas).
- the cD ⁇ A was cut with the enzymes ⁇ col and Hindlll, and cloned in vector pQ ⁇ l85 previously cut with the same enzymes, leading to plasmid 355.24, harboring GA cD ⁇ A.
- the sequence of the inserted cD ⁇ A was checked by D ⁇ A sequencing.
- Plasmid 355.24 was transformed in E. coli JM109. Expression was performed essentially as described for Q ⁇ VLP. A single colony was inoculated in LB medium containing 20 mg/L Ampicillin overnight without shaking. This inoculum was transfened the next day into a larger flask containing M9 medium supplemented with 1% casaminoacids, 0.2% glucose and 20 mg/L Ampicillin, and incubated under shaking for 14-20 h.
- GA VLP was isolated essentially as described for Q ⁇ VLP. Cells were lysed, and the cleared lysate was loaded onto a Sepharose CL-4B column (Amersham Pharmacia). The eluate was concentrated by ammonium sulphate precipitation, and rechromatographed onto a Sepharose CL-6B column (Amersham Pharmacia). The final step was either an ultracentrifugation on sucrose gradient (20-50% w/v), or on CsCl. The isolated VLPs were subsequently dialysed against 20 mM Tris, 150 mM NaCl, pH 8.0.
- VLPs produced in yeast contain small amounts of RNA which can be easily digested and so eliminated by incubating the VLPs with RNase A.
- the highly active RNase A enzyme has a molecular weight of about 14 kDa and is small enough to enter the VLPs to eliminate the undesired ribonucleic acids.
- Recombinantly produced BKV VLPs (SEQ ID NO: 12) were concentrated to 1 mg/ml in PBS buffer pH7.2 and incubated in the absence or presence of RNase A (200 ⁇ g/ml, Roche Diagnostics Ltd, Switzerland) for 3 h at 37°C.
- BKV VLPs are supplemented with 75 nmol/ml 5'- fluorescein labeled phosphorothioate G8-8-FAM oligonucleotide (oligonucleotide from SEQ ID NO: 7) and incubated for 3 h at 37°C. Subsequently BKV VLPs are subjected to DNasel digestion for 3 h at 37°C (40 u/ml AMPD1, Sigma, Division of Fluka AG, Switzerland) or loaded without DNasel digestion.
- CpG-containing oligonucleotides can be packaged into BKV VLPs.
- the RNase A treated recombinant BKV VLPs (Example 3) are supplemented with 150 nmol/ml G8-8 oligonucleotides with phosphodiester backbone or G8-8 with phosphorothioate backbone and incubated for 3 h at 37°C.
- VLP preparations for mouse immunization are extensively dialysed (10,000-fold diluted) for 24 h against PBS pH7.2 with a 300 kDa MWCO dialysis membrane (Spectrum Medical industries Inc., Houston, USA) to eliminate RNase A and the excess of CpG-oligonucleotides.
- the samples are complemented with 6-fold concentrated DNA-loading buffer (10 mM Tris pH7.5, 10% v/v glycerol, 0.4%> orange G) and run for 1 h at 65 volts in a 0.8% native tris-acetate pH7.5 agarose gel.
- BKV VLPs (15 ⁇ g) are loaded on a native 0.8% agarose gel electrophoresis and analyzed after control incubation or after digestion with RNase A and subsequent incubation with G8-8- oligonucleotides (with phosphodiester- or with phosphorothioate backbone) upon staining with ethidium bromide or Coomassie Blue in order to assess the presence of RNA/DNA or protein and the reduction of unbound CpG-oligonucleotides after dialysis.
- Immunostimulatory nucleic acids can be packaged into HBcAg VLPs comprising fusion proteins with antigens.
- HBcAg VLPs when produced in E. coli by expressing the Hepatitis B core antigen fusion protein p33-HBcAg (HBc33) (see Example 1) or the fusion protein to the peptide PI A (HBcPl A), contain RNA which can be digested and so eliminated by incubating the VLPs with RNase A.
- the gene PI A codes for a protein that is expressed by the mastocytoma tumor cell line P815.
- the dominant CTL epitope termed PI A peptide
- PI A peptide binds to MHC class I (Ld) and the complex is recognized by specific CTL clones (Brandle et al., 1998, Eur. J. Immunol. 28: 4010-4019).
- Fusion of peptide P1A-1 (LPYLGWLVF) (SEQ ID NO: 95) to the C-terminus of HBcAg (aa 185, see Example 1) was performed by PCR using appropriate primers using standard molecular biology techniques.
- a three leucine linker was cloned between the HBcAg and the peptide sequence. Expression was performed as described in Example 1.
- the fusion protein of HBcAg with PI A termed HBcPlA, formed capsids when expressed in E. coli which could be purified similar to the procedure described in Example 1.
- HBcAg-p33 Recombinantly produced HBcAg-p33 (HBc33) and HBcAg-PlA (HBcPlA) VLPs at a concentration of 1.0 mg/ml in 1 x PBS buffer (KCl 0.2g/L, KH2PO40.2g/L, NaCl 8 g L, Na2HPO4 1.15 g/L) pH 7.4, were incubated in the presence of 300 ⁇ g/ml RNase A (Qiagen AG, Switzerland) for 3 h at 37°C in a thermomixer at 650 ⁇ m.
- RNase A Qiagen AG, Switzerland
- RNAse A HBcAg-p33 VLPs are supplemented with 130 nmol/ml CpG-oligonucleotides G3-6, G6 and G8-8 (Table 1).
- the resulting plasmid produced in E. coli XLl-blue and isolated using the Qiagen Endofree plasmid Giga Kit, is digested with restriction endonucleases Xhol and Xbal and resulting restriction products are separated by agarose electrophoresis. Inserts are isolated by electro-elution and ethanol precipitation. Sequences are verified by sequencing of both strands .
- DNAse I treatment Packaged HBcAg-p33 VLPs are subsequently subjected to DNasel digestion (5 U/ml) for 3 h at 37°C (DNasel, RNase free Fluka AG, Switzerland) and were extensively dialysed (2 x against 200-fold volume) for 24 h against PBS pH 7.4 with a 300 kDa MWCO dialysis membrane (Spectrum Medical industries Inc., Houston, USA) to eliminate RNAse A and the excess of CpG-oligonucleotides.
- Benzonase treatment Since some single stranded oligodeoxynucleotides are partially resistant to DNasel treatment, Benzonase treatment is used to eliminate free oligonucleotides from the preparation. 100-120 U/ml Benzonase (Merck KGaA, Darmstadt, Germany) and 5 mM MgC12 are added and incubated for 3 h at 37°C before dialysis.
- VLP preparations packaged with immunostimulatroy nucleic acids used in mouse immunization experiments are extensively dialysed (2x against 200fold volume) for 24 h against PBS pH 7.4 with a 300 kDa MWCO dialysis membrane (Spectrum Medical Industries, Houston, US) to eliminate added enzymes and free nucleic acids.
- Analytics of packaging release of packaged immunostimulatory nucleic acids: To
- capsid solution 1 ⁇ l of proteinase K (600 U/ml, Roche, Mannheim, Germany), 3 ⁇ l 10% SDS-solution and 6 ⁇ l lOfold proteinase buffer (0.5 M NaCl, 50 mM EDTA, 0.1 M Tris pH 7.4) are added and subsequently incubated overnight at 37°C. VLPs are completed hydrolysed under these conditions. Proteinase K was inactivated by heating for 20 min at 65°C. 1 ⁇ l RNAse A (Qiagen, 100 ⁇ g/ml, diluted 250 fold) was added to 25 ⁇ l of capsid.
- proteinase K 600 U/ml, Roche, Mannheim, Germany
- 6 ⁇ lOfold proteinase buffer 0.5 M NaCl, 50 mM EDTA, 0.1 M Tris pH 7.4
- capsid 2-30 ⁇ g of capsid were mixed with 1 volume of 2x loading buffer (lxTBE, 42%o w/v urea, 12% w/v Ficoll, 0.01 % Bromphenolblue), heated for 3 min at 95°C and loaded on a 10% (for oligonucleotides of about 20 nt length) or 15%) (for > than 40 mer nucleic acids) TBE/urea polyacrylamid gel (Invitrogen). Alternatively samples are loaded on a 1% agarose gel with 6x loading dye (10 mM Tris pH 7.5, 50 mM EDTA, 10% v/v glycerol, 0.4 % orange G). TBE/urea gels are stained with SYBRGold and agarose gels with stained with ethidium bromide.
- 2x loading buffer lxTBE, 42%o w/v urea, 12% w/v Ficoll, 0.01 % Bromphenolblue
- Immunostimulatory nucleic acids can be packaged in HBcAg-wt coupled with antigens.
- HBcAg-wt VLPs were packaged after coupling with peptide p33 (CGG-KAVYNFATM) (SEQ ID NO: 83), derived from lymphocytic choriomeningitis viras (LCMV).
- CGG-KAVYNFATM CGG-KAVYNFATM
- LCMV lymphocytic choriomeningitis viras
- VLPs were dialyzed to Mes buffer (2-(N-mo ⁇ holino) ethanesulphonic acid) pH 7.4 for 2 x 2 h using MWCO 10.000 kD dialysis membranes at 4°C.
- VLPs (50 ⁇ M) were subsequently coupled to the N-terminal cysteine of the p33 peptide (250 ⁇ M) during a 2 h incubation in a thermomixer at 25°C.
- Samples were dialyzed (MWCO 300.000) extensively to lx PBS pH 7.4 to eliminate undesired free peptide.
- HBcAg-wt VLPs derivatization with SMPH and coupling to p33 peptide was analyzed on SDS-PAGE. Samples were analysed by 16% SDS PAGE and stained with Coomassie Blue. Loaded on the gel were the following samples: 1.NEB Prestained Protein Marker, Broad Range (# 7708S), 10 ⁇ l; 2. p33 peptide; 3. HBcAg-wt VLP derivatized with SMPH, before dialysis; 4. HBcAg-wt VLP derivatized with SMPH, after dialysis; 5. HBcAg- wt VLP coupled with p33, supernatant; 6.
- HBcAg-wt was visible as a 21 kD protein band. Due to the low molecular weigth of SMPH is the derivatised product only slightly larger and can not be distinguished by SDS-PAGE. Peptide alone was visible as a 3 kD band and coupled product, termed HBx33, showed a strong secondary band at approximately 24 kD accounting for more than 50% of total HBcAg- wt.
- Enzymatic RNA hydrolysis HBx33 VLPs (0.5-1.0 mg/ml, lxPBS buffer pH7.4) in the presence of RNase A (300 ⁇ g/ml, Qiagen AG, Switzerland) were diluted with 4 volumes H2O to decrease salt concentration to a final 0.2xPBS concentration and incubated for 3 h at 37°C in a thermomixer at 650 ⁇ m.
- VLP preparations for mouse immunization were extensively dialysed (2x against 200-fold volume) for 24 h against PBS pH 7.4 with a 300 kDa MWCO dialysis membrane (Spectrum Medical industries Inc., Houston, USA) to eliminate RNase A and the excess of CpG-oligonucleotides.
- Immunostimulatory nucleic acids can be packaged into Q ⁇ VLPs coupled with antigens.
- VLPs were used untreated or after coupling to p33 peptides containing an N-terminal CGG or and C-terminal GGC extension (CGG-KAVYNFATM (SEQ ID NO: 83) and KAVYNFATM-GGC (SEQ ID NO: 84)).
- Recombinantly produced Q ⁇ VLPs were derivatized with a 10 molar excess of SMPH (Pierce) for 0.5 h at 25°C, followed by dialysis against 20 mM HEPES, 150 mM NaCl, pH 7.2 at 4°C to remove unreacted SMPH.
- Q ⁇ VLPs when produced in E. coli by expressing the bacteriophage Q ⁇ capsid protein, contain RNA which can be digested and so eliminated by incubating the VLPs with RNase A.
- Q ⁇ VLPs at a concentration of 1.0 mg/ml in 20mM Hepes/150mM NaCl buffer (HBS) pH 7.4 were either digested directly by addition of RNase A (300 ⁇ g/ml, Qiagen AG, Switzerland) or were diluted with 4 volumes H2O to a final 0.2 x HBS concentration and then incubated with RNase A (60 ⁇ g/ml, Qiagen AG, Switzerland). Incubation was allowed for 3 h at 37°C in a thermomixer at 650 ⁇ m.
- RNA hydrolysis from Qb VLPs by RNase A under low and high ionic strength was analyzed on a 1% agarose gel stained with ethidium bromide and Coomassie Blue.
- Q ⁇ VLPs After RNase A digestion in 0.2 x HBS the Q ⁇ VLPs are concentrated to 1 mg/ml using Millipore Microcon or Centriplus concentrators and aliquots are dialysed against lx HBS or 0.2 x HBS.
- Q ⁇ VLPs are supplemented with 130 nmol/ml G3-6, G6 or G8-8 (Table 1) and incubated in a thermomixer for 3 h at 37°C. Subsequently Q ⁇ VLPs are subjected to Benzonase digestion (100 U/ml) for 3 h at 37°C. Samples are analysed on 1% agarose gels after staining with ethidium bromide or Coomassie Blue.
- Different immunostimulatory nucleic acids can be packaged in Q ⁇ and Qbx33 VLPs: After RNase A digestion in 0.2 x HBS the Q ⁇ VLPs or Qbx33 VLPs are concentrated to 1 mg/ml using Millipore Microcon or Centriplus concentrators and supplemented with 130 nmol/ml G3-6, G6 and G8-8 (Table 1) and incubated in a thermomixer for 3 h at 37°C. Subsequently Q ⁇ VLPs or Qbx33 VLPs are subjected to DNAse I digestion (5 U/ml) or Benzonase digestion (100 U/ml) for 3 h at 37°C.
- Disassembly 40 mg of lyophilized purified AP205 VLP (SEQ-ID: 80 or 81) were resolubilized in 4 ml 6 M GuHCl, and incubated overnight at 4°C. The disassembly mixture was centrifuged at 8000 ⁇ m (Eppendorf 5810 R, in fixed angle rotor F34-6-38, used in all the following steps). The pellet was resolubilized in 7 M urea, while the supernatant was dialyzed 3 days against NET buffer (20 mM Tris-HCl, pH 7.8 with 5mM EDTA and 150 mM NaCl) with 3 changes of buffer. Alternatively, dialysis was conducted in continuous mode over 4 days.
- NET buffer 20 mM Tris-HCl, pH 7.8 with 5mM EDTA and 150 mM NaCl
- the dialyzed solution was centrifuged at 8000 ⁇ m for 20 minutes, and the pellet was resolubilized in 7 M urea, while the supernatant was pelletted with ammonium sulphate (60% saturation), and resolubilized in a 7 M urea buffer containing 10 mM DTT.
- the previous pellets all resolubilized in 7 M urea were joined, and precipitated with ammonium sulphate (60% saturation), and resolubilized in a 7 M urea buffer containing 10 mM DTT.
- the protein concentration was estimated spectrophotometrically by measuring an aliquot of protein diluted 25-fold for the measurement, using the following fonnula: (1.55 x OD280 - 0.76 x OD260) x volume. The average concentration was of 1 nmol/ml of VLP (2.6 mg/ml). The ratio of absorbance at 280 nm vs. 260 nm was of 0.12/0.105.
- Reassembly 1.1 ml beta-mercaptoethanol was added to the sample, and the following reassembly reactions are set up:
- the EM procedure is as follows: A suspension of the proteins was absorbed on carbon-formvar coated grids and stained with 2% phosphotungstic acid (pH 6,8). The grids were examined with a JEM 100C (JEOL,Japan) electron microscope at an accelerating voltage of 80 kV.
- Photographic records are performed on Kodak electron image film and electron micrographs were obtained by printing of negatives on Kodak Polymax paper.
- the VLP reassembled in the presence of the G8-8 is purified over a Sepharose 4B column (1 X 50 cm), eluted with NET buffer (1 ml/h). The fractions are analyzed by Ouchterlony assay, and the fractions containing VLP are pooled. Samples of the reassembly reaction containing G8-8 taken after the reassembly step and before extensive dialysis are analysed on a 0.6% agarose gel stained with ethidium-bromide and Coomassie blue.
- Disassembly 100 mg of purified and dried recombinant AP205 VLP are used for disassembly as described above. All steps are performed essentially as described under disassembly in part A, but for the use of 8 M urea to solublize the pellets of the ammonium sulphate precipitation steps and the omission of the gel filtration step using a CL-4B column prior to reassembly.
- the pooled fractions of the Sephadex G-75 column containe 21 mg of protein as determined by spectroscopy using the formula described in part A.
- the ratio of absorbance at 280 nm to the absorbance at 260 nm of the sample is of 0.16 to 0.125. The sample is diluted 50 times for the measurement.
- Reassembly The protein preparation resulting from the Sephadex G-75 gel filtration purification step is precipitated with ammonium sulphate at 60% saturation, and the resulting pellet solub ⁇ ized in 2 ml 7 M urea, 10 mM DTT. The sample is diluted with 8 ml of 10%) 2-mercaptoethanol in NET buffer, and dialyzed for 1 hour against 40 ml of 10%) 2-mercaptoethanol in NET buffer. Reassembly is initiated by adding 0.4 ml of a G8- 8 solution (109 nmol/ml) to the protein sample in the dialysis bag. Dialysis in continous mode is set up, and NET buffer used as eluting buffer.
- Dialysis is pursued for two days and a sample is taken for EM analysis after completion of this dialysis step.
- the dialyzed reassembly solution is subsequently dialyzed against 50% v/v Glycerol in NET buffer, to achieve concentration.
- One change of buffer is effected after one day of dialysis.
- the dialysis is pursued over a total of three days.
- the dialyzed and concentrated reassembly solution is purified by gel filtration over a Sepharose 4-B column (1X60 cm) at a flow rate of 1 ml/hour, in NET buffer. Fractions are tested in an Ouchterlony assay, and fractions containing capsids are dried, resuspended in water, and rechromatographed on the 4-B column equilibrated in 20 mM Hepes pH 7.6. Using each of the following three formula:
- Reassembled AP205 VLP obtained as described in part B, and in 20 mM Hepes, 150 mM NaCl, pH 7.4 is reacted at a concentration of 1.4 mg/ml with a 5-fold excess of the crosslinker SMPH diluted from a 50 mM stock in DMSO for 30 minutes at 15 °C.
- the obtained so-called derivatized AP205 VLP is dialyzed 2 X 2 hours against at least a 1000- fold volume of 20 mM Hepes, 150 mM NaCl, pH 7.4 buffer.
- the derivatized AP205 is reacted at a concentration of 1 mg/ml with either a 2.5-fold, or with a 5-fold excess of peptide, diluted from a 20 mM stock in DMSO, for 2 hours at 15 °C.
- the sample is subsequently flash frozen in liquid mtrogen for storage.
- the coupling reaction is analyzed on an SDS-PAGE.
- Non-enzymatic hydrolysis of the RNA content of VLPs and packaging of immunostimulatory nucleic acids are included in the RNA content of VLPs and packaging of immunostimulatory nucleic acids.
- 150 mM NaCl was dialysed either against 2000 ml of 50 mM TrisHCl pH 8.0, 50 mM NaCl, 5% glycerol, 10 mM MgC12 or 2000 ml of 4 mM HEPES, pH 7.4, 30 mM NaCl for 2 h at 4°C in SnakeSkinTM pleated dialysis tubing (Pierce, Cat. No. 68035). Each of the dialysis buffers was exchanged once and dialysis was allowed to continue for another 16 h at 4°C.
- the dialysed solution was clarified for 10 minutes at 14 000 ⁇ m (Eppendorf 5417 R, in fixed angle rotor F45-30-11, used in all the following steps) and proteinconcentration was again determined by Bradford analysis.
- Q ⁇ VLPs in 50 mM TrisHCl pH 8.0, 50 mM NaCl, 5% glycerol, 10 mM MgC12 were diluted with the corresponding buffer to a final protein concentration of 1 mg/ml whereas Q ⁇ VLPs in 4 mM HEPES pH 7.4, 30 mM NaCl were diluted with the conesponding buffer to a final protein concentration of 0.5 mg/ml.
- This capsid-containing solutions were centrifuged again for 10 minutes at 14 000 ⁇ m at 4°C.
- the supernatants were than incubated with ZnSO4 which was added to a final concentration of 2.5 mM for 24 h at 60°C in an Eppendorf Thermomixer comfort at 550 ⁇ m. After 24 h the solutions were clarified for 10 minutes at 14000 ⁇ m and the sediment was discarded. The efficiency of the ZnSO4- dependent degradation of nucleic acids was confirmed by agarose gelelectrophoresis. The supernatants were dialysed against 5000 ml of 4 mM HEPES pH 7.4, 30 M NaCl for 2h at 4°C. 5000 ml buffer was exchanged once and dialysis continued over night at 4°C.
- ZnSO4-treated Q ⁇ VLPs was analyzed by agarose gelelectrophoresis: Q ⁇ VLPs which had been purified from E.coli and dialysed either against buffer 1 (50 mM TrisHCl pH 8.0, 50 mM NaCl, 5% glycerol, 10 mM MgC12) or buffer 2 (4 mM HEPES, pH 7.4, 30 mM NaCl) were incubated either without or in the presence of 2.5 mM zinc sulfate (ZnSO4) for 24 hrs at 60°C. After this treatment equal amounts of the indicated samples (5 ⁇ g protein) were mixed with loading dye and loaded onto a 0.8% agarose gel. After the run the gel was stained with ethidium bromide. Treatment of VLPs with ZnSO4 caused degradation of the nucleic acid content, while the mock-treated controls were unaffected.
- buffer 1 50 mM TrisHCl pH 8.0, 50 mM NaCl, 5% glycerol, 10
- oligodeoxynucleotides into ZnSO4-treated VLPs ZnSO4-treated and dialysed Q ⁇ capsids with a protein concentration (as determined by Bradford analysis) beween 0.4 mg/ml and 0.9 mg/ml (which conesponds to a concentration of capsids of 159 nM and 357.5 nM, respectively) were used for the packaging of the oligodeoxynucleotides.
- the oligodeoxynucleotides were added at a 300- fold molar excess to the of Q ⁇ -VLP capsids and incubated for 3 h at 37°C in an Eppendorf Thermomixer comfort at 550 ⁇ m .
- VLPs 25 ⁇ g of these VLPs were digested with 25 ⁇ l Benzonase (Merck, Cat. No. 1.01694.0001) according to the manufactures instructions. After heat- inactivation of the nuclease (30 minutes at 80°C) the VLPs were treated with Proteinase K (final enzyme concentration was 0.5 mg/ml) according to the manufactures instructions. After 3 hrs the equivalent of 2 ug Q ⁇ VLPs which had been digested by Benzonase and proteinase K were mixed with TBE-Urea sample buffer and loaded on a 15% polyacrylamide TBE-Urea gel (Novex®, Invitrogen Cat. No. EC6885).
- the capsids loaded in lane 2 were treated with 2.5 mM ZnSO4 in presence of buffer 1 (see above), while the capsids loaded in lane 3 were treated with 2.5 mM ZnSO4 in presence of buffer 2 (see above).
- 1 pmol, 5 pmol and 10 pmol of the oligodeoxynucleotide which was used for the reassembly reaction was loaded onto the same gel (lanes 4 - 6).
- Q ⁇ capsids which had been purified from E.coli were treated exactly the same and analyzed on the same polyacrylamide TBE-Urea gel (lane 1).
- VLPs containing containing immunostimulatory nucleic acids induce T cell responses that can be boosted by viral vectors: LCMV.
- mice were subcutaneously primed with 20 ⁇ g p33-VLPs (see EXAMPLE 1) containing immunostimulatory nucleic acids.
- p33-VLP preparations were extensively purified from unbound CpG-oligonucleotides via dialysis. 12 days later, blood was taken and frequencies of p33-specific T cells were determined by tetramer staining. The mice were boosted with 200 pfu of live LCMV strain WE and frequencies of specific T cells were determined 5 days later. Frequencies before boost were 3.5% +/- 1.8% and after boost 15.5% +/- 1.9%.
- VLPs containing immunostimulatory nucleic acids induce T cell responses that can be boosted by viral vectors: recombinant vaccinia virus.
- mice are subcutaneously primed with 20 ⁇ g p33-VLPs (see EXAMPLE 1) containing immunostimulatory nucleic acids.
- p33-VLP preparations are extensively purified from unbound CpG-oligonucleotides via dialysis. 12 days later, blood is taken and frequencies of p33 -specific T cells are determined by tetramer staining. The mice are boosted with 106 pfu of recombinant vaccina virus expressing LCMV-GP and frequencies of specific T cells are determined 5 days later.
- EXAMPLE 12 EXAMPLE 12
- VLPs containing immunostimulatory nucleic acids induce T cell responses that can be boosted by viral vectors: recombinant canary pox virus.
- mice are subcutaneously primed with 20 ⁇ g p33-VLPs containing immunostimulatory nucleic acids. Before immunization, p33-VLP preparations are extensively purified from unbound CpG-oligonucleotides via dialysis. 12 days later, blood is taken and frequencies of p33 -specific T cells are determined by tetramer staining. The mice are boosted with 107 pfu of recombinant canary pox virus expressing LCMV- GP and frequencies of specific T cells are determined 5 days later.
- VLPs containing containing immunostimulatory nucleic acids can boost T cell responses.
- mice are infected intravenously with recombinant vacccina -virus expressing LCMV-GP. 20 days later, blood is taken and frequencies of p33-specific T cells are determined by tetramer staining. The mice are boosted the same day with p33-VLP preparations containing immunostimulatory nucleic acids and frequencies of specific T cells are determined 5 days later.
- Q ⁇ VLPs were treated with RNaseA as described in Example 7 under low ionic strength conditions (20 mM Hepes pH 7.4 or 4 mM Hepes, 30 mM NaCl, pH 7.4 ).
- other VLPs such as described in Examples 2, 3, 5, and 8, i.e. GA, BKV, HBcAg, and AP205 are treated.
- Q ⁇ VLPs and AP205 VLPs were treated with ZnSO4 under low ionic strength conditions (20 mM Hepes pH 7.4 or 4 mM Hepes, 30 mM NaCl pH 7.4) as described in Example 9.
- AP205 VLP (1 mg/ml) in either 20 mM Hepes pH 7.4 or 20 mM Hepes, 1 mM Tris, pH 7.4 was treated for 48 h with 2.5 mM ZnSO4 at 50°C in an Eppendorf Thermomixer comfort at 550 ⁇ m.
- Q ⁇ and AP205 VLP samples were clarified as described in Example 9 and supernatants were dialysed in 10.000 MWCO Spectra Por® dialysis tubing (Spectrum, Cat. nr. 128 118) against first 2 1 20 mM Hepes, pH 7.4 for 2 h at 4°C and, after buffer exchange, overnight. Samples were clarified after dialysis as described in Example 9 and protein concentration in the supernatants was determined by Bradford analysis.
- RNA hydrolysis and dialysis Q ⁇ and AP205 VLPs (1-1.5 mg/ml) were mixed with 130 ⁇ l of CpG oligonucleotides (G3-6, G8-8 - cf. Table 1; 1 mM oligonucleotide stock in 10 mM Tris pH 8) per ml of VLPs. Samples were incubated for 3 h at 37°C in a thermoshaker at 650 ⁇ m. Subsequently, samples were treated with 125 U Benzonase/ml VLPs (Merck KGaA, Darmstadt, Germany) in the presence of 2 mM MgC12 and incubated for 3 h at 37°C before dialysis.
- CpG oligonucleotides G3-6, G8-8 - cf. Table 1; 1 mM oligonucleotide stock in 10 mM Tris pH 8
- Samples were incubated for 3 h at 37°C in
- Q ⁇ VLPs, packaged with ISS were coupled to p33 peptides containing a C- tenninal GGC extension (KAVYNFATM-GGC) (SEQ ID NO: 84), resulting in Qb VLPs termed Qb-ISS-33 VLPs.
- Qb-ISS-33 VLPs a C- tenninal GGC extension
- Packaged Q ⁇ VLPs in 20 mM Hepes, pH 7.4 were derivatized with a 10-fold molar excess of SMPH (Pierce) for 0.5 h at 25°C, followed by two dialysis steps of 2 hours each against 20 mM HEPES pH 7.4 at 4°C to remove unreacted SMPH.
- Peptides were added in a 5-fold molar excess to the dialysed derivatization mixture, and allowed to react for 2 h in a thermomixer at 25°C.
- Samples were dialysed in 300.000 MWCO Spectra/Por® dialysis tubing against 20 mM Hepes pH 7.4 for 2 h at 4°C, and after buffer exchange overnight against the same buffer. After dialysis samples were clarified as described in Example 9 and protein concentration in the supernatants were determined by Bradford analysis. Coupling of peptide p33 to Q ⁇ was analysed by SDS- PAGE on 16%) PAGE Tris-Glycine gels (Novex® by Invitrogen, Cat. No.
- AP205 VLPs (1.24 mg/ml) packaged with G8-8 oligonucleotide as described above were derivatized and coupled to HIVpl7 (71-85) containing a N-terminal GGC extension (CGG-GSEEIRSLYNTVATL) (SEQ ID NO: 85), resulting in AP205-G8-8- HIVpl7 VLPs.
- AP205 VLPs (packaged with G8-8), in 20 mM Hepes pH 7.4, were derivatized with a 20-fold molar excess of SMPH for 0.5 h at 25°C, and subsequently dialysed two times against 20 mM HEPES, pH 7.4 at 4°C to remove unreacted SMPH.
- Peptide was added to the dialyzed derivatization mixture in a 10-fold molar excess and allowed to react for 2 h in a thermomixer at 25°C.
- Samples were dialysed in 10.000 MWCO dialysis tubing against 20 mM Hepes pH 7.4 for 2 h at 4°C, and after buffer exchange, overnight against the same buffer. After dialysis, samples were clarified as described in Example 9 and protein concentration in the supernatants were determined by Bradford analysis. Coupling efficiency of peptide HIVpl7 to AP205 was analysed by SDS-PAGE on 16% PAGE Tris-Glycine gels.
- G8-8 oligonucleotide packaging in AP205 was analysed on 1% agarose gels and, after proteinase K digestion, G8-8 oligonucleotide amount in AP205-G8-8-HIVpl7 was analysed on TBE/urea gels as described in Example 5.
- Packaging of G8-8 oligonucleotides into Q ⁇ VLPs and subsequent coupling to p33 peptide was analyzed by agarose gelelectrophoresis.
- Q ⁇ VLPs containing G8-8 oligonucleotides and subsequently coupled to p33 peptide were termed Qb-G8-8-33 VLPs.
- Ethidium bromide staining of G8-8 packaged Q ⁇ VLPs can be seen on a 1 % agarose gel stained with ethidium bromide. Comigration of the ethidium bromide fluorescent band with the Q ⁇ VLP protein band visible on the same gel subsequently stained with Coomassie Blue demonstrates packaging. Coupling efficiency can be estimated to be 30% by SDS-PAGE analysis on a 16 % PAGE Tris-Glycine gel. Analysis of the G8-8 content of Qb-G8-8-33 VLPs after coupling was done on a 1% agarose gel, where the amount of oligonucleotide packaged was of approximately 1 nmol/100 ⁇ g Qb- G8-8-33 VLPs.
- Packaging of G8-8 oligonucleotides into AP205 VLPs was analyzed by gelelectrophoresis. Staining of G8-8 packaged AP205 VLPs can be seen on a 1 % agarose gel stained with ethidium bromide. Comigration of the AP205 VLPs protein band detected on the same gel subsequently stained with Coomassie Blue demonstrated packaging. Coupling efficiency with the HIVpl7 peptide could be estimated from the SDS-PAGE analysis on a 16 %» PAGE Tris-Glycine gel where multiple coupling bands migrating slower than the residual AP205 VLP monomer subunits, which did not react with peptide, are visible.
- Coupling efficiency was comparable to the coupling efficiency obtained for the Qb-G8-8-33 VLPs.
- Analysis of the G8-8 oligonucleotide content of AP205 VLPs after coupling to HIVpl7 can be seen on TBE/urea gel electrophoresis indicating a packaged amount of 0.5-1 nmol/100 ⁇ g AP205-G8-8-HIVpl7 VLPs.
- Qbx33 VLPs (Q ⁇ VLPs coupled to peptide p33, see Example 7) were treated with RNaseA under low ionic conditions (20 mM Hepes pH 7.4) as described in Example 7 to hydrolyse RNA content of the Qbx33 VLP. After dialysis against 20 mM Hepes pH 7.4, Qbx33 VLPs were mixed with guanosine flanked oligonucleotides (Table 1 : G3-6, G7-7, G8-8, G9-9 or G6, from a 1 mM oligonucleotide stock in 10 mM Tris pH 8) and incubated as described in Example 14.
- Qbx33 VLPs were treated with Benzonase and dialysed in 300.000 MWCO tubing.
- Samples with oligos G7-7, G8-8 and G9-9 were extensively dialysed over 3 days with 4 buffer exchanges to remove free oligo.
- Packaging was analysed on 1% agarose gels and, after proteinase K digestion, on TBE/urea gels as described in Example 5.
- oligonucleotide packaging was analyzed by agarose gelelectrophoresis. Upon oligonucleotide packaging, a fluorescent band migrating slightly slower than reference untreated Q ⁇ VLP becomes visible on the 1 % agarose gel stained with ethidium bromide indicating the presence of oligonucleotides. The signal is maintained after treatment with Benzonase, indicating packaging of the oligonucleotides within the Qbx33 VLPs. The packaging efficiency can be estimated from the TBE/urea gel electrophoresis.
- the amount of the G3-6 oligonucleotide (approximately 4 nmol/100 ⁇ g Qbx33 VLPs) packaged is much higher than the amount of packaged G8-8 oligonucleotide (approximately 1 nmol/100 ⁇ g Qbx33 VLPs). This indicates a dependence of packaging ability on the length of the guanosine nucleotides tail flanking the CpG motif.
- Q ⁇ VLPs were treated with ZnSO4 under low ionic strength conditions (20 mM Hepes pH 7.4 or 4 mM Hepes, 30 mM NaCl, pH 7.4) as described in Example 9.
- AP205 VLPs (1 mg/ml) in either 20 mM Hepes pH 7.4 or 20 mM Hepes, 1 mM Tris, pH 7.4 were treated for 48 h with 2.5 mM ZnSO4 at 50°C in an Eppendorf Thermomixer comfort at 550 ⁇ m.
- Q ⁇ and AP205 VLP samples were clarified as in Example 9 and dialysed against 20 mM Hepes, pH 7.4 as in Example 14.
- the immunostimulatory ribonucleic acid poly (I:C), (Cat. nr. 27-4732-01, poly(I) « poly(C), Pharmacia Biotech) was dissolved in PBS (Invitrogen cat. nr. 14040) or water to a concentration of 4 mg/ml (9 ⁇ M).
- Poly (I:C) was incubated for 10 minutes at 60°C and then cooled to 37°C. Incubated poly (I:C) was added in a 10-fold molar excess to either ZnSO4-treated Q ⁇ or AP205 VLPs (1-1.5 mg/ml) and the mixtures were incubated for 3 h at 37°C in a thermomixer at 650 ⁇ m.
- Q ⁇ VLPs (1 mg/ml) packaged with poly (I:C) were derivatized and coupled either to p33 peptide (KAVYNFATM-GGC) (SEQ ID NO: 84) as described in Example 14, or to MelanA peptide (MelanA 16-35A/L CGHGHSYTTAEELAGIGILTV) (SEQ ID NO: 40), resulting in Qb-pIC-33 and Qb-pIC-MelanA VLPs, respectively.
- the packaged Q ⁇ VLP was derivatized with a 2.1 -fold molar excess of SMPH (Pierce) for 0.5 h at 25°C, followed by two dialysis steps against 20 mM HEPES, pH 7.4 at 4°C to remove unreacted SMPH. Peptides were added in a 2.1 -fold molar excess and allowed to react for 1.5 h in a thermomixer at 25°C. Samples were dialysed in 300.000 MWCO Spectra/Por® CE Dispo Dialyzer against 20 mM Hepes, pH 7.2 for 3 h at 4°C, and after buffer exchange, overnight against the same buffer.
- AP205 VLPs (1 mg/ml) packaged with poly (I:C) were derivatized and coupled to HIVpl7 (71-85) containing a N-terminal GGC extension (CGG-GSEEIRSLYNTVATL) (SEQ ID NO: 85), resulting in AP205-pIC-HIVpl7 VLPs.
- AP205 VLPs, in 20 mM Hepes, pH 7.4 were derivatized with a 20-fold molar excess of SMPH for 0.5 h at 25°C, and subsequently dialysed two times against 20 mM HEPES, pH 7.4 at 4°C to remove unreacted SMPH.
- Peptide was added to the dialyzed derivatization mixture in a 10-fold molar excess and allowed to react for 2 h in a thermomixer at 25°C.
- Samples were dialysed in 10.000 MWCO dialysis tubing against 20 mM Hepes pH 7.4 for 2 h at 4°C, and after buffer exchange, overnight against the same buffer. After dialysis, samples were clarified as described in Example 9 and protein concentration in the supernatants were determined by Bradford analysis. Coupling efficiency of peptide HIVpl7 to AP205 was analysed by SDS-PAGE on 16%> PAGE Tris-Glycine gels.
- Poly (I:C) packaging was analysed on 1% agarose gels and, after proteinase K digestion, on TBE gels as described in Example 5.
- Packaging of poly (I:C) into ZnSO4 treated Q ⁇ VLPs and coupling with MelanA peptide resulting in Qb-pIC-MelanA VLPs was analyzed by agarose gelelectrophoresis. The fluorescent signal visible on an ethidium bromide stained 1 % agarose gel, indicating presence of nucleic acid, co-migrates with the protein band that became visible upon Coomassie Blue staining of the gel, demonstrating packaging.
- Coupling efficiency of the MelanA peptide was estimated by SDS-PAGE analysis on a 16 %> PAGE Tris-Glycine gel. Multiple coupling products were visible as bands migrating slower than the Q ⁇ VLP monomer subunits, which had not reacted with peptide. Coupling efficiency of MelanA was overall comparable to the coupling efficiency obtained for the Qb-G8-8-33 VLPs and the AP205-G8-8-HIVpl7 VLPS of Example 14, albeit slightly lower.
- the packaging efficiency into Qb-pIC-MelanA could be estimated from the TBE/urea gel; the packaged amount of poly (I:C) in Q ⁇ was approximately 25 pmol and remained the same upon MelanA coupling.
- Packaging of poly (I:C) into ZnSO4 treated AP205 VLPs and in the coupling product AP205-pIC-HIVpl7 after coupling to HIVpl7 was analyzed by agarose gelelectrophoresis.
- Coupling efficiency of the HIVpl7 peptide is estimated from the appearance of multiple coupling products visible as bands migrating slower than AP205 VLP subunit monomer, which did not react with peptide, after SDS-PAGE analysis on a 16 % PAGE Tris-Glycine gel electrophoresis. Coupling efficiency was overall comparable to the coupling efficiency obtained for the Qb-G8-8-33 VLPs and the AP205-G8-8-HIVpl7 VLPs (Example 14). The packaging efficiency could be estimated from the TBE gel, which showed that the packaged amounts of poly (I:C) in the AP205-pIC-HIVpl7 VLP is approximately 10 pmol/100 ⁇ g VLP.
- Packaging of G8-8 into ZnSO4-treated VLPs and coupling of immunogenic peptides to G8-8 packaged VLP can be performed accordingly.
- HBcAg VLPs are treated with RNaseA under low ionic strength conditions (20 mM Hepes pH 7.4) as described in Example 7 to hydrolyse RNA content of the VLP.
- VLPs are mixed with guanosine flanked oligonucleotides (Table 1; G3-6, G7-7, G8-8, G9-9, or G6, 1 mM stock in 10 mM Tris pH 8) and incubated as described in Example 14.
- VLPs are treated with Benzonase and dialysed in 300.000 MWCO tubing. Packaging is analysed on 1% agarose gels and on TBE/urea gels after proteinase K digestion as described in Example 5.
- GA VLPs are treated with RNaseA under low ionic conditions (20 mM Hepes pH 7.4) as described in Example 7 to hydrolyse RNA content of the VLP.
- VLPs are mixed with guanosine flanked oligonucleotides (Table 1; G3-6, G7-7, G8-8, G9-9, or G6, 1 mM stock in 10 mM Tris pH8) and incubated as described in Example 14.
- VLPs are treated with Benzonase and dialysed in 300.000 MWCO tubing. Packaging is analysed on 1% agarose gels and on TBE/urea gels after proteinase K digestion as described in Example 5.
- HBcAg VLPs are treated with ZnSO4 under low ionic strength conditions (20 mM Hepes pH 7.4 or 4 mM Hepes, 30 mM NaCl, pH 7.4 ) as described in Example 9 and are dialysed against 20 mM Hepes pH 7.4 as in Example 14.
- G8-8 is added in a 10-fold molar excess to HBcAg VLPs (1-1.5 mg/ml) and incubated for 3 h at 37°C in a thermomixer at 650 ⁇ m as described in Example 16.
- GA VLPs are treated with ZnSO4 under low ionic strength conditions (20 mM Hepes pH 7.4 or 4 mM Hepes, 30 mM NaCl, pH 7.4 ) as described in Example 9 and are dialysed against 20 mM Hepes, pH 7.4 as in Example 14.
- G8-8 is added in a 10-fold molecular excess to GA VLPs (1-1.5 mg/ml) and incubated for 3 h at 37°C in a thermomixer at 650 ⁇ m as described in Example 16.
- the solution was centrifuged 10 min at 4000 ⁇ m at 4 °C (Eppendorf 5810 R, in fixed angle rotor A-4-62 used in all following steps) in order to remove the precipitated RNA from the solution.
- the supernatant, containing the released, dimeric Q ⁇ coat protein, was used for the chromatography purification steps.
- Two-step purification method for Q ⁇ coat protein by cation exchange chromatography and size exclusion chromatography The supernatant of the disassembly reaction, containing dimeric coat protein, host cell proteins and residual host cell RNA, was applied onto a SP-Sepharose FF column (xkl6/20, 6 ml, Amersham Bioscience ).
- the absorbance at 260 nm and 280 nm was monitored.
- the column was equilibrated with 20 mM sodium phosphate buffer pH 7 and the sample was diluted 1 : 15 in water to adjust a conductivity below 10 mS/cm in order to achieve proper binding of the coat protein to the column.
- the elution of the bound coat protein was accomplished by a step gradient to 20 mM sodium phosphate / 500 mM sodium chloride and the protein was collected in a fraction volume of approx. 25 ml.
- the column was regenerated with 0.5 M NaOH.
- the isolated Q ⁇ coat protein dimer (the eluted fraction from the cation exchange column) was applied (in two runs) onto a Sephacryl S-100 HR column (xk26/60, 320 ml, Amersham Bioscience) equilibrated with 20 mM sodium phosphate / 250 mM sodium chloride; pH 6.5. Chromatography was performed at RT with a flow rate of 2.5 ml/min. Absorbance was monitored at 260 nm and 280 nm. Fractions of 5 ml were collected. The column was regenerated with 0.5 M NaOH.
- Reassembly by dialysis A stock solution of purified Q ⁇ coat protein dimer at a concentration of 2 mg/ml was used for the reassembly of Q ⁇ VLP in the presence of the oligodeoxynucleotide G8-8. The concentration of oligodeoxynucleotide in the reassembly mixture was 10 ⁇ M. The concentration of coat protein dimer in the reassembly mixture was 40 ⁇ M (approx. 1.13 mg/ml). Stock solutions of urea and DTT were added to the solution to give final concentrations of 1 M urea and 5 mM DTT respectively.
- the oligodeoxynucleotide was added as last component, together with H 2 O, giving a final volume of the reassembly reaction of 3 ml.
- This solution was dialysed at 4 °C for 72 h against 1500 ml buffer containing 20 mM TrisHCl, 150 mM NaCl, pH 8.0.
- the dialysed reassembly mixture was centrifuged at 14 000 ⁇ m for 10 minutes at 4 °C. A negligible sediment was discarded while the supernatant contained the reassembled and packaged VLPs.
- Reassembled and packaged VLPs were concentrated with centrifugal filter devices (Millipore, UFV4BCC25, 5K NMWL) to a final protein concentration of 3 mg/ml. Protein concentration was determined by Bradford analysis.
- Reassembly by diafiltration 20 ml of a stock solution of purified coat protein (1.5 mg/ml) is mixed with stock solutions of urea, DTT, oligodeoxynucleotide G8-8 and water. The oligodeoxynucleotide is added as last component. The volume of the mixture is 30 ml and the final concentrations of the components are 35 ⁇ M dimeric coat protein (reflecting 1 mg/ml), 35 ⁇ M oligodeoxynucleotide, 1 M urea and 2.5 mM DTT.
- the mixture is then diafiltrated against 300 ml of 20 mM sodium phosphate / 250 mM sodium chloride, pH 7.2, in a tangential flow filtration apparatus at RT, using a Pellicon XL membrane cartridge (Biomax 5K, Millipore).
- the total flow rate is set to 10 ml/min and the permeate flow rate set to 2.5 ml/min.
- H 2 O 2 is added to the solution to a final concentration of 7 mM and the solution is further incubated at RT for 60 min, to accelerate the formation of the stractural disulfide bonds in the formed VLPs.
- A) Hydrodynamic size of reassembled capsids Q ⁇ capsids, which had been reassembled in the presence of oligodeoxynucleotide G8-8, were analyzed by dynamic light scattering (DLS) and compared to intact Q ⁇ VLPs, which had been purified from E.coli. Reassembled capsids showed the same hydrodynamic size (which depends both on mass and conformation) as the intact Q ⁇ VLPs.
- DLS dynamic light scattering
- the reactions were then mixed with a TBE-Urea sample buffer and loaded on a 15 % polyacrylamide TBE-Urea gel (Novex ® , Invitrogen Cat. No. EC6885).
- a qualitative as well as quantitative standard 1 pmol, 5 pmol and 10 pmol of the oligodeoxynucleotide which was used for the reassembling reaction, was loaded on the same gel. This gel was stained with SYBR ® -Gold (Molecular Probes Cat. No. S- 11494).
- the SYBR ® -Gold stain showed that the reassembled Q ⁇ capsids contained nucleic acid co-migrating with the oligodeoxynucleotides which were used in the reassembly reaction.
- resistance to benzonase digestion of the nucleic acid content of the Q ⁇ VLPs which had been reassembled in the presence of oligodeoxynucleotides and isolation of the oligodeoxynucleotide from purified particles by proteinase K digestion demonstrate packaging of the oligodeoxynucleotide.
- the reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, pH 7.2 at 4°C.
- the coupled product was named Qb-MelanA 26-35.
- For MelanA 26-35 A/L SEQ ID NO: 42: A solution of 2 ml of 3.06 mg/ml Qb
- VLPs in 20 mM Hepes, pH 7.2 was reacted for 30 minutes with 37.7 ⁇ l of a solution of 50 mM SMPH in DMSO at 25°C on a rocking shaker.
- the reaction solution was subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes, pH 7.2 at 4°C.
- 2 ml of the dialyzed reaction mixture was then reacted with 18.4 ⁇ l of 50 mM peptide stock solution (in DMSO) for 4 hours at 25oC on a rocking shaker.
- the reaction mixture was subsequently dialyzed 2x 2 hours against 2 liters of 20 mM Hepes, pH 7.2 at 4°C.
- the coupled product was named Qb-MelanA 26-35 A/L.
- Figure 1 shows the SDS-PAGE analysis of Qb-MelanA VLPs. MelanA-peptides were coupled to Qb VLPs. The final products were mixed with sample buffer and separated under reduced conditions on 16 % Novex®Tris-Glycine gels for 1.5 hours at 125 V. The separated proteins were stained by soaking the gel in Coomassie blue solution. Background staining was removed by washing the gel in 50 %> methanol, 8% acetic acid. The Molecular weight marker (P 77085, New England BioLabs, Beverly, USA) was used as reference for Qb-MelanA migration velocity (lane 1).
- the MelanA 16-35 A/L peptide contains the cytotoxic T lymphocyte (CTL) epitope MelanA 26-35 and Qb-MelanA 16-35 A/L was further studied for its immunogenicity in vitro and in vivo.
- CTL cytotoxic T lymphocyte
- PBMC RPMI medium containing 10% FCS for 18h. IFN alpha in the supernatants was measured by ELISA, using an antibody set provided by PBL Biomedical Laboratories.
- PBMC were stained with mouse anti-human CD8-FITC, mouse anti-human CD19-PE and anti-human CD69-APC and analyzed by flow cytometry.
- G9-9 and G8-8 induced high levels of IFN alpha secretion (FIG. 2A). Decreasing the number of flanking Gs in the other oligonucleotides resulted in lower IFN alpha secretion.
- mice were subcutaneously immunized with Qbx33 alone or loaded with G3-6 or G6 (see Examples 14 and 16). Eight days later, mice were challenged with 1.5 x 106 pfu of recombinant Vaccinia viras, expressing the LCMV-p33 antigen. After 4 days, mice were sacrificed and the viral titers in ovaries were measured as previously described (Bachmann et al, Eur. J. Imunol. 1994, 24:2228). As depicted in Figure 3, all mice receiving the Qbx33 vaccine loaded with either G3-6 or G6 were protected from viral challenge.
- mice and mice immunized with Qbx33 alone did not eliminate the virus from the ovaries.
- VLP alone is not sufficient to induce protective CTL immune response, whereas VLP loaded with CpG are very efficient in priming naive CTL.
- immunization of mice with Qbx33 loaded with G8-8 is priming p33- specific CTL, as well as is inducing protection from recombinant Vaccinia viras challenge.
- HHD mice express a chimeric monochain class I molecule with a human ⁇ 2- microglobulin covalently linked to the N-terminus of A2 ⁇ l and ⁇ 2 domains fused with Db ⁇ 3 domain (Firat, H. et al 1999, Eur.J.Immunol., 29:3112).
- the HLA-A2 transgene expression in these mice allows investigating the capacity of Q ⁇ MelanA 16-35 A/L VLPs to be processed and presented as the CTL epitope MelanA 26-35 and to prime CTL in vivo. Furthermore, the effect of adjuvants, as ISS can be studied in vivo.
- HHD mice were either left untreated or immunized by injecting subcutaneously with 100 ⁇ g Qb-MelanA 16-35 A/L or with Qb-pIC-MelanA 16-35 A/L. Eight days later spleenocytes were isolated, resuspended in FACS buffer (PBS, 2% FCS, 5mM EDTA, pH 8.2) and stained with HLA-A2-MelanA-PE labelled tetramers for 30 min at room temperature. In a second step, rat anti-mouse CD8-APC (BD PharMingen, San Jose, USA) and anti mouse Mell4-FITC (BD PharMingen, San Jose, USA) were added for 30 min at 4°C.
- FACS buffer PBS, 2% FCS, 5mM EDTA, pH 8.2
- erythrocytes were lysed with BD-Lyzing Solution (BD Biosciences, San Jose, USA) for 10 min at room temperature. Finally, the spleen cells were analysed on a FACS Calibur using Cell Quest software. First of all, the cells were acquired in the forward scatter and side scatter and the lymphocytes were gated. From this lymphocyte population, only the CD8 positive T cells were selected for further analyses.
- the HLA-A2-MelanA-PE and Mell4— FITC labelled cells were measured with the FL2 and FL1 detector, respectively. The amount of MelanA-specific, activated CD 8+ T cells was calculated as percent HLA-A2-MelanA positive, Mel 14 negative cells on total CD8+ lymphocytes.
- the human HLA- A2 -MelanA tetramer does not bind very efficiently to mouse MelanA-specific T cells, as the protein is chimeric. Therefore we could assume a much higher degree of antigen specific T cells in these mice.
- gag-G50, nef-N56 and gag-G68n peptide antigen Coupling of gag-G50, nef-N56 and gag-G68n peptide antigen to Q ⁇ VLP
- the peptide gag-G50 (sequence: CQGQMVHQAISPRTLNAWVKA FSPEVIPMFSALSEGATPQDLNTMLNTVK) (SEQ ID NO: 86) and nef-N56 (sequence: CGVGFPVRPQVPLRPMTYKAAVDLSHFLKEKGGLE
- GPGIRYPLTFGWCFKLVPVEP (SEQ ID NO: 87) and gag-G68n (sequence: CGEIYKRWIILGLNKIVRMYQGQMVHQAISPRTLNAWVK AFSPEVIPMFSALSEGATPQDLNTMLNTVK) (SEQ ID NO: 88) were chemically- synthesized.
- the peptides were ordered from the company SynPep, P.O. Box 2999, Dublin, CA 94568, USA.
- Q ⁇ VLP (Seq-ID No. 10) was then reacted at a concentration of 1.2 mg/ml (determined in a Bradford assay), with 0.85 mM SMPH (Pierce) for 30 minutes at room temperature (RT).
- the reaction mixture was then diafiltrated against 20 mM phosphate buffer pH 7.2 and 50 mM MES pH 6.0 was added for gag-G50 coupling reactions, and 50 mM Tris pH 8.5 for nef-N56 coupling reactions.
- a 5 mM stock of peptide was dissolved in DMSO and an equimolar amount TCEP was added to the peptide in order to have reducing reaction conditions.
- the derivatised Q ⁇ particles reacted at a concentration of 1 mg/ml with 0.214 mM gag-G50, 0.214 mM nef-N56 or 0.535 mM gag-G68n.
- the coupling reaction was left to proceed for 2 hours at 25°C; samples were taken for SDS-PAGE analysis, and the reaction mixtures dialyzed 2 X 2 hours against a 1000-fold volume 20 mM phosphate, 0.05% Tween, pH 7.2.
- the dialyzed samples were flash frozen in liquid nitrogen in aliquots for storage at -80°C until further use. An aliquot was thawed, and coupling of the antigen to a Q ⁇ subunit assessed by SDS-PAGE.
- the results of the coupling reactions analyzed before the dialysis are shown in FIG. 4 and FIG. 5. Analysis of the dialyzed coupling reaction showed a similar picture.
- Q ⁇ VLP packaged with G8-8 oligonucleotide made as described in Example 14 is coupled to HIV peptides as described in Example 26.
- the sequences of the coupled peptides are gag-G50 (sequence:
- CGVGFPVRPQVPLRPMTYKAAVDLSHFLKEKGGLEGPGIRYPLTFGWCFKLVPV EP (SEQ ID NO: 87) and gag-G68n (sequence: CGEIYKRWIILGLNKIVRMYQGQMVHQAISPRTLNAWVKAFSPEVIPMFS ALSEG ATPQDLNTMLNTVK) (SEQ ID NO: 88).
- the resulting packaged and coupled Q ⁇ VLP are analysed as described in Example 7 and in Example 14.
- Q ⁇ VLP is coupled to HIV peptides gag-G50, gag-G68n, or nef-N56 as described in Example 26.
- Q ⁇ VLP coupled either to gag-G50, gag-G68n, or nef-N56 is packaged with G8-8 oligonucleotide and analysed as described in Example 7.
- Qbx33 loaded with CpG can be used in homologous as well in heterologous prime-boost regimen for the induction of a long lasting memory CD8+ T cell response
- mice were immunized with 150 ug Qbx33/NKCpG and 8 days later the frequencies of p33 -specific T cells increased from 0.4 %> +/- 0.2 %> in naive mice to 7.5% +/- 2.2%) in immunized animals as measured with antigen.
- specific MHC/peptide tetramers 20 days later the peptide specific CD8+ T population dropped down to 1.6% +/-0.7%>.
- a second-imunisaiton of these mice 30 days after the first immunisation with 150 ug Qbx33/N_ PS could boost the memory T cell response to up to 8.4% +/-1.9% specific T cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002517675A CA2517675A1 (en) | 2003-03-26 | 2004-03-25 | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US10/550,518 US7517520B2 (en) | 2003-03-26 | 2004-03-25 | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
AU2004224762A AU2004224762B2 (en) | 2003-03-26 | 2004-03-25 | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
EP04723207A EP1605973B1 (en) | 2003-03-26 | 2004-03-25 | Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses |
US12/410,085 US20100098722A1 (en) | 2003-03-26 | 2009-03-24 | Packaging of Immunostimulatory Substances Into Virus-Like Particles: Method of Preparation and Use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45734803P | 2003-03-26 | 2003-03-26 | |
US60/457,348 | 2003-03-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/410,085 Continuation US20100098722A1 (en) | 2003-03-26 | 2009-03-24 | Packaging of Immunostimulatory Substances Into Virus-Like Particles: Method of Preparation and Use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004084940A1 true WO2004084940A1 (en) | 2004-10-07 |
Family
ID=33098221
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/003165 WO2004084940A1 (en) | 2003-03-26 | 2004-03-25 | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
PCT/EP2004/003163 WO2004084939A2 (en) | 2003-03-26 | 2004-03-25 | Hiv-peptide-carrier-conjugates |
PCT/EP2004/003164 WO2004085635A1 (en) | 2003-03-26 | 2004-03-25 | Melan-a peptide analogue-virus-like-particle conjugates |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/003163 WO2004084939A2 (en) | 2003-03-26 | 2004-03-25 | Hiv-peptide-carrier-conjugates |
PCT/EP2004/003164 WO2004085635A1 (en) | 2003-03-26 | 2004-03-25 | Melan-a peptide analogue-virus-like-particle conjugates |
Country Status (13)
Country | Link |
---|---|
US (2) | US7517520B2 (en) |
EP (3) | EP1606398A1 (en) |
JP (1) | JP5022028B2 (en) |
KR (1) | KR20050115913A (en) |
CN (2) | CN100560719C (en) |
AU (3) | AU2004224762B2 (en) |
BR (1) | BRPI0408623A (en) |
CA (3) | CA2517675A1 (en) |
MX (1) | MXPA05009289A (en) |
NZ (1) | NZ542323A (en) |
RU (1) | RU2351362C2 (en) |
WO (3) | WO2004084940A1 (en) |
ZA (3) | ZA200507063B (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006056142A1 (en) | 2004-11-29 | 2006-06-01 | Changchun Huapu Biotechnology Co., Ltd. | Cpg single-strand deoxynucleotides for use as adjuvant |
WO2007039458A2 (en) * | 2005-09-21 | 2007-04-12 | Cytos Biotechnology Ag | Hiv peptide conjugates and uses thereof |
EP1807094A1 (en) * | 2004-11-05 | 2007-07-18 | Bio Clue & Solution Co., Ltd. | Therapeutic use of cpg oligodeoxynucleotide for skin disease |
WO2007144150A1 (en) * | 2006-06-12 | 2007-12-21 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
WO2008024427A2 (en) * | 2006-08-23 | 2008-02-28 | Science & Technology Corporation @ Unm | A virus-like platform for rapid vaccine discovery |
WO2008071774A1 (en) * | 2006-12-14 | 2008-06-19 | Cytos Biotechnology Ag | Purification process for coat protein of rna bacteriophages |
WO2010067286A3 (en) * | 2008-12-09 | 2010-08-05 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
WO2010122164A1 (en) | 2009-04-23 | 2010-10-28 | Cytos Biotechnology Ag | VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5 |
US7959928B2 (en) | 2004-10-05 | 2011-06-14 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
EP2366709A1 (en) * | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
WO2011113546A1 (en) * | 2010-03-16 | 2011-09-22 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
US8563506B2 (en) * | 2009-06-12 | 2013-10-22 | Morehouse School Of Medicine | Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles |
US8586728B2 (en) | 2006-12-12 | 2013-11-19 | Cytos Biotechnology Ag | Oligonucleotides containing high concentrations of guanine monomers |
US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
WO2016109310A1 (en) | 2014-12-31 | 2016-07-07 | Checkmate Pharmaceuticals, Llc | Combination tumor immunotherapy |
WO2016115456A1 (en) * | 2015-01-16 | 2016-07-21 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
AU2013204383B2 (en) * | 2006-06-12 | 2016-09-22 | Kuros Us Llc | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
WO2017173334A1 (en) | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
US20170362591A1 (en) * | 2014-12-25 | 2017-12-21 | National Institutes Of Biomedical Innovation, Health And Nutrition | Non-aggregating immunostimulatory oligonucleotides |
US10117921B2 (en) | 2013-09-19 | 2018-11-06 | Zoetis Services Llc | Oil-based adjuvants |
US10238736B2 (en) | 2008-06-27 | 2019-03-26 | Zoetis Services Llc | Adjuvant compositions |
WO2019197965A1 (en) | 2018-04-09 | 2019-10-17 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
WO2021081353A1 (en) | 2019-10-23 | 2021-04-29 | Checkmate Pharmaceuticals, Inc. | Synthetic rig-i-like receptor agonists |
EP3835414A4 (en) * | 2018-08-07 | 2022-05-25 | Institute Of Biophysics, Chinese Academy Of Sciences | Method for activating cd4+t cell |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
WO2023242155A1 (en) * | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
WO2024047091A2 (en) | 2022-08-30 | 2024-03-07 | Saiba Animal Health Ag | Veterinary compositions of modified virus-like particles of cmv and ngf antigens |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
WO2003024481A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
CN1662253A (en) * | 2002-06-20 | 2005-08-31 | 赛托斯生物技术公司 | Packaged virus-like particles for use as adjuvants: method of preparation and use |
NZ538083A (en) * | 2002-07-17 | 2006-08-31 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
BR0312792A (en) * | 2002-07-19 | 2005-05-03 | Cytos Biotechnology Ag | Vaccine compositions containing beta1-6 amyloid antigenic series |
PT2241325E (en) | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
AU2004224762B2 (en) * | 2003-03-26 | 2009-12-24 | Kuros Us Llc | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
DK1778836T3 (en) | 2004-08-19 | 2010-11-22 | Univ Cardiff | Preparation of antigen presenting human gamma delta T cells and use in immunotherapy |
CA2596248A1 (en) * | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Method to identify polypeptide toll-like receptor (tlr) ligands |
ZA200707413B (en) * | 2005-03-18 | 2009-01-28 | Cytos Biotechnology Ag | Cat allergen fusion proteins and uses thereof |
NZ563708A (en) * | 2005-05-26 | 2010-08-27 | Cytos Biotechnology Ag | Scalable fermentation process |
BRPI0612293A2 (en) * | 2005-06-14 | 2010-11-03 | Cytos Biotechnology Ag | antigenic conjugates and uses thereof |
EP1736538A1 (en) * | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
FR2887457B1 (en) | 2005-06-23 | 2007-10-05 | Fond Bettencourt Schueller | TRANSCUTANE TARGETING VACCINATION |
ATE439135T1 (en) * | 2005-07-01 | 2009-08-15 | Index Pharmaceuticals Ab | MODULATION OF RESPONSE TO STEROIDS |
ES2442090T3 (en) | 2005-07-01 | 2014-02-10 | Index Pharmaceuticals Ab | Immunostimulant method |
US7468186B2 (en) * | 2005-07-22 | 2008-12-23 | City Of Hope | Polyomavirus cellular epitopes and uses therefor |
US8338173B2 (en) * | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
BRPI0504117A (en) * | 2005-09-05 | 2007-05-22 | Fundacao De Amparo A Pesquisa | epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention. |
WO2007050034A1 (en) * | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US20080044438A1 (en) * | 2006-03-17 | 2008-02-21 | Ostroff Gary R | Yeast Cell Particles As Oral Delivery Vehicles For Antigens |
BRPI0923225A2 (en) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | Phosphorus-modified nucleic acid synthesis method |
EP2435094A2 (en) * | 2009-05-27 | 2012-04-04 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
RU2612521C2 (en) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Novel prodrugs of nucleic acids and their application methods |
DE102009034779A1 (en) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetic analogues of bacterial lipopeptides and their application for the therapy and prophylaxis of allergic diseases |
KR101851699B1 (en) | 2009-11-02 | 2018-04-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
BR112012029823A2 (en) | 2010-05-26 | 2020-09-01 | Selecta Biosciences, Inc. | dose selection of adjuvant synthetic nanovehicles |
EP2407534A1 (en) | 2010-07-14 | 2012-01-18 | Neo Virnatech, S.L. | Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions |
WO2012037078A2 (en) * | 2010-09-14 | 2012-03-22 | Stc.Unm | Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | Modified nicotinic compounds and related methods |
GB201021867D0 (en) * | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
KR20190123796A (en) | 2011-04-29 | 2019-11-01 | 셀렉타 바이오사이언시즈, 인크. | Tolerogenic synthetic nanocarriers to reduce antibody responses |
CN107365339A (en) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | The method for synthesizing functionalization nucleic acid |
WO2013019658A2 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
CN102336821B (en) * | 2011-08-11 | 2014-10-15 | 北京永泰免疫应用科技有限公司 | New Melan-A epitope peptide and application thereof in preventing and/or treating tumours |
BR112014014591A8 (en) * | 2011-12-12 | 2017-07-04 | Baylor College Medicine | process for the in vitro expansion of antigen-specific t cells, expanded autologous or allogeneic t-cell product, pharmaceutical composition, and method of treatment of a patient, and uses of an engineered cell line, mixed pulsed dendritic cells antigen-peptide, t-apcs pulsed with antigen-peptide / peptide mixtures, and antigen-peptide mixtures with pbmcs |
RU2485973C1 (en) | 2012-02-28 | 2013-06-27 | Общество с ограниченной ответственностью "НТфарма" | Recombinant trivalent influenza vaccine |
WO2013177440A2 (en) * | 2012-05-23 | 2013-11-28 | The Board Of Trustees Of The Leland Stanford Junior University | Ordered flagellin array as an immunostimulant |
JP6246121B2 (en) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | Chiral nucleic acid adjuvant |
PL2872147T3 (en) | 2012-07-13 | 2023-09-25 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
EP2948469A4 (en) | 2013-01-23 | 2016-11-02 | Univ Leland Stanford Junior | Stabilized hepatitis b core polypeptide |
US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
CN114045295A (en) | 2013-03-15 | 2022-02-15 | 宾夕法尼亚大学理事会 | Foot and Mouth Disease Virus (FMDV) consensus proteins, coding sequences thereof, and vaccines made therefrom |
EP2991685A4 (en) | 2013-05-03 | 2016-11-16 | Selecta Biosciences Inc | Local, concomitant administration of tolerogenic synthetic nanocarriers to reduce type i and type iv hypersensitivity |
CN105263491A (en) | 2013-06-04 | 2016-01-20 | 西莱克塔生物科技公司 | Repeated administration of non-immunosupressive antigen specific immunotherapeutics |
US10266544B2 (en) | 2013-09-29 | 2019-04-23 | St. Jude Children's Research Hospital, Inc. | Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents |
JP2017500313A (en) * | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー, インコーポレーテッドBullet Biotechnology, Inc. | Specific virus-like particle-CpG oligonucleotide vaccine and uses thereof |
CN104761644A (en) * | 2014-01-03 | 2015-07-08 | 百奇生物科技(苏州)有限公司 | Fusion protein MBP-MART-1 expressed by Escherichia coli, and preparation method and application thereof |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JP6382344B2 (en) | 2014-01-16 | 2018-08-29 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | Chiral design |
GB2523187A (en) * | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
CA2953507A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
MX2017002933A (en) | 2014-09-07 | 2017-05-30 | Selecta Biosciences Inc | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses. |
EA035378B1 (en) | 2015-01-15 | 2020-06-04 | Юниверсити Оф Копенгаген | Virus-like particle with efficient epitope display |
EP3786164B1 (en) | 2015-06-18 | 2024-08-14 | Ting Therapeutics LLC | Methods and compositions for the prevention and treatment of hearing loss |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
US10391163B2 (en) * | 2015-09-10 | 2019-08-27 | Academia Sinica | Bird flu vaccine combination comprising virus-like particles and novel adjuvants |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
DK3368068T3 (en) | 2015-10-30 | 2021-02-22 | Univ Copenhagen | Virus-like particles with efficient epitope display |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
EP3448364B1 (en) | 2016-04-29 | 2022-02-09 | Icahn School of Medicine at Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
EP3518956A1 (en) | 2016-09-27 | 2019-08-07 | Selecta Biosciences, Inc. | Recombinant immunotoxins for use in the treatment of cancer |
US20180193482A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
AU2018236123B2 (en) | 2017-03-11 | 2024-04-18 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
AU2018347583A1 (en) | 2017-10-13 | 2020-05-21 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector IgM responses |
EP3823676A1 (en) | 2018-07-16 | 2021-05-26 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
MX2021000637A (en) | 2018-07-16 | 2021-06-23 | Selecta Biosciences Inc | Methods and compositions of otc constructs and vectors. |
EP3902530A4 (en) * | 2018-12-28 | 2023-01-25 | Ramot at Tel-Aviv University Ltd. | Polymeric nanovaccines and uses thereof |
EP3962537A1 (en) | 2019-04-28 | 2022-03-09 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
DE102020113731B4 (en) * | 2020-05-20 | 2024-02-08 | FiberBridge Photonics GmbH | Fiberglass and fiberglass product |
MX2022015592A (en) * | 2020-06-09 | 2023-03-31 | Icosavax Inc | Method of making virus-like particle. |
US20220133864A1 (en) | 2020-11-04 | 2022-05-05 | Selecta Biosciences, Inc. | Methods and compositions for reducing immune responses against immunoglobulin proteases |
EP4274571A1 (en) | 2021-01-05 | 2023-11-15 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
MX2023011004A (en) | 2021-03-19 | 2024-01-08 | Trained Therapeutix Discovery Inc | Compounds for regulating trained immunity, and their methods of use. |
US20220323607A1 (en) | 2021-04-09 | 2022-10-13 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
US20230140196A1 (en) | 2021-10-12 | 2023-05-04 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
EP4429662A1 (en) | 2021-11-14 | 2024-09-18 | Cartesian Therapeutics, Inc. | Multiple dosing with viral vectors |
US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
US20230202978A1 (en) | 2022-03-04 | 2023-06-29 | Reset Pharmaceuticals, Inc. | Co-crystal or salt |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
US20230322884A1 (en) | 2022-03-09 | 2023-10-12 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
WO2024036324A1 (en) | 2022-08-11 | 2024-02-15 | Selecta Biosciences, Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998049195A1 (en) * | 1997-04-29 | 1998-11-05 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
WO2001022990A2 (en) * | 1999-09-27 | 2001-04-05 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2002053141A2 (en) * | 2000-12-14 | 2002-07-11 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
WO2002056905A2 (en) | 2001-01-19 | 2002-07-25 | Cytos Biotechnology Ag | Molecular antigen array |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3160926D1 (en) | 1980-04-15 | 1983-10-27 | Beecham Group Plc | Allergens modified with polysarcosines |
US5204096A (en) | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
FR2581394B1 (en) | 1985-05-02 | 1988-08-05 | Grp Genie Genetique | PARTICLES HAVING IMMUNOGENIC PROPERTIES OF THE HBS ANTIGEN AND CARRYING A FOREIGN ANTIGENIC SITE TO THE EPITOPES CARRIED BY THE HBS ANTIGEN, ANIMAL VECTORS AND CELLS FOR THE PRODUCTION OF SUCH PARTICLES AND COMPOSITIONS CONTAINING SUCH PARTICLES FOR THE PRODUCTION |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US5143726A (en) | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
ES2087997T3 (en) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES. |
US5334394A (en) | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
GB9101550D0 (en) | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
ZA934199B (en) | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
GB9213601D0 (en) * | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
CA2140542A1 (en) | 1992-07-27 | 1994-02-03 | Abeysingle Padmapriya | Oligonucleotide alkylphosphonothioates |
FR2695563B1 (en) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticles carrying antigens and their use for the induction of humoral or cellular responses. |
GB9227068D0 (en) | 1992-12-29 | 1993-02-24 | British Bio Technology | Novel proteinaceous particles |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
EP1630229B1 (en) | 1994-04-22 | 2013-04-03 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
ATE328890T1 (en) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | IMMUNOMODULATORY OLIGONUCLEOTIDES |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US5935821A (en) | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
WO1996030523A2 (en) | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
JP4359654B2 (en) | 1996-01-30 | 2009-11-04 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Gene expression vector for generating antigen-specific immune response and method of use thereof |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU753688B2 (en) * | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
JP2002508748A (en) | 1997-05-01 | 2002-03-19 | カイロン コーポレイション | Use of virus-like particles as adjuvants |
AU7690898A (en) * | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
JP4280309B2 (en) | 1997-06-06 | 2009-06-17 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Inhibitors of DNA immunostimulatory sequence activity |
ATE377022T1 (en) | 1997-06-23 | 2007-11-15 | Ludwig Inst Cancer Res | ISOLATED DECAPEPTIDES THAT BIND TO HLA MOLECULES AND THEIR USE |
US6025470A (en) | 1997-06-23 | 2000-02-15 | Ludwig Institute For Cancer Research | Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof |
FR2764826B1 (en) | 1997-06-24 | 1999-09-03 | Tempora O | METHOD FOR CLEANING POROUS SURFACE, PARTICULARLY STONE, AND SUITABLE COMPOSITION |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
DE69837094T2 (en) | 1997-09-05 | 2007-08-30 | The Regents Of The University Of California, Oakland | USE OF IMMUNE-RELATED OLIGONUCLEOTIDES FOR PREVENTING OR TREATING ASTHMA |
US5989868A (en) | 1997-09-12 | 1999-11-23 | The Board Of Regents Of The University Of Oklahoma | Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli |
US6171591B1 (en) | 1997-12-08 | 2001-01-09 | Pentamer Pharmaceuticals, Inc. | Recombinant nodavirus compositions and methods |
DK1054689T3 (en) | 1998-02-12 | 2004-01-26 | Apovia Inc | Strategically modified hepatitis B core proteins and derivatives thereof |
DE69935507T2 (en) | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM BY IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINES |
US6541438B1 (en) * | 1998-05-01 | 2003-04-01 | The Procter & Gamble Company | Laundry detergent and/or fabric care compositions comprising a modified cellulase |
US5990085A (en) | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
IL139646A0 (en) * | 1998-05-14 | 2002-02-10 | Coley Pharm Group Inc | Methods for regulating hematopoiesis using cpg-oligonucleotides |
EE04489B1 (en) | 1998-06-30 | 2005-06-15 | Om Pharma | Acyl pseudodipeptides, process for their preparation and pharmaceutical compositions containing them |
CA2333854A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | Stereoisomers of cpg oligonucleotides and related methods |
US5962636A (en) | 1998-08-12 | 1999-10-05 | Amgen Canada Inc. | Peptides capable of modulating inflammatory heart disease |
AU777225B2 (en) | 1998-09-03 | 2004-10-07 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
DE69929232T2 (en) * | 1998-10-21 | 2006-08-31 | The United States Government As Represented By The Department Of Health And Human Services | VIRUSELY PARTICLES FOR INDUCING AUTOANTIC BODIES |
US6380364B1 (en) | 1998-11-23 | 2002-04-30 | Loyola University Of Chicago | Chimeric biotin-binding papillomavirus protein |
PL192016B1 (en) | 1998-11-30 | 2006-08-31 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens, method of preparation and use |
BR9915942A (en) | 1998-12-04 | 2001-08-21 | Biogen Inc | Hbv core antigen molecules with multiple immunogenic components linked via peptide ligands |
US6551820B1 (en) | 1998-12-23 | 2003-04-22 | Boyce Thompson Institute For Plant Research | Expression of immunogenic hepatitis B surface antigens in transgenic plants |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AU3281100A (en) | 1999-02-25 | 2000-09-14 | Peptide Therapeutics Limited | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
HU229255B1 (en) | 1999-04-19 | 2013-10-28 | Smithkline Beecham Biolog | Vaccines |
AU6801800A (en) * | 1999-08-30 | 2001-03-26 | Ludwig Institute For Cancer Research | Isolated nona and decapeptides which bind to hla molecules, and the use thereof |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
EP1311288A1 (en) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7172759B2 (en) | 2000-02-01 | 2007-02-06 | Pangenetics Bv | Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
DE60122300T2 (en) | 2000-04-07 | 2007-08-30 | The University Of Leeds | HEPATITIS B CORE PROTEIN FUSION PROTEINS |
AU2001252458A1 (en) | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
ATE320493T1 (en) | 2000-06-22 | 2006-04-15 | Ucb Pharma Ltd | MODIFICATION OF HEPATITIS B CORE ANTIGEN |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
CA2492823A1 (en) | 2001-09-14 | 2003-03-27 | Martin F. Bachmann | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
WO2003024481A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US7115266B2 (en) * | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
JP4671389B2 (en) | 2001-10-05 | 2011-04-13 | サイトス バイオテクノロジー アーゲー | Angiotensin peptide-carrier complex and use thereof |
EP1455593B1 (en) | 2001-10-06 | 2013-07-24 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
US20030219459A1 (en) * | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
CN1662253A (en) * | 2002-06-20 | 2005-08-31 | 赛托斯生物技术公司 | Packaged virus-like particles for use as adjuvants: method of preparation and use |
AU2004224762B2 (en) * | 2003-03-26 | 2009-12-24 | Kuros Us Llc | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
RU2375076C2 (en) * | 2003-07-10 | 2009-12-10 | Цитос Биотехнологи Аг | Completed virus-like particles |
AU2005286475A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
CA2636139A1 (en) * | 2005-12-14 | 2007-06-21 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
-
2004
- 2004-03-25 AU AU2004224762A patent/AU2004224762B2/en not_active Expired
- 2004-03-25 BR BRPI0408623-6A patent/BRPI0408623A/en not_active IP Right Cessation
- 2004-03-25 EP EP04723203A patent/EP1606398A1/en not_active Withdrawn
- 2004-03-25 CN CNB2004800079060A patent/CN100560719C/en not_active Expired - Fee Related
- 2004-03-25 US US10/550,518 patent/US7517520B2/en not_active Expired - Lifetime
- 2004-03-25 KR KR1020057017197A patent/KR20050115913A/en not_active Application Discontinuation
- 2004-03-25 CN CN200910175527A patent/CN101675993A/en active Pending
- 2004-03-25 EP EP04723204A patent/EP1605972A2/en not_active Withdrawn
- 2004-03-25 ZA ZA200507063A patent/ZA200507063B/en unknown
- 2004-03-25 AU AU2004224761A patent/AU2004224761A1/en not_active Abandoned
- 2004-03-25 JP JP2006504862A patent/JP5022028B2/en not_active Expired - Fee Related
- 2004-03-25 CA CA002517675A patent/CA2517675A1/en not_active Abandoned
- 2004-03-25 RU RU2005129727/13A patent/RU2351362C2/en not_active IP Right Cessation
- 2004-03-25 NZ NZ542323A patent/NZ542323A/en unknown
- 2004-03-25 WO PCT/EP2004/003165 patent/WO2004084940A1/en active Application Filing
- 2004-03-25 CA CA002517839A patent/CA2517839A1/en not_active Abandoned
- 2004-03-25 WO PCT/EP2004/003163 patent/WO2004084939A2/en active Application Filing
- 2004-03-25 MX MXPA05009289A patent/MXPA05009289A/en active IP Right Grant
- 2004-03-25 AU AU2004223736A patent/AU2004223736B2/en not_active Ceased
- 2004-03-25 EP EP04723207A patent/EP1605973B1/en not_active Expired - Lifetime
- 2004-03-25 WO PCT/EP2004/003164 patent/WO2004085635A1/en active Application Filing
- 2004-03-25 CA CA002519165A patent/CA2519165A1/en not_active Abandoned
- 2004-03-25 ZA ZA200507562A patent/ZA200507562B/en unknown
-
2005
- 2005-08-16 ZA ZA200506541A patent/ZA200506541B/en unknown
-
2009
- 2009-03-24 US US12/410,085 patent/US20100098722A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998049195A1 (en) * | 1997-04-29 | 1998-11-05 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2001022990A2 (en) * | 1999-09-27 | 2001-04-05 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
WO2002053141A2 (en) * | 2000-12-14 | 2002-07-11 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
WO2002056905A2 (en) | 2001-01-19 | 2002-07-25 | Cytos Biotechnology Ag | Molecular antigen array |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
Non-Patent Citations (9)
Title |
---|
COHEN ET AL., CANCER RESEARCH, vol. 54, 1994, pages 1055 |
GERBER S ET AL: "Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 10, May 2001 (2001-05-01), pages 4752 - 4760, XP002246338, ISSN: 0022-538X * |
GOLDBERG A.L. ET AL., MOL. IMMUNOL., vol. 39, 2002, pages 147 - 164 |
GOLMOHAMMADI, R. ET AL., STRUCTURE, vol. 4, 1996, pages 543 - 554 |
KLINMAN D M ET AL: "THE USE OF CPG ODN AS ANTIALLERGENS, ANTICANCER AGENTS AND IMMUNOPROTECTIVE AGENTS HAS ATTRACTED CONSIDERABLE INTEREST. IMMUNOTHERAPEUTIC APPLICATIONS OF CPG-CONTAINING OLIGODEOXYNUCLEOTIDES", DRUG NEWS AND PERSPECTIVES, XX, XX, vol. 13, no. 5, 2000, pages 289 - 296, XP000999966, ISSN: 0214-0934 * |
KOZLOVSKA, T. M. ET AL., GENE, vol. 137, 1993, pages 133 - 37 |
KRUG A ET AL: "Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.", EUROPEAN JOURNAL OF IMMUNOLOGY. JUL 2001, vol. 31, no. 7, July 2001 (2001-07-01), pages 2154 - 2163, XP002292085, ISSN: 0014-2980 * |
KURAMOTO E ET AL: "OLIGONUCLEOTIDE SEQUENCES REQUIRED FOR NATURAL KILLER CELL ACTIVATION", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 83, no. 11, November 1992 (1992-11-01), pages 1128 - 1131, XP008024190, ISSN: 0910-5050 * |
YUAN ET AL., J. VIROL., vol. 73, 1999, pages 10122 - 10128 |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959928B2 (en) | 2004-10-05 | 2011-06-14 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
EP1807094A1 (en) * | 2004-11-05 | 2007-07-18 | Bio Clue & Solution Co., Ltd. | Therapeutic use of cpg oligodeoxynucleotide for skin disease |
EP1807094B1 (en) * | 2004-11-05 | 2012-01-11 | Bio Clue & Solution Co., Ltd. | Therapeutic use of cpg oligodeoxynucleotide for skin disease |
WO2006056142A1 (en) | 2004-11-29 | 2006-06-01 | Changchun Huapu Biotechnology Co., Ltd. | Cpg single-strand deoxynucleotides for use as adjuvant |
EP1829887A1 (en) * | 2004-11-29 | 2007-09-05 | Changchun Huapu Biotechnology Co., Ltd. | Cpg single-strand deoxynucleotides for use as adjuvant |
EP1829887A4 (en) * | 2004-11-29 | 2008-06-25 | Changchun Huapu Biotechnology | Cpg single-strand deoxynucleotides for use as adjuvant |
WO2007039458A2 (en) * | 2005-09-21 | 2007-04-12 | Cytos Biotechnology Ag | Hiv peptide conjugates and uses thereof |
WO2007039458A3 (en) * | 2005-09-21 | 2007-06-07 | Cytos Biotechnology Ag | Hiv peptide conjugates and uses thereof |
US9404126B2 (en) | 2006-06-12 | 2016-08-02 | Kuros Biosciences Ag | Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages |
RU2476595C2 (en) * | 2006-06-12 | 2013-02-27 | Цитос Биотехнологи Аг | Methods of packaging of oligonucleotides into virus-like particles of rna-containing bacteriophages |
AU2013204383B2 (en) * | 2006-06-12 | 2016-09-22 | Kuros Us Llc | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
US9902972B2 (en) | 2006-06-12 | 2018-02-27 | Kuros Biosciences Ag | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
US8541559B2 (en) | 2006-06-12 | 2013-09-24 | Cytos Biotechnology Ag | Process for producing aggregated oligonucleotides |
US10358656B2 (en) * | 2006-06-12 | 2019-07-23 | Kuros Biosciences Ag | Oligonucleotides packaged into virus-like particles of RNA bacteriophages |
KR101552227B1 (en) | 2006-06-12 | 2015-09-10 | 사이토스 바이오테크놀로지 아게 | - processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
WO2007144150A1 (en) * | 2006-06-12 | 2007-12-21 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
EP2530086A1 (en) | 2006-06-12 | 2012-12-05 | Cytos Biotechnology AG | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
CN101466720B (en) * | 2006-06-12 | 2013-01-02 | 赛托斯生物技术公司 | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
US20180171358A1 (en) * | 2006-06-12 | 2018-06-21 | Kuros Biosciences Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
AU2007260236B2 (en) * | 2006-06-12 | 2013-05-16 | Kuros Us Llc | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
WO2008024427A3 (en) * | 2006-08-23 | 2008-04-17 | Stc Unm | A virus-like platform for rapid vaccine discovery |
WO2008024427A2 (en) * | 2006-08-23 | 2008-02-28 | Science & Technology Corporation @ Unm | A virus-like platform for rapid vaccine discovery |
US9803189B2 (en) | 2006-08-23 | 2017-10-31 | Stc.Unm | Virus-like platform for rapid vaccine discovery |
US9914746B2 (en) | 2006-12-12 | 2018-03-13 | Kuros Biosciences Ag | Oligonucleotides containing high concentrations of guanine monomers |
US8586728B2 (en) | 2006-12-12 | 2013-11-19 | Cytos Biotechnology Ag | Oligonucleotides containing high concentrations of guanine monomers |
WO2008071774A1 (en) * | 2006-12-14 | 2008-06-19 | Cytos Biotechnology Ag | Purification process for coat protein of rna bacteriophages |
US10238736B2 (en) | 2008-06-27 | 2019-03-26 | Zoetis Services Llc | Adjuvant compositions |
EP2865389A1 (en) * | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | IgE CH3 peptide vaccine |
US9216229B2 (en) | 2008-12-09 | 2015-12-22 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
WO2010067286A3 (en) * | 2008-12-09 | 2010-08-05 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
WO2010122164A1 (en) | 2009-04-23 | 2010-10-28 | Cytos Biotechnology Ag | VIRUS-LIKE PARTICLES OF BACTERIOPHAGE φCB5 |
US8563506B2 (en) * | 2009-06-12 | 2013-10-22 | Morehouse School Of Medicine | Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles |
US8871708B2 (en) | 2009-06-12 | 2014-10-28 | Morehouse School Of Medicine | Compositions and methods for treating AIDS or cancer by inhibiting the secretion of microparticles |
US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
WO2011113546A1 (en) * | 2010-03-16 | 2011-09-22 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
US10526387B2 (en) | 2010-03-16 | 2020-01-07 | Biontech Protein Therapeutics Gmbh | Tumor vaccination involving a humoral immune response against self-proteins |
US9617321B2 (en) | 2010-03-16 | 2017-04-11 | Johannes Gutenberg-Universitat Mainz | Tumor vaccination involving a humoral immune response against self-proteins |
EP2366709A1 (en) * | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
US8840902B2 (en) | 2010-03-16 | 2014-09-23 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
US10117921B2 (en) | 2013-09-19 | 2018-11-06 | Zoetis Services Llc | Oil-based adjuvants |
US11701415B2 (en) | 2013-09-19 | 2023-07-18 | Zoetis Services Llc | Oil-based adjuvants |
US10953080B2 (en) | 2013-09-19 | 2021-03-23 | Zoetis Services Llc | Oil-based adjuvants |
US20170362591A1 (en) * | 2014-12-25 | 2017-12-21 | National Institutes Of Biomedical Innovation, Health And Nutrition | Non-aggregating immunostimulatory oligonucleotides |
US11268098B2 (en) * | 2014-12-25 | 2022-03-08 | National Institutes Of Biomedical Innovation, Health And Nutrition | Non-aggregating immunostimulatory oligonucleotides |
WO2016109310A1 (en) | 2014-12-31 | 2016-07-07 | Checkmate Pharmaceuticals, Llc | Combination tumor immunotherapy |
EP3835312A1 (en) | 2014-12-31 | 2021-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
US10682365B2 (en) | 2014-12-31 | 2020-06-16 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
CN107106674A (en) * | 2015-01-16 | 2017-08-29 | 硕腾服务有限责任公司 | Aftosa vaccine |
EP4248992A3 (en) * | 2015-01-16 | 2023-12-27 | Zoetis Services LLC | Foot-and-mouth disease vaccine |
WO2016115456A1 (en) * | 2015-01-16 | 2016-07-21 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
US10478487B2 (en) | 2015-01-16 | 2019-11-19 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
CN114699518A (en) * | 2015-01-16 | 2022-07-05 | 硕腾服务有限责任公司 | Foot and mouth disease vaccine |
WO2017173334A1 (en) | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11939346B2 (en) | 2017-10-09 | 2024-03-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
WO2019197965A1 (en) | 2018-04-09 | 2019-10-17 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
US12084655B2 (en) | 2018-04-09 | 2024-09-10 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
EP3835414A4 (en) * | 2018-08-07 | 2022-05-25 | Institute Of Biophysics, Chinese Academy Of Sciences | Method for activating cd4+t cell |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
WO2021081353A1 (en) | 2019-10-23 | 2021-04-29 | Checkmate Pharmaceuticals, Inc. | Synthetic rig-i-like receptor agonists |
WO2023242155A1 (en) * | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
WO2024047091A2 (en) | 2022-08-30 | 2024-03-07 | Saiba Animal Health Ag | Veterinary compositions of modified virus-like particles of cmv and ngf antigens |
WO2024047090A2 (en) | 2022-08-30 | 2024-03-07 | Saiba Animal Health Ag | Modified virus-like particles of cmv |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004224762B2 (en) | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use | |
AU2009200115B2 (en) | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use | |
US20180015160A1 (en) | In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus-Like Particles | |
AU2002339224A1 (en) | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use | |
US20110097417A1 (en) | Melan-a-carrier conjugates | |
US20060210588A1 (en) | Hiv-peptide-carrier-conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2517675 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/07063 Country of ref document: ZA Ref document number: 200507063 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006251677 Country of ref document: US Ref document number: 2381/CHENP/2005 Country of ref document: IN Ref document number: 10550518 Country of ref document: US Ref document number: 2004224762 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004224762 Country of ref document: AU Date of ref document: 20040325 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004224762 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004723207 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004723207 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10550518 Country of ref document: US |